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Abstract 
Human papillomaviruses (HPV) are responsible for 5 % of all annual cancer cases worldwide 
and thus present a major health problem. HPVs can cause oropharyngeal and anogenital 
cancers. More than 60 % of the HPV-induced cancers are caused by HPV16. Therapeutic anti-
tumor vaccination against the two HPV oncoproteins E6 and E7 represents an attractive 
treatment option because these proteins are expressed in all tumor stages and are 
indispensable for tumor initiation and survival. Therapeutic vaccination could combine long-
term immunity with reduced treatment side effects compared to conventional therapies 
such as surgery and chemotherapy. Preclinical studies for the development of a therapeutic 
HPV vaccine have yielded promising results. However, most clinical studies could not 
reproduce these findings. One obstacle to achieving better translatability of preclinical 
findings is the absence of a mouse model that allows the exclusive study of human HPV 
epitopes. A2.DR1 mice express two of the most common major histocompatibility complex 
(MHC) molecules, HLA-A2 and HLA-DR1, without the expression of any interfering murine 
MHCs. The aim of this PhD project was to develop a HPV16 tumor model for these mice, and 
to test various formulations of epitope-specific therapeutic anti-HPV16 vaccines. This work 
shows that the newly established PAP-A2 tumor cells express HPV16 E6/E7 and present four 
epitopes on HLA-A2 that can also be found on HPV16-transformed human tumor cells. The 
immunogenicity of all four epitopes in A2.DR1 mice was shown by the induction of CD8+ T 
cell responses after vaccination with these epitopes. Comparing emulsion-based, mRNA-
based and different amphiphilic peptide-based vaccines, it was observed that amphiphilic 
peptides induced the highest frequencies of E7/11-19-specific CD8+ T cells. Furthermore, it 
could be demonstrated that therapeutic vaccination with an amphiphilic version of the 
minimal epitope E7/11-19 induces complete PAP-A2 tumor rejection in 50 % of animals. 
Interestingly, upon vaccination with the other three epitopes or combination vaccination 
with the four different epitopes we observed decreased anti-tumor responses compared to 
single E7/11-19 vaccination. In summary, this study presents the first HPV16 E6/E7-positive 
tumor model that allows the exclusive analysis of HPV16 epitopes in fully MHC-humanized 
mice and shows pronounced anti-tumor effects by minimal epitope vaccination. These 
results emphasize the need for the careful selection and combination of minimal epitope 
vaccines and could improve the efficacy of future therapeutic HPV vaccines. 
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Zusammenfassung 
Humane Papillomviren (HPV) verursachen 5 % aller Krebsfälle weltweit und stellen somit ein 
wichtiges Gesundheitsproblem dar. HPVs können sowohl oropharyngeale als auch 
anogenitale Tumoren auslösen. Mehr als 60 % aller HPV-induzierten Krebsfälle werden von 
HPV16 ausgelöst. Therapeutische anti-Tumor Impfungen gegen die zwei HPV Onkoproteine 
E6 und E7 stellen eine attraktive Behandlungsoption dar, da diese Proteine in allen 
Tumorstadien exprimiert werden und unentbehrlich für die Tumorentstehung und das 
Tumorwachstum sind. Therapeutische Impfungen könnten Langzeit-Immunität mit 
reduzierten Nebenwirkungen, verglichen zu konventionellen Therapien wie operative 
Eingriffe und Chemotherapien, verbinden. Präklinische Studien für die Entwicklung einer 
therapeutischen HPV Impfung konnten vielversprechende Ergebnisse generieren, die 
meisten klinischen Studien konnten diese Ergebnisse jedoch nicht reproduzieren. Ein 
Hindernis, das der besseren Übertragbarkeit von präklinischen Studien zu klinischen 
Ergebnissen im Wege steht, ist das Fehlen eines Maus Modells, welches die exklusive 
Erforschung von humanen HPV Epitopen erlaubt. A2.DR1 Mäuse exprimieren zwei der 
häufigsten Haupthistokompatibilitätskomplex (MHC) Moleküle, HLA-A2 und HLA-DR1, ohne 
die Expression von interferierenden murinen MHC Molekülen. Das Ziel dieser Doktorarbeit 
war die Entwicklung eines HPV16 Tumor Modells für diese Mäuse, und die Evaluierung 
verschiedener Formulierungen therapeutischer HPV16 Impfungen mit definierten 
Minimalepitopen. Diese Arbeit zeigt, dass die neu entwickelte PAP-A2 Tumorzelllinie HPV16 
E6/E7 exprimiert und vier HLA-A2-restringierte Epitope präsentiert, die auch auf HPV16-
transformierten humanen Tumorzelllinien gefunden werden. Die Immunogenität von allen 
vier Epitopen in A2.DR1 Mäusen konnte durch die Induktion von CD8+ T Zell-Antworten nach 
Impfung mit den vier Epitopen gezeigt werden. Im Vergleich von Emulsionsformulierungen, 
mRNA Vakzinen und Vakzinen basierend auf amphiphilen Peptiden konnte beobachtet 
werden, dass amphiphile Vakzine die höchsten Frequenzen von E7/11-19-spezifischen CD8+ 
T Zellen induzierten. Weiterhin konnte gezeigt werden, dass eine therapeutische Impfung 
mit einer amphiphilen Version des Minimalepitops E7/11-19 eine vollständige 
Tumorabstoßung in 50 % der Tiere induziert. Interessanterweise wurden geringere anti-
Tumor Effekte als die durch Einfach-Impfung mit E7/11-19 nach Impfung mit den drei 
anderen Epitopen oder Kombinationsimpfungen beobachtet. Zusammengefasst präsentiert 
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diese Arbeit das erste HPV16 E6/E7-positive Tumormodell, dass die exklusive Analyse von 
HPV16 Epitopen in vollständig MHC-humanisierten Mäusen erlaubt und zeigt starke anti-
Tumor Effekte durch Impfung mit Minimalepitopen. Diese Ergebnisse betonen die 
Notwendigkeit der sorgfältigen Auswahl und Kombination von Vakzinen basierend auf 
Minimalepitopen und könnten die Wirksamkeit von zukünftigen therapeutischen HPV 
Impfungen verbessern. 
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1 Introduction 
1.1 The immune system 
The human body is under constant attack by pathogens like bacteria, viruses, fungi and 
parasites. The immune system evolved to counter these attacks and consists of two major 
parts: The innate and the adaptive immune system. The immune system is made up of 
organs, cellular components and soluble components. The organs that make up the immune 
system are the primary lymphoid organs with the bone marrow and thymus and the 
secondary lymphoid organs with the spleen, lymph nodes and the lymph system (Murphy et 
al., 2016). 
1.1.1 Innate immune system 
The innate immune system is able to detect and attack pathogens quickly due to their 
expression of conserved features that are shared by many pathogens. This recognition is 
achieved by pattern recognition receptors (PRR) expressed on cells of the innate immune 
system. In general, the components of the innate immune system comprise cellular 
components such as natural killer (NK) cells, macrophages, dendritic cells (DC), neutrophils 
and the soluble components of the complement system. Macrophages and especially DCs 
are at the interface of the innate and the adaptive immune system due to their ability to 
present components of pathogens to cells of the adaptive immune system and thus trigger 
an adaptive immune response (Murphy et al., 2016). 
1.1.2 Adaptive immune system 
The adaptive immune system cannot respond to the first encounter with a pathogen as 
quickly as the innate immune system but its highly specific and powerful effector 
mechanisms often eradicate a pathogen that is only kept in check by the innate immune 
system. Additionally, it can provide protection for the host, i.e. make it immune, to 
subsequent exposure to the same pathogen by its memory function. Like the innate immune 
system, the adaptive immune system is made up of cellular and soluble components. 
Lymphocytes make up the cellular part of the adaptive immune system and they are 
categorized into B lymphocytes (B cells) and T lymphocytes (T cells). The soluble components 
are called antibodies (ABs), which can bind to virtually all structures, and thus inactivate 
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them and mark them for phagocytosis by cells of the innate immune system. The names B 
and T cell stem from the site of their maturation, the bone marrow for B cells and the thymus 
for T cells (Murphy et al., 2016). Both cell types carry a receptor, the B cell receptor (BCR) 
and T cell receptor (TCR), respectively. A high diversity of receptors is generated from a 
limited number of receptor genes by a process called V(D)J recombination and by the 
random addition of nucleotides to these genes during the development of these cells 
(Hozumi and Tonegawa, 1976; Schatz, 2004). Due to the partly random nature of the 
generation process, the receptor is unique to a clonal cell. The important distinguishing 
factor between the adaptive immune system and the innate immune system is that the 
adaptive immune system does not have to rely on conserved pathogen structures but that 
its cells can recognize virtually all structures of pathogens via the BCRs and TCRs. B and T cell 
antigen recognition results in activation and rapid clonal expansion after which they exercise 
their effector functions. The B cell receptor recognizes unprocessed structures that are 
present on pathogens (Murphy et al., 2016). After activation and clonal expansion, B cells 
differentiate into plasma cells that secrete ABs into the blood stream. In contrast, the 
receptors of T cells recognize processed peptides that are presented on membrane-bound 
molecules called major histocompatibility complex (MHC). T cells are divided into CD4+ and 
CD8+ T cells, which differ in their function and the MHCs they recognize. CD4+ T cells are also 
called helper T cells (TH) and recognize epitopes presented on MHC class II, whereas CD8+ T 
cells are also called cytotoxic T cells and recognize epitopes presented on MHC class I. The 
function of CD4+ T cells is to provide B cells and macrophages with signals that allow them 
to fulfill their specific functions, hence their name. Due to their helper function they can also 
improve the activation of CD8+ T cells. Cytotoxic CD8+ T cells recognize tumor cells and cells 
infected with intracellular pathogens, such as viruses, and kill the cell to prevent a spread of 
the infection or the tumor (Murphy et al., 2016).  
Peptides that bind MHC and can be recognized by T cells are called epitopes and can be 
derived from self or non-self proteins. The name MHC is derived from the finding that tissue 
cannot be transplanted between two individuals who differ in their MHC molecules (Snell 
and Higgins, 1951). MHC molecules are divided into classical and non-classical MHCs, the 
focus here will be on classical MHCs. Non-classical MHCs have diverse functions such as iron 
uptake, tasks in the innate immune system and protection of the fetus from a maternal 
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immune response. The classical MHCs are categorized into MHC class I and MHC class II 
(Figure 1).  
The MHC loci are highly polymorphic and each allele has different binding affinities for 
different epitopes (Murphy et al., 2016). It is assumed that this variety evolved to enable 
MHCs to present epitopes from as many pathogens as possible. In humans, MHCs are called 
human leukocyte antigen (HLA). Despite this variety, certain MHC class I alleles are more 
common in the human population than others, e.g. HLA-A*0201, often abbreviated as HLA-
A2, is the most frequent HLA class I allele in the Caucasian population. For example, in the 
USA, it has a frequency of 47.8 % among Caucasians (González-Galarza et al., 2015).  
MHC class I is expressed by virtually all nucleated cells and is formed by the association of a 
membrane-bound heavy chain consisting of five domains (α1, α2 and α3, a transmembrane 
domain and a cytoplasmic tail with the soluble β2 microglobulin (β2m) (Figure 1, left side). 
α1 and α2 make up the peptide-binding groove to which peptides of 8-11 amino acids can 
bind (Murphy et al., 2016).  
MHC class II molecules are expressed by professional antigen-presenting cells (APC) such as 
B lymphocytes, DCs and macrophages. This MHC class is formed by the association of two 
membrane-bound subunits, which are called α chain and β chain (Figure 1, right side). Since 
the peptide binding groove is open at both ends, MHC class II molecules bind longer epitopes 
(12-14 amino acids) than MHC class I molecules (Murphy et al., 2016). 
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Figure 1. MHC class I und class II 
The two classes of MHCs are characterized by different structures. MHC class I consists of one heavy chain 
(the alpha chain), consisting of three extracellular domains (α1-α3), a transmembrane domain and a 
cytoplasmic tail (not depicted) and the associated β2 microglobulin. MHC class II molecules are formed by 
the association of two proteins, the α chain and the β chain (Murphy et al., 2016). 
 
The peptides that are loaded onto MHC class I and class II differ not only in their length but 
also in the way they are produced and in their place of origin. Peptides that are presented 
on MHC class I are derived from intracellular proteins that get degraded by the proteasome, 
a cytosolic multi-subunit protease. The generated peptides are transported via the 
transporter associated with antigen processing (TAP) into the endoplasmic reticulum (ER) 
where they get further trimmed to the correct length by aminopeptidases such as the 
endoplasmic reticulum amino-peptidase I (ERAP I). After this, the peptides are loaded onto 
a MHC class I molecule that assembles with β2m. Subsequently, the newly assembled MHC 
class I:peptide complexes are transported to the cell surface and present the peptides to 
CD8+ T cells. MHC class I molecules are expressed on all nucleated cells, thus allowing CD8+ 
T cells to recognize infected cells by their presentation of endogenously produced, pathogen-
derived epitopes. Furthermore, the expression of MHC class I inhibits killing by NK cells (Kärre 
et al., 1986). 
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MHC class II-presented epitopes are derived from extracellular proteins that professional 
APCs such as DCs, macrophages or B cells have taken up by phagocytosis. These peptides are 
generated in the endosome. The MHC class II molecules are transported from the ER to the 
endosomes. These MHC II molecules are loaded with a placeholder peptide called invariant 
chain to prevent premature binding of self-peptides. The vesicles containing MHC class II 
molecules fuse with the endosome and the invariant chain is exchanged with a peptide that 
was generated in the endosome. Subsequently, the fully assembled MHC class II:peptide 
complexes are transported to the cell surface where patrolling CD4+ T cells can recognize 
their epitope. By a process called cross-presentation, epitopes derived from phagocytosed 
proteins can also be presented on MHC class I. For this, APCs load endosome-derived 
epitopes onto MHC class I by processes that have not been fully elucidated yet (Murphy et 
al., 2016).  
Peptide presentation on MHC class I and MHC class II by professional APCs activates naïve T 
cells that carry the T cell receptor for the respective epitope. Generally, macrophages, B cells 
and DCs are classified as professional APCs since they have the ability to activate CD4+ and 
CD8+ T cells. The cell type most professionalized for this process is the DC. To activate a T 
cell, three signals are necessary.  
1.1.3 Initiation of an immune response 
Once a pathogen has breached the anatomical barriers of the body, it comes into contact 
with the immune system. Cells of the innate immune system, for example DCs, phagocytose 
the pathogen and get activated when their PRRs recognize conserved pathogen patterns, for 
instance in the case of viruses, double stranded RNA, which is recognized by the DC’s toll-
like receptor 3 (TLR3). The DC responds to this activation with the expression of 
costimulatory molecules on its surface, such as CD80/CD86, and with the secretion of 
immune stimulatory molecules, such as interleukin 6 (IL-6) or interferon-γ (IFN-γ). 
Additionally, MHC expression is upregulated. The generation of epitopes by the DC and their 
presentation on MHC results in the presence of all three signals required to activate T cells 
(Figure 2). The first signal is the binding of the TCR to a peptide-loaded MHC molecule on the 
DC. The second signal is provided by the binding of the DC’s costimulatory molecules (e.g. 
CD80/CD86) to their counterpart on T cell side (CD28). The third signal is provided by soluble 
molecules, such as interferons or interleukins. Taken together, these three factors fully 
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activate the T cell and clonal expansion is induced. The DC’s expression of CD80/CD86 and 
thus the activation of T cells can further be increased by a CD40/CD40L-mediated feedback 
process when a CD4+ TH recognizes its epitope presented on MHC class II on the DC (Bennett 
et al., 1998; Ridge, Di Rosa and Matzinger, 1998; Schoenberger et al., 1998).  
After expansion, these clonal CD8+ T cells patrol the whole body and kill cells presenting this 
epitope. When the pathogen has been eliminated from the body, the majority of the 
pathogen-specific T cells dies and only a few differentiate into long-lived memory T cells that 
can expand rapidly after renewed exposure to the pathogen’s epitope (Murphy et al., 2016). 
 
To prevent an overshooting immune response, cells can express inhibitory molecules on 
their surface, such as programmed death-ligand 1 (PD-L1), which decrease the activity of T 
cells (Freeman et al., 2000). These “brakes” of the immune system have become a very 
important field of research since their manipulation, e.g. with blocking ABs, allows to 
reinvigorate an anti-cancer immune response that was dampened by the cancer cells’ 
expression of inhibitory molecules (Iwai et al., 2002). 
 
Figure 2. T cell activation requires three signals from professional antigen-presenting cells 
The activation of T cells requires three signals: Signal 1 is the recognition of the peptide presented on MHC 
on the surface of the professional APC. Signal 2 is made up by the recognition of the APC’s costimulatory 
molecules CD80/CD86 by the T cell’s CD28. Last, cytokines secreted by the APC provide signal 3 and thus 
fully activate the T cell. Figure taken from (Gutcher and Becher, 2007). 
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1.1.4 Basic principles of prophylactic and therapeutic vaccination 
The term vaccination describes the process of exposing the immune system of an individual 
to a stimulus, e.g. dead or attenuated strains of a pathogen, which activates the adaptive 
immune system to generate immunity against this pathogen. In general, there are two kinds 
of vaccinations: Prophylactic and therapeutic vaccination. In the case of prophylactic 
vaccination, the immune system is stimulated with a vaccine before the individual has come 
into contact with the pathogen. Thus, immunity can be acquired e.g. by the generation of 
neutralizing ABs which effectively prevent an infection with the pathogen (Murphy et al., 
2016). Prophylactic vaccinations are among the most effective medical interventions and 
have saved millions of lives since their invention and broad availability (Nabel, 2013). In 
contrast, a therapeutic vaccination is administered after the infection with the pathogen and 
mostly works via the induction of antigen-specific T cells. Due to the highly specific targeting 
system of T cells, therapeutic vaccines can also be applied as a therapy for neoplastic 
malignancies since T cells are able to discriminate healthy from malignant cells.  
Depending on the immune response that is required to either prevent (mostly humoral 
immune responses, i.e. ABs) or to treat an infection (mostly cellular immune responses, i.e. 
cytotoxic T cells), the vaccine formulation has to be chosen accordingly. In general, the 
response to a vaccination follows the same pattern as a natural initiation of an immune 
response by activation of APCs and subsequent clonal expansion of specific lymphocytes. 
The vast majority of vaccines approved today are prophylactic vaccines that often use 
attenuated strains of the pathogen or inactivated pathogens. These pathogen-based 
vaccines have good intrinsic immunostimulatory capabilities due to the presence of 
microbial or viral components. However, other forms of vaccine delivery (e.g. subunit 
vaccines like synthetic peptides) do not include the pathogen-associated molecular patterns 
(PAMP) that activate DCs and are therefore poorly immunogenic (Foged, 2011). In these 
cases, DC-activation signals have to be supplied by different means. To this end, adjuvants, 
which unspecifically stimulate the immune system, are included in the vaccine formulation. 
Examples of adjuvants are aluminum salts (alum), oil emulsions (Bonhoure and Gaucheron, 
2006) and various natural or synthetic TLR agonists such as monophosphoryl lipid A (MPLA) 
(TLR4), polyinosinic:polycytidylic acid (poly I:C or pIC) (TLR3) or CpG (TLR9) (Adams, 2009). 
The mechanism of action of these adjuvants, however, is different and has not yet been 
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elucidated for many adjuvants (Ghimire, 2015). While the TLR agonists directly engage PRRs 
on DCs, alum and oil emulsions mostly work by binding the antigen and generating an 
antigen-rich depot at the injection site accompanied by general inflammation (Reinhardt et 
al., 2003; Redmond and Sherman, 2005; Ghimire, 2015). While alum is an adjuvant broadly 
used for the induction of protective immunity via ABs, this adjuvant does not induce CD8+ T 
cell responses that can mediate anti-tumor effects. The water-in-oil emulsion incomplete 
Freund’s adjuvant (IFA) has for a long time been the gold standard adjuvant for induction of 
CD8+ T cell responses. However, despite the induction of antigen-specific T cells, this 
emulsion-based vaccine formulation induces the sequestration of the specific T cells to the 
subcutaneous antigen depot and thus renders them dysfunctional (Hailemichael et al., 
2013). Newer subunit vaccines featuring peptides overcome this problem by making use of 
non-persistent formulations that, for example, can also target peptides to lymph nodes 
where they are taken up and processed by professional APCs such as DCs (Cho et al., 2013; 
Liu et al., 2014). These formulations are used in conjunction with TLR agonists, such as CpG 
or pIC, which mimic an acute infection by engaging TLRs on APCs. Thus, the activation of 
specific T cells is induced. Some studies give backing to the theory that MHC class II epitopes 
should be included in the vaccine formulation since this would lead to CD4+-mediated help 
for the activation of CD8+ T cells (BenMohamed et al., 2000; Wiesel and Oxenius, 2012; 
Grabowska, Kaufmann and Riemer, 2014). However, there is abundant evidence for 
successful anti-tumor vaccines not containing MHC class II molecules (Cho et al., 2013; Liu et 
al., 2014). 
Another strategy to improve immune responses is to target the antigens contained in the 
vaccine to DCs (reviewed in (Macri et al., 2016)). This can be achieved by ABs specific for 
surface molecules expressed on DCs or by specific formulations and application routes e.g. 
for mRNA vaccines that induce mRNA expression almost exclusively in professional APCs 
(Kranz et al., 2016). The latter approach offers the additional benefit that the mRNA at the 
same time encodes the antigen and serves as the TLR agonist. It has been shown that it is 
beneficial for vaccination success to deliver both components to the same DC (Blander and 
Medzhitov, 2006; Yarovinsky et al., 2006).  
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1.2 Human papillomavirus 
Papillomaviruses are strictly host specific and infect mammals, birds and reptiles (Bravo, de 
Sanjosé and Gottschling, 2010). Around 300 types of papillomavirus are known, around 200 
of which infect humans (Van Doorslaer et al., 2013, 2017). In groundbreaking research Harald 
zur Hausen and his team demonstrated that human papillomaviruses (HPV) are the most 
important causative agents for cervical cancer development (Dürst et al., 1983; Boshart et 
al., 1984). 
HPVs are small double stranded non-enveloped DNA viruses with a genome size of 
approximately 8 kb (Doorbar et al., 2015) (Figure 3). They contain six early genes (E1, E2, E4, 
E5, E6, E7) and two late genes (L1 and L2). The latter are coding for the proteins forming the 
virion particles (Doorbar et al., 2015) (Figure 3). The missing member of the E1-E7 sequence, 
E3, was misidentified due to an error in the initial sequencing of a bovine papillomavirus 
(Doorbar et al., 2015). 
 
Figure 3. A) HPV virions and B) HPV genes and their functions 
The virions of HPVs are 52-55 nm in size (IARC Working Group on the Evaluation of Carcinogenic Risk to 
Humans, 2007) and made up by the two proteins L1 and L2. The circular DNA genome of HPV contains the 
genes for 8 proteins and an upstream regulatory region (URR). A) modified from (Schiffman et al., 2016), B) 
modified from (Riemer et al., 2010). 
 
HPVs are categorized into 5 genera (alpha-, beta-, γ-, nu- and mu-papillomaviruses), species 
and types (Bernard et al., 2010). An isolate is defined as a new type when the gene sequence 
of the capsid protein L1 differs more than 10 % from other known types (Bernard et al., 
2010). The types are numbered according to the sequence of their first discovery (De Villiers 
et al., 2004). The alpha-papillomaviruses, which are highly relevant for overall disease 
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burden in humans, can further be classified into low-risk cutaneous, low-risk mucosal or 
high-risk with regard to their connection to cancers (Doorbar et al., 2015) (Figure 4). High-
risk types are carcinogenic and low-risk types can cause warts. 13 high risk types which are 
carcinogenic have been found so far (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and 11 
types that are probably carcinogenic (26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85) (IARC Working 
Group on the Evaluation of Carcinogenic Risk to Humans, 2007; Geraets et al., 2012; Doorbar 
et al., 2015).  
 
Figure 4. Phylogenetic tree of HPV 
The phylogenetic tree was generated by sequence comparison of E1, E2, L1 and L2. The alpha-papillomavirus 
types are categorized according to their anatomical site preference and their association with cancer: low-
risk cutaneous (light brown); low-risk mucosal (yellow); or high-risk (pink). Taken from (Egawa et al., 2015). 
 
In addition to cervical cancer, HPVs cause oropharyngeal and anogenital cancers in both 
sexes and penile cancer in men (Walboomers et al., 1999; Moody and Laimins, 2010). In 
total, approximately 5 % of all cancer cases are caused by HPV (Plummer et al., 2016). 
Worldwide, virtually 100 % of the annual 530.000 cervical cancer cases are the result of the 
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previous infection with a high-risk HPV (Walboomers et al., 1999; Moody and Laimins, 2010). 
In 2012, 270.000 women died from cervical cancer (WHO, 2018), making cervical cancer the 
fourth most common cause of death from cancer in women (World Health Organization, 
2014). The majority of cervical cancer cases is dependent on infection with only two of the 
high-risk HPV types, namely HPV16 (61 %) and HPV18 (10 %) (Serrano et al., 2015). The 
contribution of these two high risk types to the number of HPV-induced head and neck 
cancers is even larger, since 85 % of all HPV-induced head and neck cancers are caused by 
HPV16 and HPV18 (de Martel et al., 2017). 
1.2.1 HPV infection, replication cycle and cancer induction 
The HPV replication cycle starts with a HPV virion reaching the basement membrane of an 
epithelium (e.g. cervical epithelium) laid open by a microabrasion induced by local trauma 
(Figure 5) (Mirkovic et al., 2015). Here, the capsid protein L1 binds to heparan sulfate 
proteoglycans, causing a conformational change in L2, which exposes its amino terminus to 
the extracellular protease furin. Furin cleaves L2, which can then bind to basal keratinocytes 
and thus induces the endosomal uptake of the virion by the target cell (Day et al., 2010). 
While the L1 proteins are degraded, L2 together with the genome hitchhike on retromer 
processes to the nucleus (Day et al., 2013; Lipovsky et al., 2013). The HPV life cycle is 
absolutely dependent on cell cycle progression during the first instances of infection (Pyeon 
et al., 2009). Only during mitosis the nuclear membrane integrity is partly compromised, 
which is used by the L2/genome complex to enter the nucleus, upon which transcription of 
the viral early 1 (E1) gene is initiated (Pyeon et al., 2009). Expression of the viral proteins E1 
and E2 drives a multiplication of the viral genome to approximately 50-100 episomal copies 
per cell (Day et al., 2004). By making use of the high fidelity of the host’s replication 
machinery, the virus achieves a low error rate resulting also in a smaller rate of evolution 
(Pastrana et al., 2001).  
In a healthy epithelium, cells divide only in the basal layers and differentiate during their 
migration to the top layer. HPV is dependent on this ordered differentiation of the 
epithelium in the generation of new virions but it is also dependent on cell cycle progression 
to replicate the viral genome (zur Hausen, 2002). The virus ensures continued cell cycling by 
expression of the three proteins E5, E6 and E7 (reviewed in (zur Hausen, 2002)). This 
progression enables the virus to switch to a high copy state (more than 1000 genome 
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copies/cell) (Roden and Stern, 2018). The three proteins drive the induction of S-phase by 
manipulating cellular processes, such as e.g. E5 triggering epidermal growth factor receptor 
(EGFR) signaling (Fehrmann, Klumpp and Laimins, 2003; Genther et al., 2003).  
The main function of E6 is to induce degradation of the cell cycle arrest protein p53. This is 
achieved by binding the E3-ligase E6-AP which in turn leads to increased ubiquitination of 
p53 and subsequent proteasomal p53 degradation (Werness, Levine and Howley, 1990). 
Thus, cell cycle arrest due to the accumulation of p53 is prevented. Furthermore, E6 
decreases telomere shortening in the host cell’s genome by the induction of telomerase 
expression, thus hampering cell cycle arrest due to shortened telomeres (Klingelhutz, Foster 
and McDougall, 1996; Galloway et al., 2005). E7 binds to the retinoblastoma protein (pRb), 
targeting it for degradation and thus activates the transcription factor E2F1 (Dyson et al., 
1989). Importantly, this process also leads to the strong upregulation of p16INK4A (Kiyono et 
al., 1998). Due to this strong upregulation, p16INK4A is used as a surrogate marker for HPV 
infection (Klaes et al., 2001). Finally, in the terminally differentiated cells of the uppermost 
epithelial layers, the capsid proteins L1 and L2 are expressed (Doorbar et al., 2015). The 
virions are assembled from capsomeres consisting of L1 (80 %) and L2 (20 %) (Modis, Trus 
and Harrison, 2002) and the viral genome is packaged. Several studies suggest that the E4 
protein facilitates virion release but this has not been formally proven (reviewed in (Doorbar, 
2013)). However, it has been shown that virion production does not lead to cell lysis but that 
the virions are released by physiological shedding of epithelial squamae. 
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Figure 5. HPV replication cycle 
The replication cycle of HPV starts when a HPV virion attaches to the basement membrane which is exposed 
by a microabrasion. After conformational changes induced by the binding to the basement membrane and 
protease cleavage, basal epithelial cells take up the virion. In this early stage of the infection, the virus uses 
the cellular replication machinery to establish 50-100 viral genome copies in the basal cells, controlled by E1 
and E2. In suprabasal layers, the expression of the viral proteins E5, E6 and E7 keeps the cells in the cell cycle, 
allowing continuous viral gene replication. The virus-infected epithelial cells migrate towards the outer 
layers of the epithelium and along the way they differentiate into cornified keratinocytes. Here, the viral 
proteins L1 and L2 are expressed, assemble with the viral genomes and form new virions. The virion release, 
which is likely facilitated by E4-dependent effects, occurs during the physiological process of shedding the 
outermost layer of the epithelium. Taken from (Roden and Stern, 2018). 
 
Infection with high-risk HPV and the resulting expression of viral proteins has many effects 
on the host cell that can lead to cancer (Figure 6). Apart from the uncontrolled cell replication 
induced by the combined effects of E6 and E7, an especially important event in the process 
of carcinogenesis is the integration of the viral DNA into the host cell’s genome. This event 
often leads to the disruption of the E2 gene, which is a repressor of E6/E7 expression, and 
results in high levels of E6/E7 (zur Hausen, 2002; Isaacson Wechsler et al., 2012; McBride 
and Warburton, 2017). This leads to an increase in genetic errors since both E6 and E7 disturb 
cellular processes that normally prevent mutations and genetic abnormalities (Isaacson 
Wechsler et al., 2012). These processes do not immediately lead to cancer but first to 
dysplasia of increasing severity. In general, carcinogenesis occurs as an undesired byproduct 
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of the viral replication cycle, resulting from the viral protein effects as well as from the 
ensuing genomic instability. The induction of cancer offers no evolutionary benefit for the 
virus since it does not improve but actually diminishes virus production. 
In the cervical area, which is highly susceptible to HPV infection, dysplasias are graded from 
CIN-I to CIN-III (cervical intraepithelial neoplasia). Dysplasias can resolve spontaneously but 
high grade dysplasias have a higher risk to develop into cancer than low grade dysplasias 
(McCredie et al., 2008; Roden and Stern, 2018). For example, while 50 % of CIN-III develop 
into cancer, the development of CIN-I into malignant disease is much lower (McCredie et al., 
2008). Large screening programs, using the cytological Papanicolaou-tests (Pap-tests) and 
HPV DNA tests that allow the detection of abnormal and HPV-positive cells, are undertaken 
in the developed world to find CIN patients. If a CIN lesion is discovered, it is monitored and 
in - case of progression - surgical intervention is performed. 
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Figure 6. High-risk HPV E6/E7 induce hallmarks of cancer 
After the integration of the viral genome, E2-mediated repression of E6/E7 expression is often abrogated. 
These two oncogenic proteins influence a variety of cellular processes, thus leading to carcinogenesis. One 
of the carcinogenic actions of the E6 protein is the induction of telomerase, leading to immortalization of 
the host cells. Furthermore, E6 prevents the p53-mediated stop of cell cycle progression, which stops the 
cell’s ability to respond adequately to genomic damage. Therefore, mutations accumulate, further reducing 
physiological cellular behavior. One of the main carcinogenic functions of E7 is the binding to pRB, which 
induces unrestricted cell cycle progression, another hallmark of cancer. Taken from (Roden and Stern, 2018). 
 
Usually, (in more than 90 % of the cases (Plummer et al., 2007)) the HPV infection is cleared 
by the combined action of the innate and adaptive immune system (Trimble et al., 2010) 
within less than 2 years (Rosa et al., 2008; Bosch et al., 2013). Virus clearance is achieved by 
T cells that recognize E2-, E6- and E7-derived epitopes and kill infected cells (de Jong et al., 
2004). The importance of the immune system in resolving HPV infections is also underlined 
by the finding that immunocompromised individuals (e.g. organ transplant recipients or HIV- 
infected patients) have a higher likelihood to develop HPV-induced cancers than fully 
immunocompetent people (Denny et al., 2012; Wieland, Kreuter and Pfister, 2014).  
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On the other hand, HPVs employ several strategies in their replication cycle to evade 
detection by the immune system. First, HPVs do not infect cells below the basement 
membrane where immune cells are more abundant (Grabowska and Riemer, 2012). 
Additionally, HPV protein expression drives skin-resident DCs, Langerhans cells, out of the 
infected areas and thus impairs their sentinel function (Laurson et al., 2010; Jemon et al., 
2016). After infection, the expression of the non-secreted viral proteins is kept at low levels 
which makes the detection of infected cells by T cells difficult since only few copies of 
immunogenic epitopes can be presented on MHC by infected cells (Crum et al., 1986; Stoler 
et al., 1992; Kanodia, Fahey and Kast, 2007). Even potentiating this effect is the fact that 
HPVs alter the antigen processing machinery, for example by the overexpression of the 
aminopeptidase ERAP I, thus leading to the destruction of HPV epitopes (Steinbach et al., 
2017). Furthermore, HPVs do not induce viremia, which would expose virions to a systemic 
immune response (Doorbar, 2005). In the last stage of the replication cycle, HPVs do not 
induce cell death to release newly assembled virions, but rely on the physiological shedding 
of terminally differentiated keratinocytes, which also does not give rise to an immune 
response (Stanley, 2012).  
1.2.2 Prophylactic HPV vaccination 
After the connection between HPV infection and cervical cancer formation had been 
established (Dürst et al., 1983; Boshart et al., 1984; Muñoz et al., 1992), efforts were 
undertaken to develop a vaccine preventing the infection with high-risk HPV types. Vaccine 
development was made possible by the finding that recombinantly produced L1 protein can 
assemble into virus-like particles (VLPs), which, when injected, induce strong neutralizing AB 
responses (Deschuyteneer et al., 2010). Two vaccines were brought to the market: Cervarix 
in 2007, which contains VLPs of HPV 16 and HPV 18 adjuvanted with aluminum hydroxide 
and MPLA, and Gardasil in 2006, which contains VLPs of HPV-6, HPV-11, HPV-16 and HPV-18 
adjuvanted with aluminum hydroxyphosphate sulfate (AHSS) (Einstein et al., 2014). VLPs of 
the two low-risk HPV types HPV-6 and HPV-11 were included in the Gardasil vaccine since 
they are the HPV types causing more than 90 % of genital warts (Roden and Stern, 2018). 
Both vaccines were shown to be very effective in preventing CIN-III lesions (Arbyn et al., 
2018). In general, the VLPs induce type-specific immunity but a cross-protection effect could 
be observed with the stronger adjuvanted Cervarix vaccine (Lehtinen et al., 2012; Kuhs et 
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al., 2014). After vaccination, vaccinated individuals were protected against 93 % of all CIN-III 
lesions although only 52 % of CIN-III lesions are caused by HPV-16 and HPV-18. Both vaccines 
induce higher titers of neutralizing ABs than a natural infection (Einstein et al., 2014). This is 
necessary to induce sterilizing immunity since the anti-L1/L2 ABs cannot alter the process of 
infection after virion uptake by the host cells anymore. Thus, to prevent infection, it is 
necessary to scavenge all virions before they reach host cells.  
Another formulation of Gardasil (Gardasil 9) is now available, which covers HPV-6, HPV-11 
and the seven most prevalent high-risk HPV types (Joura et al., 2015), thus also preventing 
>90 % of cervical cancers. More vaccines are currently being developed, with one of the 
major development goals being the decrease of vaccine cost. Additional goals are to increase 
the number of virus types covered by the vaccine and to develop a vaccine that has 
prophylactic as well as therapeutic effects by inducing AB responses and cellular responses 
(reviewed in (Schiller and Müller, 2015)). 
Prophylactic HPV vaccination is now recommended in several countries for girls and in some 
countries for girls and boys. However, vaccination rates are still low when compared to the 
rate of infected people, since it is estimated that almost every sexually-active individual will 
contract a high-risk HPV type at least once in their lifetime (Woodman, Collins and Young, 
2007). In the USA, 49.5 % of 13-17 year old girls (boys: 37.5 %) received at least two injections 
of the vaccine (Walker et al., 2017). In Germany, 44.6 % of 17-year old females received at 
least two injections (Robert Koch Institut, 2018a). A vaccination recommendation for boys 
has been issued in Germany only in June 2018 (Robert Koch Institut, 2018b), therefore the 
vaccination coverage in boys currently is assumed to be negligible. Worldwide, overall 
vaccination coverage is still very low, especially in low-middle income countries. In 
developed regions, 33.6 % of females 10-20 years of age received the recommended number 
of vaccinations, in contrast, the same holds true only for 2.7 % of females of the same age 
range in less developed countries (Bruni et al., 2016). Epidemiologically, this is of particular 
importance, since in less developed countries no effective screening programs for 
precancerous lesions are in place, which leads to the fact that the vast majority of HPV-
attributable cancer cases (86 %) are observed in these countries (Formana et al., 2012; Bruni 
et al., 2016; Plummer et al., 2016; de Martel et al., 2017). Importantly, not only vaccinated 
people benefit from high vaccination coverage, but also non-vaccinated individuals are 
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protected from HPV infection by the effect of herd immunity. In Australia, a reduction of HPV 
lesions could be observed also in heterosexual men after the implementation of large-scale 
vaccination programs targeting women (Chow et al., 2017).  
1.2.3 Therapeutic HPV vaccination 
Vaccination against cancer or cancer precursor lesions represents an attractive treatment 
option due to long term immune surveillance and low side effects compared to conventional 
cancer treatments like surgery, chemotherapy and radiation therapy (Gulley, 2013). Side 
effects of conventional treatments of HPV-induced cancers range from lesion site-specific 
problems, such as premature deliveries after surgery to treat cervical HPV lesions 
(Albrechtsen et al., 2008), significant loss of quality of life after surgery for oral (Rathod et 
al., 2015) or anal lesions to the general side effects of chemotherapy as cancer treatment. 
Prevention of HPV infection by prophylactic vaccination against HPV will likely be a major 
contributor in reducing the number of new cases. However, since vaccination coverage to 
date is still low in most countries (Bruni et al., 2016) and the latency period from HPV 
infection to development of lesions is long (McCredie et al., 2008), only a small portion of 
HPV-induced cancers will be prevented by the prophylactic vaccinations performed so far. 
530.000 cases of cervical cancer alone occur every year and since the current worldwide 
vaccination coverage is only 1.4 %, this number is not expected to decrease drastically in the 
next decades (Bruni et al., 2016). This bad prognosis despite effective prophylactic vaccines 
is based on the fact that the prophylactic vaccines targeting capsid proteins are not effective 
against established infections (Hildesheim et al., 2007, 2016). Cellular immune responses 
against the L1 protein can be detected (Steele et al., 2002) but this protein is not expressed 
in the cells close to the basement membrane since only early genes are expressed in these 
layers (Stern et al., 2012; van der Burg et al., 2016).  
Among all therapeutic anti-cancer vaccinations, HPV-induced malignancies represent an 
ideal target for two reasons (Cheever et al., 2009; Chabeda et al., 2018). First, the two 
oncoproteins E6 and E7 are obligatory for the malignant phenotype. Thus, immune escape 
by abrogating expression of these proteins is not an option for the cancer cell. Second, since 
E6 and E7 are viral proteins, they are not subject to central immune tolerance, and high-
affinity cytotoxic T cells should therefore be present. Despite these positive characteristics, 
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therapeutic vaccination against HPV infections has proven to be challenging due to the viral 
immune evasion mechanisms.  
There has been a plethora of tested immunotherapy approaches including vaccinations with 
recombinantly produced protein, subunit vaccines (minimal epitopes, synthetic long 
peptides (SLP)), virus-based and bacteria-based vaccines as well as nucleic acid-based (DNA 
and RNA) and cell-based (DC-based and adoptive T cell transfer) approaches (reviewed in 
(Khallouf, Grabowska and Riemer, 2014; Vici et al., 2016; Yang et al., 2016; Kim and Kim, 
2017; Chabeda et al., 2018; Hancock, Hellner and Dorrell, 2018)). Most therapeutic HPV 
vaccination approaches focus on HPV16 E6 and E7, since the other early proteins are not 
expressed in cancer or are not necessary for tumor cell malignancy (Stern et al., 2012; van 
der Burg et al., 2016).  
Despite the multitude of favorable preclinical data, results from clinical trials have not met 
the high expectations of researchers. No therapeutic anti-HPV vaccines against either HPV 
infections or HPV-induced cancers have been approved by regulatory agencies so far 
(Chabeda et al., 2018). One of the most successful studies to date was a randomized, double 
blind, placebo-controlled phase IIb trial using the DNA vaccine VGX-3100, which induced 
histopathological regression in 49.6 % of CIN-II/-III patients (30.6 % in the placebo group) 
(Trimble et al., 2015). A study with the subunit vaccine ISA101 (E6/E7 SLPs emulsified in 
ISA51) led to complete response 12 months after treatment in 47 % of high-grade vulvar 
intraepithelial (VIN) neoplasia patients (Kenter et al., 2009). Importantly, spontaneous 
regression in this disease stage occurs in only 1.5 % of the cases within 10 months after 
diagnosis. However, the positive results of this study in VIN patients could not be reproduced 
- neither in patients with advanced or recurrent HPV16-induced gynecological carcinoma 
(van Poelgeest et al., 2013), nor in patients with high-grade CIN (de Vos van Steenwijk et al., 
2012) nor with low-grade pre-malignant disorders of the cervix (de Vos van Steenwijk et al., 
2014). Interestingly, in all studies HPV16-specific T cell responses could be detected but 
apparently did not lead to clinical benefits. 
SLPs are peptides with a length of 15-36 amino acids and belong to the class of subunit 
vaccines, which is why they require additional immune stimulation by adjuvants like IFA. The 
advantage of SLP vaccines is, next to safety and ease of production, that mixtures of SLPs can 
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be administered that contain epitopes for all MHC types. A disadvantage connected to SLPs 
is that they do not focus the immune response on specific epitopes. Focusing the immune 
response induced by a therapeutic anti-HPV vaccine could be highly beneficial since due to 
the immune evasion mechanisms employed by HPVs (such as e.g. ERAP I-mediated 
destruction of HPV epitopes (Steinbach et al., 2017) or other effects on the antigen 
processing machinery), not all possible HPV epitopes are indeed presented on the surface of 
infected or transformed cells. Therefore, inducing immune responses with SLPs against 
epitopes that are not presented on infected cells or tumor cells would lead to unproductive 
immune responses, since these T cells could not recognize their targets. This disadvantage 
also holds true for all other vaccination approaches that do not use defined epitopes. This 
problem could be overcome by using synthetic short peptides (SSP), which have a length of 
8-11 amino acids. The SSPs included into a vaccine have to be matched to the patient’s HLA-
type to make sure that the vaccine contains epitopes binding to the patient’s MHC class I 
molecules. Developing vaccines suitable for MHC class I alleles with a high frequency in the 
human population, such as HLA-A*0201, allows a broader applicability of these vaccines. 
However, HLA types can be grouped into supertypes, which have similar peptide binding 
characteristics (Sidney et al., 2008). By combining SSPs to a vaccine that contains peptides 
binding to the 5 major supertypes, a population coverage of >95 % could be achieved. 
Another requirement for successful application of this technology is that the HPV E6/E7 
epitopes presented by tumor cells have to be known for the MHC alleles with the highest 
frequency in the population. A first indication of which peptides are presented on tumor cells 
can be derived from analyzing the E6/E7 protein sequences with algorithms that predict the 
potential affinity of peptides contained in the analyzed sequences to a given HLA type. 
However, these algorithms do not take into account altered epitope-processing patterns 
induced by the expression of HPV proteins. Ever more sensitive technology has allowed to 
directly verify the MHC-mediated presentation of epitopes on the cell surface with mass 
spectrometry (MS) (Di Marco, Peper and Rammensee, 2017). The detection of HPV epitopes 
on cells of HPV-induced cancers is particularly challenging since these epitopes are presented 
at low abundance on the cell surface (Kanodia, Fahey and Kast, 2007). Nevertheless, two 
studies report the detection of HPV epitopes on cell lines of cervical cancer by mass 
spectrometry (Riemer et al., 2010; Blatnik et al., 2018). 
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Another challenge for developing effective therapeutic HPV vaccines is the mucosal location 
of many HPV-induced tumors, since the mucosae are continuously in contact with the 
exterior and therefore have a more tolerogenic milieu. Additionally, only T cells carrying a 
certain molecular signature migrate into these specific tissues. Therefore, systemically-
induced T cells do not readily migrate into mucosal areas (reviewed in (Nardelli-Haefliger, 
Dudda and Romero, 2013)). Therefore, efforts have been undertaken to specifically target 
virus-specific T cells to the mucosal tumor site e.g. via induction of mucosal T cells (Sun et 
al., 2015) or via prime-pull approaches (Domingos-Pereira et al., 2013; Soong et al., 2014; 
Tan et al., 2017). For example, oral vaccination targeting HPV E7 was shown to elicit E7-
specific mucosal immunity in the cervix of CIN-III patients (Kawana et al., 2014).  
In summary, HPV infection and the resulting malignancies represent a major global health 
burden. Improvement of prophylactic vaccination coverage and the development of better 
treatment alternatives, of which a therapeutic vaccine is the most attractive option, are 
expected to decrease the prevalence of HPV-induced morbidity and mortality in the near 
future. 
1.3 Mouse models used in HPV research and HPV16 E6/E7-positive tumor 
models 
Mice are by far the most commonly used mammals in medical research, since 99 % of their 
genes have counterparts in humans (Gunter, 2002), they can be bred as inbred lines, can be 
genetically altered and can be kept in a cost-effective way (The Jackson Laboratory, 2018b). 
Additionally, mice have a much shorter life span than many other mammals, thus allowing 
life cycle studies and tumor experiments in a shorter time frame (The Jackson Laboratory, 
2018b). These characteristics also make mouse models indispensable tools for HPV research 
and in particular for research for anti-HPV immunotherapies. 
1.3.1 Wildtype mice 
Mice have been kept as inbred lines since the beginning of the 20th century and many 
different lines have been established, among these the lines C57BL/6 and C3H. Wildtype 
mice express murine MHC class I and MHC class II molecules. The genes encoding for murine 
MHC molecules are called H-2, with the MHC class I subclasses H-2K, H-2D and H-2L. The 
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subclasses of MHC class II molecules are H-2A and H-2E, which are also called IA and IE (from 
immune response (Ir)) (Murphy et al., 2016) (Figure 7).  
 
Figure 7. Human (A) and murine (B) MHC locus 
A & B, The direct comparison of the human and murine MHC locus reveals the shared features. H-2K, H-2D 
and H-2L are MHC class I subclasses (B, striped boxes), their equivalents in the human genome are HLA-A, 
HLA-B and HLA-C (A). Spotted boxes represent genes involved in antigen processing for the MHC class I 
pathway. Genes for MHC class II molecules (IA and IE in mice; DP, DQ and DR in humans) are presented as 
black boxes and the respective antigen processing for MHC class II is done by genes depicted as white boxes. 
Gray ovals (B) represent three genes in the mouse MHC locus coding for non-classical MHC class I heavy 
chains. Figure adapted from (Pascolo 2005). 
 
1.3.1.1 C57BL/6 
Of the many mouse strains used in medical research, the C57BL/6 strain is the most common 
one. This strain and the various congenic substrains are used in all fields of medical and 
biological research, among them cardiovascular, diabetes, obesity and immunological 
research (The Jackson Laboratory, 2018a).  
Since the H-2L gene is deleted in C57BL/6 mice (Pascolo 2005), these mice only express H-2K 
and H-2D as MHC class I molecules on the cell surface of their nucleated cells. In addition, 
the MHC class II protein IA is expressed on professional APCs. Complete IE molecules cannot 
be detected on the cell surface since the IEα gene is a pseudogene in C57BL/6 mice (Pajot, 
Michel, et al., 2004). Like all other inbred strains, C57BL/6 only express one allele of each 
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expressed subclass. This characteristic is called the haplotype. The haplotype of C57BL/6 is 
b. Therefore, the MHCs are named as the gene (H-2K) with the haplotype in superscript (e.g. 
H-2Kb). The MHC expression of a C57BL/6 APC is depicted in Figure 8. 
 
Figure 8. C57BL/6: Expression of MHC class I and class II 
C57BL/6 mice express the two MHC class I subclasses H-2D and H-2K, both in the b haplotype. Furthermore, 
these mice express the MHC class II molecule IAb. Many other mouse strains additionally express the MHC 
class II molecule IE but since the IEα gene is a pseudogene in C57BL/6, no IE molecules can be found on the 
cells of the C57BL/6 strain. 
 
To be able to study anti-tumor responses directed against HPV16 E6/E7 epitopes in C57BL/6 
mice, TC-1 tumor cells were generated by transducing C57BL/6 lung cells with a 
constitutively activated version of h-ras and with HPV16 E6 and E7 (Lin et al., 1996). Most 
anti-HPV16 immunotherapy studies so far have been conducted with this model. Another 
HPV16 E6/E7-positive tumor model derived from C57BL/6 mice is the C3 cell line that was 
generated from embryonic cells by transfection with h-ras (EJ-ras) and HPV16 E6/E7 
(Feltkamp et al., 1993). Finally, the EL4 E7 cell line (Tindle et al., 1995; Fernando et al., 1998) 
is a H-2b-positive thymoma cell line that was transfected with HPV16 E7. Initially, all of the 
transplantable tumor models mentioned above were used as subcutaneous or as pulmonary 
metastases models (Ji et al., 1998) but in the last years, especially the TC-1 model was also 
used in orthotopic settings (Decrausaz et al., 2011; Sandoval et al., 2013). This means that 
the tumor cells are implanted at the sites HPV-related tumors naturally occur, in these cases 
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the oropharyngeal area (Sandoval et al., 2013) and the female vaginal area (Decrausaz et al., 
2011). The orthotopic localization offers the advantage that the immune response in these 
areas against HPV-related cancers can be studied in a setting that more closely resembles 
the natural situation. This is necessary since the immune environment in mucosal areas such 
as the genital tract has special properties regarding immune responses (Mestecky, 
Moldoveanu and Russell, 2005). T cells that have been primed in non-mucosal regions often 
do not readily migrate into mucosal areas since T cells need special homing signals to do so 
(also see 1.2.3). To be able to monitor the tumor growth of these orthotopic models it is 
necessary to engineer the tumor cells to express markers such as luciferase so that the tumor 
size can be inferred from the intensity of light radiating from the tumor cells after injection 
of luciferin.  
Transplantable tumor models like TC-1 or C3 offer many advantages such as fast availability, 
reliable tumor induction and relatively fast tumor growth (depending on the injected cell 
number). However, some characteristics of tumors that are important for studies of 
immunotherapeutic approaches, such as gradual induction of an immunosuppressive tumor 
microenvironment, are lost with transplantable models. Furthermore, the injection of cells 
always induces tissue destruction and thus also some inflammation at the injection site. All 
these characteristics reduce the translatability of results generated in a transplantable tumor 
model to the clinical setting in which a tumor gradually developed from healthy cells, which 
are always in contact and in communication with the cells and especially immune cells 
surrounding them.  
In addition to transplantable HPV tumor models, there are also transgenic HPV mouse 
models available (reviewed in (Santos et al., 2017)) such as the K14E6 and K14E7 strains 
(Brake et al., 2003). The process of carcinogenesis in these models very closely resembles 
the one observed after natural infection. Therefore, it is believed, that these models can 
more closely mimic the clinical situation. However, the slow process of carcinogenesis offers 
experimental hurdles that make these models less attractive than transplantable models. 
Although some of the models express HPV oncogenes in relevant sites, the expression of the 
oncogenes is widespread, thus inducing immune tolerance, rendering these models not 
useful for the testing of immunotherapeutic interventions (Trimble and Frazer, 2009). 
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All of the above-mentioned transplantable tumor models have in common that the cells 
express the HPV16 oncogene E7 on a H-2Db background. Therefore, all the tumor models 
present the immunodominant E7-derived H-2Db-restricted epitope E7/49-57 (RAHYNIVTF). 
This epitope has an outstanding role in immunotherapeutic interventions since it has been 
shown that apart from being very immunogenic, it is immunodominant in the H-2Db 
background. It has been observed that high frequencies of CD8+ T cells specific for this 
epitope can be induced by various vaccination approaches and that TC-1 tumors can be 
effectively killed by these vaccination-induced T cells (Berraondo et al., 2007; Cho et al., 
2013; Liu et al., 2014; Kranz et al., 2016). E7/49-57 is the only H-2Db-restricted epitope 
derived from E7 and there seem to be no E6-derived H-2Db-restricted epitopes (Peng et al., 
2004). However, since C57BL/6 mice also express H-2Kb, T cells of these mice can also 
respond to the H-2Kb-restricted HPV16 E6 epitope, E6/50-57 (YDFAFRDL) (Peng et al., 2004).  
1.3.1.2 C3H 
The C3H mouse strain, which expresses H-2Kk, H-2Dk, IAk and IEk (Charles River, 2018), was 
the first mouse strain in which a orthotopic model for HPV16-associated head and neck 
cancers was generated. The cell line AT-84 was isolated from a naturally-occurring oral 
squamous cell carcinoma and then transfected with HPV16 E7 and luciferase to generate 
AT-84 E7 (Paolini et al., 2013). 
1.3.2 MHC-humanized mice 
MHC-humanized mice are mice that carry one or several genetic modifications that result in 
an immune system that partly resembles the human immune system. This can be achieved 
by the expression of one or several human MHC molecules and this strategy is, in newer 
models, also expanded by knocking out the respective murine genes. The transgenes used 
are most often MHC alleles (e.g. HLA-A*0201) with a high frequency in the human population 
to allow generation of results relevant for a maximal number of people. Therefore, these 
mice are attractive tools to study immune responses specific for the human immune system 
in vivo (Pascolo 2005). MHC-humanized mice are used as animal models for diseases like 
arthritis (Kuon et al., 1997, 2004; Kollnberger et al., 2004), for the identification of epitopes 
from viruses (Drexler et al., 2003; Gallez-Hawkins et al., 2003) and malignant cells (Theobald 
et al., 1997; Berard et al., 2000; Carmon et al., 2000), but the most important utilization of 
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HLA-transgenic mice is the evaluation of vaccination approaches using human epitopes 
(Pascolo, 2005).  
In general, three generations of MHC class I-humanized mice are distinguished (reviewed in 
(Pascolo, 2005)). The mice of the first generation were transgenic for fully human MHC class I 
molecules. In these mouse models, there was only little evidence of murine T cells 
recognizing epitopes on HLA class I. After the discovery that the α3 domain of the human 
MHC class I heavy chain is not well recognized by murine CD8 co-receptor molecules (Irwin, 
Heath and Sherman, 1989), the chimeric HHM molecule (α1 human, α2 human, α3 murine, 
see Figure 9) was developed, with epitope-binding regions from different HLA-types (Kalinke, 
Arnold and Hämmerling, 1990; Vitiello et al., 1991; Alexander et al., 1997; Borenstein et al., 
2000). Mice of this second generation were able to successfully mount immune responses 
against epitopes presented on these modified HLA molecules. However, it was shown that 
there is a preferential induction of immune responses against murine epitopes (Firat et al., 
1999; Ureta-Vidal et al., 1999; Pajot, Pancré, et al., 2004) if the murine MHCs are still present. 
To overcome this problem, the third generation of HLA class I transgenic mice was 
developed. In these mice, immune responses are necessarily restricted by HLA class I since 
murine H-2 molecules are absent. The first attempts to generate mice without H-2 
expression focused on the knockout of β2m since most MHC class I molecules are only stable 
on the cell surface when they are in a complex with β2m and a peptide with affinity for the 
respective MHC binding groove (Williams et al., 1989; Murphy et al., 2016). Thus, the 
knockout of β2m led to the virtual absence of H-2K and H-2D on these cells (Koller et al., 
1990; Zijlstra et al., 1990). However, some researchers found that despite the lack of murine 
β2m, residual amounts of H-2Db could be detected on the cell surface (Allen et al., 1986; Bix 
and Raulet, 1992). After a knockout of the H-2Db gene, no protein could be detected on the 
cell surface (Pascolo, 2005). The H-2Db-/- β2m-/- mice were crossed with mice expressing the 
HHD molecule, giving rise to the HHD mouse strain (Pascolo et al., 1997). The HHD molecule 
is an HHM molecule with the α1 and α2 domain from HLA-A*0201 and the α3 from H-2Db, 
hence its name (α1 human, α2 human, α3 H-2Db) (Pajot, Michel, et al., 2004). To allow 
surface expression of this chimeric MHC class I molecule in the absence of endogenous 
murine β2m, Pascolo et al. made use of the results of Mage et al. (Mage et al., 1992) who 
had shown that a single chain MHC class I molecule containing the β2m represented a 
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functional MHC molecule. Therefore, the HHD molecule contains β2m that is covalently 
bound to the α1 domain of the MHC class I heavy chain via a 15 amino acid-long linker thus 
allowing the surface presentation of this chimeric HLA class I molecule independently of the 
endogenous murine β2m. The covalent linkage holds special importance since it prevents re-
expression of endogenous H-2 molecules.  
In recent days, Harada et al. generated further strains of 3rd generation HLA class I transgenic 
mice by introducing different chimeric monochain HLA molecules into the endogenous 
murine β2m locus. Reportedly, this led to HLA monochain expression concomitant with the 
disruption of the β2m gene resulting in abrogated surface expression of H-2Db and H-2Kb. 
This strategy abolishes the need for time-consuming cross-breeding with H-2Db and β2m KO 
mice and was used to generate four single knock-in (HLA-A*0201, HLA-A*0301, HLA-
A*2402,and HLA-A*3101) and one double knock-in mouse strain (HLA-A*2402/HLA-A*0301) 
(Harada et al., 2017).  
1.3.2.1 AAD mice 
AAD mice were bred on the C57BL/6 background and belong to the 2nd generation of 
humanized mice since they express a chimeric MHC class I heavy chain consisting of α1 and 
α2 (epitope binding regions) of HLA-A*0201 and the α3 domain of H-2Dd (Newberg et al., 
1996) (see Figure 9). The difference between these mice and 3rd generation transgenic mice 
is that AAD mice express the full set of H-2 molecules (class I and class II). Therefore, AAD 
mice can also mount immune responses against epitopes restricted by H-2Db, H-2Kb and IAb.  
Two different HPV16 tumor models have been developed for AAD mice: TC-1/A2 cells (Peng 
et al., 2006) and the HLF16 cell line (Eiben et al., 2002; Daftarian et al., 2007). TC-1/A2 cells 
are C57BL/6-derived TC-1 cells that were transduced with a vector encoding for a HHM (Dd) 
molecule (Newberg et al., 1996; Peng et al., 2006). In this MHC-humanized model, immune 
responses against the strongly immunogenic H-2Db-restricted E7/49-57 epitope are 
preferentially induced (Peng et al., 2006). Researchers tried to avoid this problem by 
excluding this epitope from their vaccine (Peng et al., 2006) but it cannot be excluded that T 
cells against E7/49-57 or against E6-derived epitopes such as E6/50-57 are generated by 
antigen spreading.  
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In contrast, HLF16 cells were generated by transducing heart fibroblasts of AAD mice 
(Newberg et al., 1996; Eiben et al., 2002) with HPV16 E6/E7 (with E7 lacking the E7/49-57 
epitope) and a constitutively activated version of h-ras to make the cells tumorigenic. The 
deletion of the immunodominant epitope was performed to make anti-tumor immune 
responses against this epitope impossible. Since the E6/E7 sequences do not contain any 
more H-2Db-restricted epitopes, immune responses against HPV16 epitopes cannot be 
mediated by this MHC allele in this tumor model. However, H-2Kb-restricted anti-HPV16 
immune responses (Peng et al., 2004), cannot be excluded by this approach.  
In addition, both models allow for H-2Db and H-2Kb-restricted immune responses against 
neoepitopes. At least the parental TC-1 cell line was found to have mutations resulting in 
H-2Db-restricted neoepitopes (Zottnick, 2017).  
 
Figure 9. AAD: Expression of MHC class I and class II 
AAD mice express all murine MHC molecules and, in addition, a HHM molecule (in this case called AAD) in 
which the epitope-binding regions are derived from the human HLA-A2 molecule. Therefore, immune 
responses in this mouse model can be restricted by murine MHCs and by HLA-A2. 
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1.3.2.2 A2.DR1 mice 
A2.DR1 mice (Altmann et al., 1995; Madsen et al., 1999; Pajot, Michel, et al., 2004) were also 
generated on the C57BL/6 background. These mice belong to a new class of humanized mice 
since they combine the advantages of 3rd generation HLA class I-humanized mice with the 
ones offered by MHC class II-humanized mice. A2.DR1 mice carry the transgene for the HHD 
molecule (antigen-binding domains of HLA-A*0201, α3-domain from H-2Db, covalently 
bound β2m, cf. Figure 10) as a MHC class I molecule. In addition, these mice express one of 
the most common MHC class II molecules in the human population, HLA-DR1, which consists 
of HLA-DRA1*0101 and HLA-DRB1*0101 (Altmann et al., 1995; Klitz et al., 2003). In A2.DR1 
mice, the gene coding for murine β2m was knocked out by the insertion of a neomycin 
resistance cassette and also the expression of H-2Db was abrogated by a direct knockout. 
Furthermore, the whole MHC class II locus is also knocked out (Madsen et al., 1999). Due to 
these sophisticated modifications, A2.DR1 mice only express MHC molecules that bind 
epitopes for two of the most common types of HLA class I and class II. Therefore, any 
immune responses are necessarily restricted by HLA-A2 or HLA-DR1. 
Experimental evaluation demonstrated that indeed fully functional immune responses (AB 
responses, CD4+ T cells, CD8+ T cells) against the same epitopes as in humans could be 
induced in A2.DR1 mice upon vaccination with a DNA vaccine (Pajot, Michel, et al., 2004).  
Two versions of A2.DR1 mice are available. In the older of the two versions (named in this 
thesis “A2.DR1old”) the absence of the murine MHC class II molecules is achieved by 
inactivation of the IAβb gene. However, it could be shown that unconventional 
HLA-DRα/H-2IEβb hybrid molecules may form at least in the absence of HLA-DRβ (Lawrance 
et al., 1989). In addition, in these mice only β2m but not H-2Db is knocked out. Therefore, 
the newer version of A2.DR1 mice was generated (in this work referred to simply as 
“A2.DR1”) in which the murine β2m, H-2Db and the whole MHC class II locus are knocked 
out. If not specifically stated otherwise, all work in this thesis was performed with the new 
version of A2.DR1 mice (A2.DR1). 
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Figure 10. A2.DR1: Expression of MHC class I and class II 
A2.DR1 mice express only two MHC molecules: The HHD molecule (MHC class I), which has the epitope-
binding domains α1 and α2 of HLA-A*0201 and the α3 domain of the murine H-2Db, covalently linked to 
human β2m. In addition, APCs express the fully human HLA-DR1 heterodimeric molecule (MHC class II). No 
murine MHC class I and MHC class II molecules are present on cells of these mice. Therefore, all immune 
responses are necessarily restricted by HLA-A2 and HLA-DR1. 
 
To date, there are only two syngeneic tumor models published for this mouse model. One 
model is the 2277NS cell line, a chemically induced sarcoma derived from A2.DR1old mice 
(Quandt, 2012). This cell line was transfected with a gene coding for an IDH1 mutation 
variant (Schumacher et al., 2014) or a gene for a histone mutation variant (Ochs et al., 2017), 
giving rise to two cell lines used for the validation of immunotherapeutic targets and 
immunotherapy approaches. The other cell line, SARC-L1, was generated by several in vivo 
passages of a naturally occurring sarcoma in A2.DR1old mice (Rangan et al., 2017).  
However, to date, no HPV16 tumor model has been published that is suitable for A2.DR1 
mice, which is a prerequisite for studying anti-tumor responses directed against HPV16 
antigens in this advanced and sophisticated mouse model of human immune responses. 
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2 Aims of the study 
The immunogenicity of human HPV16 E6/E7-derived, HLA-A2-binding epitopes can only be 
studied in genetically modified mice, such as the A2.DR1 mouse model. To improve 
translatability of our findings to the human setting, we chose this mouse model as a tool for 
the development of a therapeutic HPV16 vaccine.  
2.1 Genotyping for A2.DR1 mice 
A2.DR1 mice are a highly sophisticated mouse model since they underwent a multitude of 
genetic alterations to exhibit the HLA-A2+/HLA-DR1+, H-2- phenotype. To guarantee the 
genetic identity of our A2.DR1 breeding colony, the implementation of reliable genotyping 
methods was the first aim of this work. 
2.2 Generation of a HPV16 E6/E7-positive tumor model suitable for 
A2.DR1 mice 
Prior to this study, no HPV16 tumor model was available that allows the exclusive 
investigation of HLA-restricted anti-tumor responses. Therefore, the second aim of this work 
was the development of such a HPV16 tumor model that is suitable for A2.DR1 mice. This 
tumor model should be established on the basis of the syngeneic 2277NS tumor cell line by 
transduction with the HPV16 proteins E6 and E7.  
2.3 Epitope-specific vaccination against HPV16 E6/E7-positive tumors 
Due to HPV16 immune evasion mechanisms, focusing the immune response on epitopes 
actually presented by HPV16+ tumor cells is important to increase vaccine efficacy. Only 
some of the therapeutic vaccination approaches used so far allow the usage of selected 
epitopes. The third aim of this work was therefore to adapt the most promising vaccination 
approaches, which allow the use of defined epitopes, for the use with selected HPV16 
epitopes and compare them for immunogenicity and anti-tumor effects in the A2.DR1 mouse 
model. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Mice 
Strain Specifications Source 
A2.DR1  
Described in detail in 1.3.2.2. Mice were kept in 
individually ventilated cages in the mouse 
facility of the DKFZ 
Initial breeding stock kindly 
provided by the Institut 
Pasteur (Paris, France) 
 
3.1.2 Reagents 
Name Specifications Manufacturer 
Agarose NEEO   Roth, Karlsruhe 
Ammonium chloride   Merck, Darmstadt 
Carboxyfluorescein 
succinimidyl ester (CFSE) 
#C1157 
Thermo Fisher Scientific, 
Waltham, USA 
CD8+ isolation AB beads 
(untouched) 
#130-104-075 
Miltenyi Biotech, Bergisch 
Gladbach  
CellTrace Far Red (FR) #C34564 
Thermo Fisher Scientific, 
Waltham, USA 
Complete mini protease 
inhibitor cocktail 
#11 836 153 001 Roche, Basel, Switzerland 
CpG ODN1826 TLR grade 
Enzo Biochem, Farmingdale, 
USA 
DMSO (dimethylsulfoxide)  Sigma-Aldrich, Taufkirchen 
DNA ladder, 50 bp #SM1133 
Thermo Fisher Scientific, 
Waltham, USA 
DNA-primers  Sigma-Aldrich, Taufkirchen 
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Name Specifications Manufacturer 
DSPE-NHS COATSOME® FE-8080SU5 
NOF America Corporation, 
New York, USA 
DSPE-PEG2000-maleimide 
(1,2-distearoyl-3-sn-
phosphatidylethanolamine)-
PEG-maleimide 
Laysan Bio Inc., Arab, USA 
Ethanol  Sigma-Aldrich, Taufkirchen 
Ethylenediaminetetraacetic 
acid (EDTA) 
 Roth, Karlsruhe 
Formaldehyde 37 % 
Avantor Performance 
Materials, Center Valley, USA 
G418  Roth, Karlsruhe 
GelRed  Biotium, Fremont, USA 
Glycine   Sigma-Aldrich, Taufkirchen 
Ionomycin #10634 Sigma-Aldrich, Taufkirchen 
ISA51 Montanide ISA51 VG Seppic, Paris, France 
Methanol  Sigma-Aldrich, Taufkirchen 
OneComp eBeads #01-1111-42 
Thermo Fisher Scientific Ltd., 
Loughborgh, UK 
XS15 Synthetic variant of Pam3Cys 
Kindly supplied by Prof. Hans-
Georg Rammensee, 
University of Tübingen 
Phorbol myristate acetate 
(PMA) 
#P8139 Sigma-Aldrich, Taufkirchen 
Polyinosinic:polycytidylic acid 
(poly I:C) 
High molecular weight poly 
I:C, #vac-pic, used as stock 
solution of 1 mg/ml 
Thermo Fisher Scientific, 
Waltham, USA 
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Name Specifications Manufacturer 
Potassium bicarbonate 
(KHCO3) 
 Roth, Karlsruhe 
RNA for vaccination In vitro transcribed 
Kindly supplied by BioNTech, 
Mainz 
RNase-free water #T143.3 Roth, Karlsruhe 
RNase-free NaCl  5 M, #AM9760G 
Thermo Fisher Scientific, 
Waltham, USA 
Skim milk powder  Gerbu, Heidelberg 
Sodium acetate   Roth, Karlsruhe 
Sodium azide  AppliChem, Darmstadt 
Sodium chloride  Sigma-Aldrich, Taufkirchen 
Sodium dodecyl sulfate (SDS) #13904 Gerbu, Heidelberg 
Tris(hydroxymethyl)amino-
methane (TRIS) 
 AppliChem, Darmstadt 
Trypan blue #T10282 Sigma-Aldrich, Taufkirchen 
Tween20  Gerbu, Heidelberg 
Zombie Aqua dead cell dye used 1:200, #423101 Biolegend, San Diego, USA 
β-mercaptoethanol #11528926 
Thermo Fisher Scientific, 
Waltham, USA 
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3.1.3 Solutions  
Name Composition/specification Manufacturer 
ACK buffer 
155 mM NH4Cl 
10 mM KHCO3 
0.1 mM EDTA 
pH 7.2 – 7.4 
Self-produced 
Blocking solution WB 
5 % (w/v) milk powder 
1 % bovine serum albumin (BSA) 
Self-produced 
Enhanced chemiluminescence  
(ECL) solution 
#32209 
Thermo Fisher 
Scientific, Waltham, 
USA 
High sensitivity ECL solution #RPN2232 
GE Healthcare, 
Chalfont St Giles, 
UK  
Laemmli buffer (4x sample 
buffer) 
222 mM Tris (pH 6.8) 
3.5 % (w/v) SDS 
35 % (w/v) glycerol 
0.016 % (w/v) bromophenol blue 
10 % (v/v) β-mercaptoethanol 
Self-produced 
Lysis buffer 
10 mM Tris-HCL (pH 7.5) 
50 mM KCl 
2 mM MgCl2 
1 % (v/v) Triton X-100 
14.3 % (v/v) of protease inhibitor 
cocktail (1 tablet in 750 µl H2O) 
Self-produced 
MACS buffer 
0.5 % BSA 
2 mM EDTA 
in PBS  
Self-produced 
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Name Composition/specification Manufacturer 
Matrigel #734-0270 
BD, Franklin Lakes, 
USA 
Flow cytometry fix buffer 
1 % FCS 
2.5 % Formaldehyde 
in PBS 
Self-produced 
Running buffer for SDS-PAGE 
0.303 % (w/v) Tris 
1.44 % (w/v) glycine 
0.1 % SDS 
Self-produced 
Staining buffer 
0.1 % BSA  
0.1 % sodium azide 
in PBS 
Self-produced 
TAE buffer (50x) 
24.2 % (w/v) Tris  
2.05 % (w/v) C2H3NaO2  
1.85 % (w/v) EDTA  
pH 7.8 
Self-produced 
Transfer (semidry blot) buffer 
0.36 % (w/v) Tris  
1.728 % (w/v) glycine 
20 % (v/v) methanol  
Self-produced 
Water (double distilled)  Self-produced 
 
3.1.4 Cell lines  
Name Specifications Source 
2277NS cell line 
Chemically (MCA) induced sarcoma 
cell line derived from A2.DR1 mice 
(Schumacher et al., 2014) 
Kindly provided by Dr. Theresa 
Bunse (DKFZ) 
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Name Specifications Source 
PAP-A2 cell line 
2277NS cells transduced with 
HPV16 E6 (flag-tagged) and HPV16 
E7 (strep-tagged) 
Generated in the course of this 
PhD project  
(3.2.6 Generation of the PAP-
A2 cell line) 
CaSki cell line 
HPV16+ cell line derived from a 
cervical carcinoma 
(Pattillo et al., 1977) 
Purchased from ATCC 
 
3.1.5 Cell culture solutions 
Name Specifications Source 
2277NS medium 
(for PAP-A2 medium add 
2 µg/ml puromycin)  
85 % (v/v) DMEM 
10 % (v/v) FCS  
1 % (v/v) HEPES 
0.1 % (v/v) β-mercaptoethanol (50 mM)  
1 % (v/v) gentamicin (10 mg/ml) 
2 % (v/v) glutamine (200 mM) 
1 % (v/v) sodium pyruvate (100 mM) 
For 2 µg/ml puromycin add: 0.02 % (v/v) 
puromycin (10 mg/ml) 
Self-produced 
CaSki medium 
DMEM 
10 % (v/v) FCS  
Self-produced 
Dulbecco's Modified 
Eagle Medium (DMEM) 
#D5671 
Sigma-Aldrich, 
Taufkirchen 
Fetal calf serum (FCS) #10270 
Thermo Fisher 
Scientific, Waltham, 
USA 
Gentamicin #4-07F00-H 
Bioconcept, Allschwil, 
Switzerland 
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Name Specifications Source 
HEPES #15630080 
Thermo Fisher 
Scientific, Waltham, 
USA 
L-glutamine #MT25005CI Corning, Corning, USA 
Phosphate buffered 
saline (PBS) 
137 mM NaCl 
2.7 mM KCl 
12 mM PO4 
pH 7.2-7.4 
Self-produced 
Puromycin P9620-10ML 
Sigma-Aldrich, 
Taufkirchen 
Roswell Park Memorial 
Institute medium (RPMI 
1640)  
#R0883 
Sigma-Aldrich, 
Taufkirchen 
Sodium pyruvate #MT25000CI Corning, Corning, USA 
T cell medium 
90 % (v/v) αMEM 
10 % (v/v) FCS 
1 % (v/v) glutamine (200 mM) 
0.1 % (v/v) β-mercaptoethanol  
(50 mM) 
Self-produced 
Trypsin-EDTA #T3924 
Sigma-Aldrich, 
Taufkirchen 
αMEM #M4526 
Sigma-Aldrich, 
Taufkirchen 
β-mercaptoethanol  
(cell culture) 
#31350-010 
Thermo Fisher 
Scientific, Waltham, 
USA 
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3.1.6 Kits 
Name Specification Manufacturer 
BD Cytofix/Cytoperm™ kit #554714 BD, Franklin Lakes, USA 
Detergent compatible (DC) protein 
assay kit 
#5000116 Biorad, Hercules, USA 
DirectPCR Lysis Reagent Tail kit #31-101-T VWR, Darmstadt 
peqGold Gel Extraction kit #732-2777 VWR, Darmstadt 
QIAmp DNA Mini kit #51304 Qiagen, Hilden 
REDTaq kit #D4309 
Sigma-Aldrich, 
Taufkirchen 
 
3.1.7 Proteins 
Name Specifications Manufacturer 
Bovine serum albumin 
(BSA) 
 
GE Healthcare, Chalfont St 
Giles, UK 
BSA standard  BioRad, Hercules, USA 
Murine interferon-γ (IFN-γ)  #34-8311-82 
Thermo Fisher Scientific, 
Waltham, USA 
Protein marker  
Precision plus Protein™ 
standards kaleidoscope (10-
250 kDa) 
BioRad, Hercules, USA 
Proteinase K 20 mg/ml, #1014023 Qiagen, Hilden 
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3.1.8 Peptides 
Peptide Sequence Supplier 
E7/7-15 TLHEYMLDL 
DKFZ peptide production 
facility 
E7/11-19 YMLDLQPET 
DKFZ peptide production 
facility 
E7/82-90 LLMGTLGIV 
DKFZ peptide production 
facility 
E6/25-33 ELQTTIHDI 
DKFZ peptide production 
facility 
SLHEYMLDL SLHEYMLDL 
DKFZ peptide production 
facility 
Survivin96-104 (Surv) LMLGEFLKL 
DKFZ peptide production 
facility 
PADRE 
AK-Cha-VAAWTLKAAA 
(Cha = Cyclohexylalanin) 
DKFZ peptide production 
facility 
E7 pool 
pool of 22 peptides (15mers with 
11 aa overlap) 
JPT Peptide Technologies 
GmbH, Berlin 
Pam2KFVM-E7/11-19 see Figure 27 
Peptide Specialty 
Laboratories GmbH, 
Heidelberg 
Pam1KFVM-E7/11-19  
Department of Nuclear 
Medicine, Heidelberg 
University Hospital, 
Heidelberg 
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Peptide Sequence Supplier 
Stea2KFVM-E7/11-19  
Department of Nuclear 
Medicine, Heidelberg 
University Hospital, 
Heidelberg 
Lipo-PEG-peptides (LPPs) see Figure 29 
Department of Nuclear 
Medicine, Heidelberg 
University Hospital, 
Heidelberg; 
Peptides & elephants, 
Hennigsdorf 
 
3.1.9 Antibodies  
Name Clone/specification Dilution Provider 
α-alpha-tubulin #T6074 1:5000 
Sigma-Aldrich, 
Taufkirchen 
αCD19-PE-Cy5.5 #RM7718 1:100 
Thermo Fisher 
Scientific, Waltham, 
USA 
αCD3-PE-Cy7 #552774 1:100 
BD, Franklin Lakes, 
USA 
αCD4-FITC  #553047 1:200 
BD, Franklin Lakes, 
USA 
αCD8-PE #sc-53473 PE 1:100 
BD, Franklin Lakes, 
USA 
αE6 (HPV16) E6-6F4 1:1000 
Euromedex, 
Souffelweyersheim, 
France 
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Name Clone/specification Dilution Provider 
αE7 (HPV16) NM2 1:1000 
Kindly provided by 
Prof. M. Müller, DKFZ 
αHLA-A2-FITC BB7.2, #551285 1:100 
BD, Franklin Lakes, 
USA 
αIFN-γ-APC #562018 1:200 
BD, Franklin Lakes, 
USA 
α-mouse-HRP #62-6520 1:5000 
Thermo Fisher 
Scientific, Waltham, 
USA 
αTNF-α-eFluor450 #48-7321-82 1:100 
Thermo Fisher 
Scientific, Waltham, 
USA 
 
3.1.10 Plastics and consumables 
Name Specifications Manufacturer 
Cell culture flasks  
25 cm2, 75 cm2, 
150 cm2 
TPP, Trasadingen, Switzerland 
Cell culture plates 96-well TPP, Trasadingen, Switzerland 
Cell strainer  70 µm Merck, Darmstadt 
Eppendorf tubes  0.5 ml, 1.5 ml, 2 ml Eppendorf, Hamburg 
Eppendorf tubes (low DNA-
binding) 
#30108078 Eppendorf, Hamburg 
FACS tubes round bottom BD, Franklin Lakes, USA 
Falcon tubes 15 ml, 50 ml BD, Franklin Lakes, USA 
Hollow needle 20G, 26G, 27G Braun, Melsungen 
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Name Specifications Manufacturer 
LS+ Positive MACS column #130-042-401 
Miltenyi Biotech, Bergisch 
Gladbach 
MACS SmartStrainer, 70 μM #130-098-462 
Miltenyi Biotech, Bergisch 
Gladbach 
Mini-protean TGX AnykD™ 
polyacrylamide gel 
#4569036 BioRad, Hercules, USA 
Pipette tips small, medium, big Starlab, Hamburg  
Scalpel No. 20 Feather, Osaka, Japan 
Sterile filter low binding, 0.22 µm Merck, Darmstadt 
Syringe connector #MX494P1 
Smiths Medical, Minneapolis, 
USA 
Syringes  1 ml, 3 ml  Braun, Melsungen 
Whatman chromatography paper #88600 
GE Healthcare, Chalfont St 
Giles, UK 
 
3.1.11 Laboratory equipment, machines & instruments 
Name Specifications Manufacturer 
Anesthesia device (isoflurane) 
Isoflurane Vet. Med. 
Vapor 
Dräger Medizintechnik GmbH, 
Lübeck 
Analytical balance  Ohaus, Nänikon, Switzerland 
Automated cell counter 
Countess® Automated 
Cell Counter 
Thermo Fisher Scientific, Waltham, 
USA 
Centrifuge (table top), #5418 Eppendorf, Hamburg 
Centrifuge  (table top), #5407 Eppendorf, Hamburg 
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Name Specifications Manufacturer 
Centrifuge  
(falcons, plates), 
Multifuge® 16R 
Heraeus, Hanau 
Chemiluminescence reader  
INTAS ECL Chemocam 
Imager 
Intas Science Imaging Instruments, 
Göttingen 
Digital calipers  Hogetex, Nieder-Olm 
Electrophoresis chamber 
(agarose gels) 
Owl Easycast B2 
Owl Separation Systems, 
Portsmouth, USA 
Electrophoresis chamber 
(SDS-PAGE) 
Mini-PROTEAN® Tetra 
Cell 
Biorad, Hercules, USA 
Flow Cytometer FACS Canto II BD, Franklin Lakes, USA 
Gel analyzer (agarose gels) Gel Jet Imager 2006 Intas, Göttingen 
Heating shaker 
Eppendorf 
Thermomixer 
Eppendorf, Hamburg 
Incubator (cell culture) Heracell 150i 
Thermo Fisher Scientific, Waltham, 
USA 
Laminar flow hood 
SterilGard® Class II Typ 
A B3 
The Baker Company, Sanford, USA 
Light microscope 
Wilovert Standard 30 
microscope 
Hund Wetzlar, Wetzlar 
Liquid nitrogen tank 
Locator 8 plus 
ARPEGE110 NU 
Barnstead/Thermolyne, Dubuque, 
USA 
Cryopal, Bussy-Saint-Georges, 
France 
MACS magnet Quadro MACS Miltenyi Biotech, Bergisch Gladbach 
Magnetic stirrer MR-Hel Standard Heidolph Instruments, Schwabach 
Mr. Frosty freezing container #9400945 Faust, Klettgau 
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Name Specifications Manufacturer 
Multilable plate reader 
Multiskan™ FC 
microplate photometer 
Thermo Fisher Scientific, Waltham, 
USA 
Nano Drop  ND-1000 VWR, Darmstadt 
PCR cycler 
PTC-200 
TProfessional Trio48 
MJ Research, Canada 
Biometra, Göttingen 
pH Meter 
MP220 InLab 
Microelectrode 
Mettler Toledo, Glostrup, Denmark 
Pipetboy Pipetboy acu Integra Biosciences, Biebertal 
Pipettes  
2 µl, 10 µl, 20 µl, 
200 µl, 1,000 µl 
Gilson, Middleton, USA 
Platform shaker 
STR6 
Rotamax 
3013 
Stuart Bibby Scientific, 
Staffordshire, UK 
Heidolph Instruments, 
Schwabach 
GFL, Burgwedel 
Power supply for 
electrophoresis 
EPS500-400, EPS3500 
MP 250V  
PowerPac300 
Pharmacia, Uppsala, Sweden 
MS Major Science, Saratoga, USA 
BioRad, Hercules, USA 
Rolling shaker CAT RM5 Zipperer, Staufen 
Surgical tweezers and scissors  Dimeda, Tuttlingen 
Thermomixer Thermomixer compact Eppendorf, Hamburg 
Trans-blot semidry transfer 
cell 
 Biorad, Hercules, USA 
Vortexer Vortex-Genie 2 Scientific Industries, Bohemia, USA 
Water bath  GFL, Burgwedel 
 
 Materials and Methods 
  
 
 
46 
 
3.1.12 Software 
Software Manufacturer 
FACSDIVA v6.1.2 BD, Franklin Lakes, USA 
Flowjo 10 Treestar, Ashland, USA 
Graph Pad Prism 5 GraphPad Software Inc., La Jolla, USA 
ImageJ (Schneider, Rasband and Eliceiri, 2012) 
Inkscape 0.91 The Inkscape Team, www.inkscape.org 
Mendeley  Elsevier B.V., Amsterdam, Netherlands 
Microsoft Office 2010 Microsoft Corporation, Redmond, USA 
SnapGene GSL Biotech LLC, Chicago, USA 
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3.2 Methods 
3.2.1 Polymerase chain reaction (PCR) 
The polymerase chain reaction allows the multiplication of a given stretch of DNA by using 
parts of the cellular replication machinery (Saiki et al., 1985; Mullis et al., 1986). The 
components of a PCR reaction are: Template DNA, nucleotides, primers and heat-stable DNA 
polymerase (often from thermophilic bacteria such as Thermus aquaticus, abbreviated as 
Taq) in a buffer solution providing suitable conditions for the DNA polymerase. The primers 
are short fragments of DNA that bind to their complementary DNA stretch on the template 
DNA. To amplify specific template DNA sequences, one primer that binds upstream (forward 
(F) primer) and one that binds downstream (reverse (R) primer) of the sequence of interest 
is used.  
PCR reactions follow steps with defined temperatures: Denaturation of the double-stranded 
DNA into single-strands at 94 °C, primer annealing at a primer-specific temperature and 
elongation at a polymerase-specific temperature (for the Taq polymerase 72 °C). One series 
of denaturation, annealing and elongation completes one cycle. Often, an initial 
denaturation step for 7 min at 94 °C ensuring complete initial denaturation and a terminal 
elongation step for 7 min at 72 °C ensuring complete synthesis of all fragments are included 
in the PCR program.  
In the elongation step, the DNA polymerase elongates the primers by adding nucleotides to 
the 3’ end of the primer. After one cycle, the number of DNA copies has doubled. Therefore, 
the number of DNA fragments increases exponentially with the number of cycles, thus 
allowing also the detection of minuscule amounts of DNA. For the detection of the amplified 
fragments, the fragments are first separated by size during an electrophoretic migration 
through an agarose gel. Smaller fragments migrate faster through the pores of the gel than 
larger fragments. DNA migrates to the plus pole due to its negatively charged phosphate 
backbone.  
Usually the agarose gel is supplemented with ethidium bromide. Ethidium bromide 
intercalates in DNA (Waring, 1965) which induces a change in its fluorescence spectrum upon 
exposure to UV light (Le Pecq and Paoletti, 1966). This allows the detection of the DNA bands 
under UV light.  
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3.2.2 A2.DR1 genotyping by PCR 
Animals used for breeding were routinely genotyped by PCR to monitor the genetic identity 
of the breeding colony. Specific primers were used to either verify the existence of a 
transgene in the genomic DNA or the absence of a gene that was knocked out. Mice were 
tailed at weaning and the tails were lysed with the DirectPCR Lysis Reagent Tail kit (with 
proteinase K (0.2 mg/ml)) for 3-16 h at 55 °C in a rotating heater. Proteinase K was 
inactivated for 45 min at 85 °C and the lysate was subsequently used as a template for the 
genotyping PCR reactions using REDTaq® ready mix, which contains nucleotides, buffer 
solutions and the REDTaq® DNA polymerase. PCR reactions were carried out according to 
the manufacturer’s instructions with 6.75 µl REDTaq® mix, 0.5 µl template, and 0.125 µl of 
each primer, topped up to 12.75 µl with DNase free water supplied with the REDTaq® Ready 
mix. 
Primers and PCR programs are depicted in Table 1. PCR products were analyzed for correct 
size by visualizing them in agarose gels after gel electrophoresis. TAE buffer-based 2 % 
agarose gels were used for all analyses except for the H-2Db WT PCR product, which was 
analyzed in 1 % gels due to the longer fragments amplified by this PCR. The agarose gels were 
supplemented with 10 µl/100 ml GelRed as a safer and more sensitive replacement for 
ethidium bromide.  
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Table 1. PCR programs and primers for A2.DR1 genotyping 
PCR name 
PCR 
product 
Primers Primer sequences PCR program 
HHD 400 bp 
HHD F 
CAT TGA GAC AGA GCG 
CTT GGC ACA GAA GCA G 
94°  7 min 
94°  0.5 min 
66°  0.5 min 
72°  1 min 
72°  4 min 
4°  ∞ 
HHD R 
GGA TGA CGT GAG TAA 
ACC TGA ATC TTT GGA 
GTA CGC 
HLA-DRA1 153 bp 
HLA DRA 1 F 
CTC CAA GCC CTC TCC 
CAG AG 
94°  7 min 
94°  0.5 min 
66°  0.5 min 
72°  1 min 
72°  4 min 
4°  ∞ 
HLA DRA 1 R 
ATG TGC CTT ACA GAG 
GCC CC 
HLA-DRB1 228 bp 
HLA DRB 1 F 
TTC TTC AAC GGG ACG 
GAG CGG GTG 
94 °  5 min 
94 °  1 min 
57 °  1 min 
72 °  2 min 
72 °  5 min 
4 °  ∞ 
HLA DRB 1 R 
CTG CAC TGT GAA GCT 
CTC ACC AAC 
β2 
microglobulin 
KO: 600 bp 
WT: 270 bp 
ß2m0 
CTG AGC TCT GTT TTC GTC 
TG 
94 °  5 min 
94 °  1 min 
57 °  1 min 
72 °  2 min 
72 °  5 min 
4 °  ∞ 
ß2m4 
CTT AAC TCT GCA GGC 
GTA TG 
Neo 55 A 
CCT GCC GAG AAA GTA 
TCC A 
x 40 
x 40 
x 40 
x 40 
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PCR name 
PCR 
product 
Primers Primer sequences PCR program 
H-2Db KO 340 bp 
H2 DB KO F 
CAG CAG AAA CAT ACA 
AGC TGT C 
94 °  7 min 
94 °  1 min 
60 °  2 min 
72 °  2 min 
72 °  7 min 
4 °  ∞ 
H2 DB KO R 
AAC GAT CAC CAT GTA 
AGA GTC AGT 
H-2Db WT 1600 bp 
Db-WT-F SMO 
130 
ATT GGG AGC GGG AAA 
CAC AG 
95 °  5 min 
95 °  30 sec 
64 °  40 sec 
72 °  70 sec 
72 °  10 min 
4 °  ∞ 
Db-WT-R SMO 
131 
TCC GAC CCC AAG TCA 
CAG 
MHC class II 
KO: 209 bp 
WT: 178 bp 
oIMR1020 
Mutant 
CGG AAG TGC TTG ACA 
TTG G 
94 °  3 min 
94 °  30 sec 
61 °  45 sec 
72 °  1 min 
72 °  3 min 
4 °  ∞ 
oIMR1021 
Mutant 
GTA TTG ACC GAT TCC 
TTG CG 
oIMR1273 WT 
AAC CTT CAG GAT CTG 
TGA TCC 
oIMR1274 WT 
GTG GCT GTT GCC TTA 
AGA CC 
 
3.2.3 Mouse experiments 
Mice were kept in individually ventilated cages in the DKFZ animal facility. Prior to an 
experiment, age-matched groups of female mice (7-15 weeks old) were selected and pooled 
in experimental cages. Group sizes ranged from 3 mice for the testing of individual tumor 
cell clones, to usually 6 mice for the comparison of vaccine formulations to up to 15 mice in 
anti-tumor vaccination experiments. 
3.2.4 Cell culture 
Newly acquired cell lines were tested for mycoplasma contamination and cell line 
authentication (done by Multiplexion, Immenstaad) was performed. Cell culture was 
x 40 
x 35 
x 35 
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performed in a laminar flow hood. Cells were cultured at 37 °C, 95 % relative humidity and 
5 % CO2 in an incubator. CaSki, 2277NS and PAP-A2 cell lines exhibit adherent growth. To 
subculture these cell lines, cells have to be detached by incubation with Trypsin-EDTA. 
Trypsin enzymatically digests cell adhesion molecules and EDTA chelates Ca2+, thus 
weakening Ca2+-dependent cell-cell and cell-matrix interactions. For this, the medium was 
taken off and cells were washed once with phosphate buffered saline (PBS) to remove 
residual medium containing large quantities of proteins. This was done because the proteins 
in the medium slow down the enzymatic digestion of cell adhesion molecules after addition 
of a trypsin solution. Sufficient amounts of Trypsin-EDTA to cover the growth area were 
added to the cells. After all cells were detached, medium containing fetal calf serum (FCS) 
was added to provide excess protein and thus to slow down the enzymatic digestion of 
cellular components. Cells were resuspended, counted with a Countess® automated cell 
counter, transferred to a tube and spun down (422 g, 4 min, RT). Subsequently, the medium 
containing the trypsin solution was decanted and cells were taken up in fresh medium and 
subcultured or used in experiments. 
3.2.4.1 Freezing and thawing of cells 
For freezing, cells were harvested by trypsin detachment and taken up in the respective 
medium for the cell line supplemented with 50 % FCS and 10 % DMSO as a cryoprotectant 
that reduces the formation of harmful ice crystals (freezing medium). The medium 
containing the cells was transferred to cryovials. Cryovials were collected in a freezing 
container (Mr. Frosty) that ensures a constant cooling rate of 1 °C per minute when stored 
at -80 °C. The slow rate of temperature reduction also decreases the generation of ice 
crystals in the cells. After 1 day at -80 °C, cells were transferred from -80 °C to liquid nitrogen 
for long term storage. 
For thawing of cells, a cryovial was taken out of the liquid nitrogen storage and thawed in a 
water bath, which was preheated to 37 °C. Once the ice was thawed, the medium containing 
the cells was transferred to a tube containing 20 ml of the respective medium and inverted 
once. Cells were immediately spun down (422 g, 4 min, RT) and the medium containing 
DMSO was decanted. Cells were taken up in the respective medium and seeded in cell 
culture flasks or plates. 
 Materials and Methods 
  
 
 
52 
 
3.2.4.2 Treatment of cells with IFN-γ 
Cells upregulate the expression of MHC class I molecules upon stimulation with IFN-γ. To test 
the ability of the 2277NS cell line to respond adequately to this stimulus, cells were cultured 
to a density of 60-70 %. Subsequently, the medium was taken off and replaced with 2277NS 
medium containing 100 ng/ml murine IFN-γ. The cells were cultured for 48 h, harvested and 
stained with fluorophore-coupled ABs specific for HLA-A2. 
3.2.5 Flow cytometry 
Flow cytometry allows the rapid analysis of a large number of single cells. In this technique, 
cells are passed by a laser as single cells in a liquid stream. The laser beam is scattered when 
hitting the cell and cellular characteristics such as cell size and granularity can be inferred 
from the scatter pattern. Additionally, fluorophore-coupled ABs can be used to stain live or 
dead cells for surface markers or permeabilized cells for intracellular molecules. Unstained 
cells and cells stained with a suitable isotype control were used to assess autofluorescence 
and background AB-binding of the examined cells and to adjust the sensitivity of the 
detectors. 
3.2.5.1 Staining of adherent cells for assessment of HLA-A2 surface expression by 
flow cytometry  
Cells were harvested by trypsin detachment, washed once in PBS and taken up in 50 µl 
staining buffer (1 % FCS in PBS). 0.5 µl of FITC-coupled anti-HLA-A2 AB were added and the 
cells were incubated at 4 °C for 20 min in the dark. After incubation, cells were washed three 
times with 200 µl staining buffer and were taken up in 200 µl staining buffer for direct 
analysis by flow cytometry. Analysis was performed using a FACS Canto II which was provided 
and maintained by the DKFZ flow cytometry core facility. 
3.2.5.2 Staining of non-adherent cells for flow cytometry analysis 
Non-adherent cells were stained for surface and intracellular protein expression and 
subsequently analyzed by flow cytometry as described in 3.2.17. 
3.2.6 Generation of the PAP-A2 cell line 
2277NS cells (Quandt, 2012; Schumacher et al., 2014) were cultured in 2277NS medium and 
transduced with the lentiviral vector pWPI HPV16 E6/E7 (Figure 16) by Ruwen Yang (DKFZ). 
Successfully transduced cells were selected with 2277NS medium containing 2 µg/ml 
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puromycin. Surviving cells were stained for HLA-A2, and HLA-A2-high cells were single cell-
sorted in 96-well flat bottom plates. Clones were tested for E6, E7 and HLA-A2 expression 
(for detailed results see 4.2). Subsequently, clonal cell lines were each injected into three or 
four A2.DR1 mice (0.75x106 - 1x106). Only one of the cell injections resulted in tumor growth. 
The respective clone, IVA2, exhibited medium expression of HLA-A2, medium E6 and 
medium E7 expression compared to the other clonal cell lines. The IVA2-derived tumor was 
excised aseptically, mashed with the help of a metal sieve and taken up in 2277NS medium 
supplemented with 2 µg/ml puromycin. The cell line growing from this outgrowing tumor 
was called PAP-A2. The HPV16 E6/E7 sequence identity in PAP-A2 cells was confirmed by 
DNA sequencing (performed by GATC-Biotech, Konstanz). For this, genomic DNA of PAP-A2 
cells was isolated with the QIAmp DNA Mini kit from a cell pellet. To generate genomic DNA, 
cells were lysed, the DNA was precipitated and bound to a silica gel matrix. After washing, 
the DNA was eluted from the matrix by the addition of water. The E6/E7 DNA was PCR-
amplified with the PCR programs and primers depicted in Table 2. After confirming the 
correct length of the PCR products through agarose gel (2 %) electrophoresis, the gel bands 
containing the fragments of interest were cut out and the DNA was extracted from the 
agarose gel. For this, the gel piece was dissolved by heating and the DNA was bound to a 
silica column. After washing, DNA was eluted with water. This DNA was sent to GATC Biotech 
and served as a template for the sequencing reaction with the primers depicted in Table 2. 
The sequence of the pWPI HPV16 E6/E7 vector was compared to the sequencing results with 
the help of the SnapGene® software. Both sequences were found to be identical.  
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Table 2. PCR programs and primers for HPV16 E6/E7 sequence authentication 
PCR name 
PCR 
product 
Primers Primer sequences PCR Program 
HPV16 E6 932 bp 
3Flag-P2A-pWPI-F 
TAAGCAACGCGTGATTACAA
GGATGACGACGAT 
94°  5 min 
94°  1 min 
54.3°  0.5 min 
72°  2 min 
72°  5 min 
4°  ∞ 
 
IRES rev CCGCCTTTGCAGGTGTATCT 
HPV16 E7 640 bp 
Human elongation 
factor-1a promoter 
(EF1a F) 
TCAAGCCTCAGACAGTGGTT
C 
94°  5 min 
94°  1 min 
66°  0.5 min 
72°  1 min 
72°  5 min 
4°  ∞ 
 
Strep-P2A-pWPI-R4 
TTTTTCGAACTGCGGGTGGCT
CCACGATCCACCTCCCGATCC 
 
3.2.7 SDS-PAGE and Western blot 
SDS (sodium dodecyl sulfate) polyacrylamide gel electrophoresis (PAGE) (Laemmli, 1970) 
allows the separation of proteins according to their size in a polyacrylamide gel. In a SDS-
PAGE, the migration distance in the polyacrylamide gel is dependent on the size of the 
respective protein since negatively charged SDS is bound to all amino acids of a protein and 
thus masks the natural charge of the amino acids.  
3.2.7.1 Preparation of cell extracts for SDS-PAGE 
For the preparation of cell extracts suitable for SDS-PAGE, cultured cells were detached by 
trypsin treatment, washed and lysed with lysis buffer (80 µl/106 cells). For protein samples 
from tumor tissue, a tumor was excised and homogenized in lysis buffer (20 µl/µg of tumor 
tissue). The samples were kept on ice and vortexed shortly every 2 minutes for 20 min. 
Subsequently, lysates were cleared of cell debris by centrifugation (20.817 g, 10 min, 4 °C). 
The protein-containing supernatant was mixed with 4 x Laemmli buffer containing β-
mercaptoethanol as a reducing agent, which is breaking up disulfide bonds, and was heated 
x 40 
x 40 
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for 5 min at 95 °C to fully denature all proteins. Subsequently, protein samples were stored 
at -80 °C or directly used for SDS-PAGE.  
3.2.7.2 Detergent compatible (DC) protein assay 
To determine the protein concentration in a sample before the addition of Laemmli buffer, 
the DC protein assay kit was used. In this assay, the protein concentration is derived from a 
color change induced by the reactions of the amino acids tyrosine, tryptophan, cysteine and 
histidine with copper tartrate and Folin reagent. The color intensity induced by the proteins 
in the samples to be analyzed is compared to that of a standard curve generated with BSA 
samples of known concentration.  
3.2.7.3 SDS-PAGE and Western blot  
In this study, the SDS-PAGE system according to Laemmli (Laemmli, 1970) with a Tris-glycine 
buffer was used. Usually, 15 µg of protein were loaded into the pockets of the 
polyacrylamide gels and the gel was run at 300 V with maximal current for 15-20 minutes. 
5 µl of a protein molecular weight marker were used for every gel. After separation of the 
protein bands via SDS-PAGE, the proteins were immobilized on a methanol-activated PVDF 
membrane by Western blot. For this process, the proteins were electrophoretically 
transferred to the PVDF membrane in a semidry blot chamber for 25 min at 150 mA and 
maximal voltage. The proteins were thus fixed to the membrane via dipole and hydrophobic 
interactions.  
Subsequently, detection of proteins via specific ABs was performed. To saturate protein 
binding sites on the membrane, the membrane was blocked for 45 min in blocking solution 
(5 % low-fat milk powder/1 % BSA/0.2 % Tween-20 in PBS). For the detection of proteins 
immobilized on the PVDF membrane, the membrane was incubated with the respective 
specific primary AB in blocking solution for 1 h at RT or overnight at 4 °C on a rocking shaker. 
After washing three times for 5 min on a rocking shaker with 0.2 % Tween-20 in PBS (PBS-T), 
the secondary ABs coupled to horseradish peroxidase diluted in blocking solution was added 
and incubated for 1 h at RT on a rocking shaker. After 3 subsequent washes for 5 min at RT 
with PBS-T, the Western blot was developed. For this, the membranes were shortly washed 
in PBS, excess PBS was taken off by dabbing the membrane’s edges on tissue paper and 
500 µl of ECL solution were spread on the membrane. To allow the visualization of the low 
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protein levels of E6 and E7 bands, high sensitive ECL solution was used for these Western 
blots. Since the expression levels of the loading control protein α-tubulin is much higher, 
normal ECL solution gave rise to sufficient chemiluminescent reaction to allow detection of 
the emitted light signal. The light signal was detected with a chemiluminescence reader. 
Quantification of band intensities was performed with ImageJ software.  
3.2.8 Peptide and peptide conjugate synthesis 
Reference sequences for HPV16 E6 (NCBI Reference Sequence: NC_001526.2) and E7 (NCBI 
Reference Sequence: NC_001526.2) were used as shown in (8 Annex). 
3.2.8.1 Peptide synthesis 
Peptides were produced by the DKFZ Peptide Production Unit (Prof. Stefan Eichmüller, GMP 
& T Cell Therapy Unit, DKFZ, Heidelberg) with a purity of > 95 %. The peptides were 
synthesized by solid phase synthesis using the Fmoc strategy (Merrifield, 1963; Carpino and 
Han, 1972). For this, preloaded Wang-Resins and 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) as a coupling agent were used with a fully 
automated multiple Syro II synthesizer (MultiSyn Tech, Germany). Purification took place by 
preparative high-performance liquid chromatography (HPLC) with 0.1 % trifluoroacetic acid 
in water (A) and 80 % acetonitrile in water (B). Elution was achieved by a successive linear 
gradient of 25 % B to 80 % B in 30 min at a flow rate of 10 ml/min. The purified peptides 
were lyophilized and taken up in DMSO to a final concentration of 50 mM.  
3.2.8.2 Synthesis of Pam2-E7/11-19 
For the synthesis of Pam2-E7/11-19 (done by Peptide Specialty Laboratories GmbH, 
Heidelberg), the lysine in the peptide KFVMYMLDLQPET was palmitoylated on its amino-
groups. The linker KFVM was selected since this linker had already been successfully used by 
Cho et al. (Cho et al., 2013). The resulting product was difficult to purify, therefore its final 
purity was only estimated to be approximately 20 %. 
3.2.8.3 Synthesis of Pam1-E7/11-19 
The synthesis of Pam1-E7/11-19 was done by Dr. Max Sauter (Department of Nuclear 
Medicine, Heidelberg University Hospital, Heidelberg, Germany). For this synthesis, the 
lysine in the peptide KFVMYMLDLQPET was palmitoylated on one of its amino groups. The 
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product was lyophilized and subsequently purified by preparative HPLC. The purity of this 
compound was calculated on the basis of HPLC analysis to be approximately 95 %. 
3.2.8.4 Synthesis of Stea2-E7/11-19 
The amphiphilic peptide Stea2-E7/11-19 was synthesized by Dr. Philipp Uhl and Dr. Max 
Sauter (Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, 
Germany) by coupling DSPE-NHS (N-(Succinimidyloxy-glutaryl)-L-α-
phosphatidylethanolamine, distearoyl) to the N-terminal lysine of KFVMYMLDLQPET. For 
this, DSPE-NHS and the peptide were dissolved in a 3:1 (v/v) mixture of DMSO/PBS pH 8.16. 
Both compounds were mixed in the stoichiometric ratio of 1:2 and stirred overnight at RT 
for coupling. The product was lyophilized and subsequently purified by preparative HPLC. 
The purity of this compound was calculated on the basis of HPLC analysis to be approximately 
70 %. 
3.2.8.5 Synthesis of LPPs 
The synthesis of the lipo-PEG-peptides (LPPs) was performed by Dr. Philipp Uhl and Dr. Max 
Sauter and the company peptides & elephants (Hennigsdorf, Germany). N-terminally 
cysteinylated peptides were dissolved in a 2:1 (v/v) mixture of PBS pH 5.5 and acetonitrile. 
DSPE-PEG-maleimide ((1,2-distearoyl-3-sn-phosphatidylethanolamine)-PEG-maleimide) was 
dissolved in a 1:1 mixture of DMSO/PBS pH 5.5. Coupling of peptides to DSPE-PEG-maleimide 
was done by mixing both solutions in a stoichiometric ratio of 2:1 (peptide/DSPE-PEG-
maleimide) and stirring overnight at RT. The product was lyophilized and subsequently 
purified by preparative HPLC. The purity of the final compound was assessed by HPLC and 
HPLC-MS and was usually higher than 70 %. LPPs were dissolved in DMSO to a final 
concentration of 25 mM and stored in aliquots at -80 °C. 
3.2.9 mRNA production 
In vitro transcribed mRNA was produced by the company BioNTech (Mainz, Germany) as 
described in (Kreiter et al., 2007). In brief, “pST1-A120 based plasmids were linearized 
behind the poly(A) tail, purified by phenol chloroform extraction and sodium acetate 
precipitation and used as templates for in vitro transcription (IVT) with Message-Machine Kit 
(Ambion, Austin, USA). The RNA concentration and quality were assessed by 
spectrophotometry and agarose/formaldehyde gel electrophoresis” (Kreiter et al., 2007). 
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3.2.10 Vaccination with emulsion-based formulations 
To generate incomplete Freund’s adjuvant (IFA) vaccine emulsions, ISA51 mineral oil was 
used in conjunction with PBS and peptides with or without TLR-agonists. 1 ml of ISA51 was 
taken up in a 3 ml syringe and 1 ml of PBS containing the peptide (100 nmol E7/11-19/mouse 
and 100 nmol PADRE/mouse) and the TLR-agonists (20 µg MPLA/mouse or 40 µg 
XS15/mouse) in another 3-ml syringe. Both syringes were connected with an i-connector 
after removal of any air in the syringes and the connector. ISA51 was pressed through the 
connector into the other syringe where both liquids were thus mixed. Subsequently, the 
mixture was pressed into the first syringe again. With this, the first cycle of mixing was 
completed. To complete the first stage of mixing, 19 more slow cycles with 1 cycle per 
8 seconds were performed, followed by the second stage with 40 fast cycles in 
approximately 20 seconds. The resulting emulsion was dropped onto a water surface for 
quality control. A good emulsion forms a stable ball of emulsion that does not disperse on 
the water surface.  
100 µl of the emulsion were injected subcutaneously into the flank of each mouse. 12 days 
after the injection, mice were sacrificed for analysis of vaccination-induced T cells by 
intracellular IFN-γ staining. 
3.2.11 Vaccination with mRNA-lipoplexes (mRNA-LPX) 
To generate mRNA lipoplexes, 40 µg of in vitro transcribed RNA per mouse were mixed with 
RNase-free water in low-DNA binding Eppendorf tubes and vortexed. Subsequently, RNase-
free 5 M NaCl solution was added and the solution was vortexed. Finally, liposomes 
(liposome composition is proprietary knowledge of BioNTech) were added, the resulting 
solution was inverted four times and incubated at RT for 10 min. A correctly prepared mRNA 
lipoplex solution is slightly opaque and does not contain any precipitates. For injection, mice 
were anesthetized by isoflurane inhalation and 200 µl of RNA-LPX were injected retro-
orbitally into the bloodstream. A prime immunization at day 0, and booster immunizations 
on days 7, 14 and 21 were performed. Mice were sacrificed on day 28 for analysis of 
vaccination-induced T cells by intracellular IFN-γ staining.  
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3.2.12 Vaccination with free E7/11-19 peptide 
Per mouse, 100 nmol of E7/11-19 peptide were mixed with PBS and 50 µg pIC. The volume of 
PBS was adjusted so that the volume of the peptide plus pIC and PBS reached 100 µl. 100 µl of 
the resulting solution were injected on day 0 and day 6 subcutaneously into the flank of the mice. 
Mice were sacrificed on day 19 for analysis of vaccination-induced T cells by intracellular IFN-γ 
staining. 
3.2.13 Vaccination with Pam2-E7/11-19 and Pam1-E7/11-19 
Per mouse, approximately 30 nmol of Pam2-E7/11-19 (for 1x Pam2-E7/11-19) or 
approximately 60 nmol of Pam2-E7/11-19 (for 2x Pam2-E7/11-19) or 100 nmol of Pam1-
E7/11-19 were mixed with PBS and 50 µg pIC. The volume of PBS was adjusted so that the 
volume of the peptide compound plus pIC and PBS reached 100 µl. 100 µl of the resulting 
solution were injected on day 0 and day 14 subcutaneously into the flank of the mice. Mice 
were sacrificed on day 21 for analysis of vaccination-induced T cells by intracellular IFN-γ 
staining. 
3.2.14 Vaccination with Stea2-E7/11-19  
Per mouse, 33 nmol of Stea2-E7/11-19 were mixed with PBS and 50 µg pIC. The volume of 
the PBS was adjusted so that the volume of the peptide compound plus pIC and PBS reached 
100 µl. 100 µl of the resulting solution were injected on days 0, 7 and 14 intravenously or 
subcutaneously into the flank of the mice. Mice were sacrificed on day 21 for analysis of 
vaccination-induced T cells by intracellular IFN-γ staining. 
3.2.15 Vaccination with LPPs  
Per mouse, 50 nmol of LPPs or DSPE-PEG-maleimide without peptide as a vehicle control 
were mixed with sterile PBS and 50 µg pIC or 1.24 nmol CpG. The volume of PBS was adjusted 
so that the volume of the peptide compound plus pIC and PBS reached 100 µl. 100 µl of the 
resulting solution were injected subcutaneously into the flank of the mice. In tumor bearing 
mice (see 3.2.21), injections were performed on the contralateral flank.  
For the vaccination with combinations of LPPs, mice were injected with 50 nmol of each of 
the LPPs in separate sites on the left flank of the mice. Each mouse received a total amount 
of 50 µg pIC, which were distributed equally over all injections. 
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3.2.16 Isolation of splenocytes 
Mice were sacrificed by CO2 asphyxiation or cervical dislocation and the spleen was removed 
aseptically and stored in ice-cold PBS. In a laminar flow hood, the spleen was put into a 70 µm 
nylon cell strainer and minced with a scalpel. Subsequently, the piston of a disposable plastic 
syringe was used to press the splenocytes through the cell strainer. Splenocytes were 
washed out of the strainer with 5 ml ice-cold PBS into a 50 ml Falcon tube. The remaining 
spleen fragments were again mashed with the piston and leftover splenocytes were washed 
out with 5 ml ice-cold PBS and collected in the Falcon tube. The cells were spun down for 
4 min at 422 g at 4 °C. The supernatant was discarded and incubation in 4 ml ACK-buffer for 
50 seconds was used to osmotically disrupt red blood cells. After 50 seconds, 46 ml ice-cold 
PBS were added to the tube to restore physiological osmotic pressure. Cells were spun down 
for 4 min at 422 g at 4 °C, the supernatant was discarded and the cells were taken up in 50 ml 
ice-cold PBS. The cells were counted with a Countess® cell counter. Cells were spun down 
for 4 min at 422 g at 4 °C, the supernatant was discarded and cell concentration was adjusted 
to 2x106/100 µl with RPMI/10% FCS. 
3.2.17 Intracellular cytokine staining (IFN-γ/TNF-α) 
CD8+ T cells which recognize their specific peptide presented on MHC class I become 
activated and produce IFN-γ and/or TNF-α. This mechanism was used to quantify 
vaccination-induced CD8+ T cells by restimulating splenocytes of vaccinated mice with the 
cognate peptide and control peptides in the presence of compounds (GolgiStop™ and 
GolgiPlug™) that inhibit Golgi apparatus-mediated cytokine secretion. IFN-γ and other 
cytokines are thus retained in the cell and can be rendered detectable by intracellular 
staining with specific fluorophore-coupled ABs. The frequency of IFN-γ+ and/or TNF-α+ and 
thus epitope-specific CD8+ T cells was subsequently assessed by flow cytometry analysis. 
For IFN-γ/TNF-α intracellular staining, 2x106 splenocytes (see 3.2.16) were incubated in 
200 µl RPMI/10 % FCS with GolgiStop™ (1,5 µl/ml) and Golgi Plug™ (1 µl/ml) in the presence 
of either PMA (10 ng/ml) + ionomycin (1000 ng/ml) as a positive control, cognate peptides 
(10 µM) or an irrelevant HLA-A2-binding peptide (Survivin/96-104, Surv, 10 µM) as a negative 
control in a round bottom 96-well plate. After 5 h of incubation at 37 °C, cells were spun 
down for 3 min at 568 g in a cooled centrifuge (4 °C), after which the supernatant was 
discarded. A mastermix of the respective ABs (CD3, CD4, CD8, CD19) and Zombie Aqua in 
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staining buffer was prepared and 50 µl were added to each well. The cells were incubated at 
4 °C in the dark for 30 min. 150 µl staining buffer were added as the first washing step and 
cells were spun down for 3 min at 568 g at 4 °C. The supernatant was discarded and the cells 
were washed two additional times with 200 µl staining buffer. 100 µl of the 
fixation/permeabilization solution from the BD Cytofix/Cytoperm™ Kit were added to the 
cells. By incubating the cells in this buffer, the cellular proteins are crosslinked by 
formaldehyde and the cell membrane is disrupted by the detergents in the buffer. The cells 
are thus fixed and permeabilized. After 10 min of incubation in the dark at 4 °C, 100 µl 
1x wash buffer from the BD Cytofix/Cytoperm™ Kit were added and the cells were spun 
down for 3 min at 568 g at 4 °C. The cells were washed two times more with 200 µl of 1x wash 
buffer. IFN-γ and TNF-α ABs were diluted in staining buffer. 50 µl of this mixture were added 
to each well, followed by incubation in the dark at 4 °C for 30 min. 150 µl 1x wash buffer 
were added to the cells and the cells were spun down for 3 min at 568 g at 4 °C. The cells 
were washed two times more with 200 µl of 1x wash buffer. Subsequently, the cells were 
taken up in 200 µl flow cytometry fix buffer. 
3.2.18 In vitro T cell expansion from splenocytes 
To expand specific T cells in vitro, splenocytes (containing CD4+ T cells, CD8+ T cells and 
professional APCs) isolated from vaccinated mice were cultured in upright standing flasks in 
T cell medium supplemented with the cognate epitope (100 nM). For harvesting of these 
non-adherent cells, cells were thoroughly resuspended in the culture medium and then used 
in further experiments. 
3.2.19 Isolation of CD8+ T cells 
CD8+ T cells were isolated according to the manual for the “untouched CD8+ isolation kit” 
from BD. 1x107 cultured splenocytes were taken up in 40 µl of MACS buffer and 10 µl of a 
cocktail of biotinylated ABs (CD4, CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, 
MHC-class II, Ter-119 and TCRγ/δ) were added. Cells were incubated for 5 min at 4 °C. Thus, 
all cell populations except CD8+ T cells were bound by ABs. 30 µl of MACS buffer and 20 µl of 
streptavidinylated iron beads were added to the cells. Subsequently, cells were incubated at 
4 °C for 10 min. The streptavidin on the iron beads binds strongly to the biotin coupled to 
the ABs. Thus, all non-CD8+ T cells are attached to iron beads. After the incubation time, the 
volume of the solution was adjusted to 500 µl by the addition of MACS buffer. A LS MACS 
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column was placed in a MACS magnet and rinsed with 3 ml MACS buffer. Afterwards, the cell 
suspension was applied to the column. The column was washed two times with 1 ml MACS 
buffer. In this step, all CD8+ T cells were washed out of the column while all other cells were 
magnetically retained in the column since they were coupled to iron micro beads. The 
unlabeled (untouched) CD8+ T cells were collected and counted for subsequent experiments. 
3.2.20 Cytotoxicity assay – Vital-FR 
To assess the specific cytotoxicity of T cells, in vitro expanded T cells were magnetically 
isolated and used as effector cells in a flow cytometry-based cytotoxicity assay (Stanke et al., 
2010). The working principle of the Vital-FR assay is illustrated in Figure 36.  
For this assay, PAP-A2 specific target cells were labeled with CFSE (in PBS with 2.5 µM CFSE), 
2277NS unspecific target cells with FarRed dye (FR) (in PBS with 0.5 µM FR) for 15 min at 
37 °C in an incubator. After the incubation period, cells were spun down (422 g, 4 min, RT), 
the supernatant was discarded and cells were washed three times with RPMI/10 % FCS. 
Subsequently, both specific target cells and unspecific target cells were cultured for 24 h, 
harvested by trypsinization and then mixed at a 1:1 ratio. 3,000 target cells (1,500 specific 
target cells plus 1,500 unspecific target cells) were seeded in triplicates into the wells of a 
96-well plate.  
For the comparison of specific peptide-loaded 2277NS/unspecific peptide-loaded 2277NS, 
cells were labeled and cultured for 24 h as described above. Subsequently, cells were loaded 
with the respective minimal epitope. For this, they were incubated for 1.5 h in an incubator 
in 1 ml RPMI/10 % FCS containing 10 µM of the respective peptide. After incubation, cells 
were washed three times with 1 ml RPMI/10 % FCS and spun down (422 g, 4 min, RT) before 
they were seeded in 96-well plates.  
MACS-isolated CD8+ T cells were added in different ratios to the wells containing the target 
cells. Ratios ranged from zero CD8+ up to 20:1 (20 times more effector cells than target cells). 
After 48 h of co-incubation of target cells and T cells, the medium was taken off, the well was 
carefully washed once with PBS and the cells in the well were harvested by trypsinization. 
Cells were spun down for 4 min at 422 g, the supernatant was discarded, cells were taken up 
in flow cytometry fix buffer and stored at 4 °C in the dark until flow cytometry analysis. The 
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frequency of live CFSE+ and live FR+ cells was determined and specific killing was calculated 
using the formula depicted below. 
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑘𝑖𝑙𝑙𝑖𝑛𝑔 =  100 −
(
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑇 𝑐𝑒𝑙𝑙𝑠
% 𝑢𝑛𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑇 𝑐𝑒𝑙𝑙𝑠
)
(
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑇
% 𝑢𝑛𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑡𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑇 𝑐𝑒𝑙𝑙𝑠
)
𝑥100 
 
3.2.21 Tumor inoculation 
A2.DR1 mice were housed under specific pathogen free conditions. Seven to 15-week-old 
animals were selected for experiments and pooled in age-matched groups at least seven 
days prior to experiments. For tumor challenges, PAP-A2 cells were harvested by 
trypsinization and subsequent stopping of the process by addition of 2277NS medium. Cells 
were spun down for 4 min at 422 g and the supernatant was discarded. Cells were taken up 
in 50 ml PBS and counted. The required number of cells was taken out, spun down again, 
taken up in PBS and transferred to 2 ml Eppendorf tubes. Cells were spun down again (194 g, 
4 min, RT) and the supernatant was taken off completely with a pipette. Cells were taken up 
in PBS (for the injection of 1,5x106 PAP-A2 cells: 50 µl PBS/1,5x106 cells) and put on ice. After 
the cell suspension had cooled down to 4 °C, an equal volume of matrigel was added. The 
mixture was resuspended thoroughly by pipetting. The mixture was kept on ice until 
injection. The subcutaneous injection into the flank of the mice was performed with 
precooled syringes and 27G needles. After tumor inoculation, tumor growth was monitored 
by measuring with digital calipers every 2-4 days. Animals were sacrificed when the tumor 
volume exceeded 1000 mm3 or when the animals exhibited signs of distress such as extreme 
weight loss or apathy. The tumor volume was calculated using the formula below. 
𝑡𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 = 𝑙𝑒𝑛𝑔𝑡ℎ 𝑥 𝑤𝑖𝑑𝑡ℎ2 𝑥 0.6 
 
3.2.22 Statistics 
For calculation of statistical significance, GraphPad Prism 5 software was used. The used 
statistical tests are indicated in the legends for the respective figures. 
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4 Results 
4.1 Establishment of genotyping PCRs for A2.DR1 mice 
The genotypic background of all mice used for breeding was monitored throughout the work 
presented here to exclude breeding errors. To fully verify the genetic identity of A2.DR1 
mice, seven genotyping PCRs are needed. Three different PCRs show the presence of the 
three transgenes: the HHD molecule (a chimeric molecule consisting of the α3 domain from 
H-2Db and the α1 and α2 domains from HLA-A*0201, covalently linked to human β2m), HLA-
DRA1 and HLA-DRB1. The presence of all three transgenes could be confirmed in our A2.DR1 
mice (Figure 11). Unexpectedly, we sometimes observed weak bands in the PCR products 
generated from C57BL/6 negative controls migrating at the same level as the bands 
indicating the presence of the HLA-DR1 transgenes in A2.DR1 mice. To control for substrain-
specific effects we included DNA samples from the two C57BL/6 substrains C57BL/6N and 
C57BL/6J in our analysis.  
 
Figure 11. Genotyping PCRs confirm the presence of the HHD, HLA-DRA1 and HLA-DRB1 
transgenes in the genome of A2.DR1 mice 
The three PCRs (HHD, HLA-DRA1, HLA-DRB1) were performed with the primers and PCR programs as 
described in Table 1. The sizes of the PCR-amplified fragments are: HHD=400 bp, HLA-DRA1=153 bp, HLA-
DRB1=228 bp. H2O and DNA obtained from biopsies of C57BL/6 mice served as negative controls for DNA 
obtained from A2.DR1 breeding animals. 
 
We hypothesized that the large degree of sequence similarity between HLA-DR1 and murine 
MHC class II sequences allowed the HLA-DR1 primers to bind to murine MHC class II genes, 
thus giving rise to the weak bands observed upon analysis of the PCR product. Therefore, we 
tested the same primer combinations also in an experiment with DNA from MHC class II KO 
mice as additional negative template controls. Interestingly, DNA templates from MHC 
 Results 
  
 
 
65 
 
class II KO mice also induced some bands, but no bands migrating at the same level as the 
bands consisting of the amplified sequences of HLA-DRA1 and HLA-DRB1 (Figure 12).  
 
Figure 12. No amplification of a fragment resembling the HLA-DR1 PCR fragment from MHC 
class II KO mice template DNA 
The PCRs for the detection of the transgenes HLA-DRA1 and HLA-DRB1 were performed with the primers 
and PCR programs as described in Table 1. H2O and DNA obtained from biopsies of C57BL/6 mice served as 
negative controls for DNA obtained from A2.DR1 breeding animals. In contrast to the experiment shown in 
Figure 11, in this experiment, DNA obtained from biopsies of MHC class II KO mice were included as 
additional negative controls. 
 
In addition to the presence of the transgenes, also the knockout of murine β2m, of H-2Db 
and of the murine MHC class II locus needed to be assessed. Due to a mix of three primers, 
two different bands are generated in the β2m PCR depending on whether the template DNA 
was obtained from a C57BL/6 or an A2.DR1 sample (Figure 13, upper left panel) verifying the 
presence or KO of murine β2m, respectively. The same holds true for the MHC class II KO 
PCR with the only difference that this PCR reaction uses 4 primers (Figure 13, upper right 
panel). The KO of the H-2Db gene in A2.DR1 is assessed via two different PCRs: one PCR (H-
2Db WT) amplifies the wildtype H-2Db, resulting in no PCR product in A2.DR1 mice. The other 
PCR (H-2Db KO) amplifies the resistance cassette used to interrupt the H-2Db gene in A2.DR1 
mice (Figure 13, lower panels). In all these PCRs, samples generated from A2.DR1 mice and 
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C57BL/6 control mice gave rise to the expected band patterns during the analysis of the PCR 
products. 
 
Figure 13. Genotyping PCRs show the KO of murine antigen presentation-related genes in 
A2.DR1 mice 
The four PCRs (β2m, MHC class II KO, H-2Db KO and H-2Db WT) were performed with the primers and PCR 
programs as described in Table 1. The sizes of the PCR-amplified fragments are: β2m KO=600 bp, murine 
β2m=270 bp, MHC class II KO=209 bp, murine MHC class II=178 bp, H-2Db WT=1600 bp, H-2Db KO=340 bp. 
H2O and DNA obtained from biopsies of C57BL/6 mice served as controls for DNA obtained from A2.DR1 
breeding animals. 
 
The exemplary results shown in Figure 11 - Figure 13 could be reproduced for all the A2.DR1 
mice used for breeding in this study. This finding proves that the A2.DR1 breeding colony 
had the desired genotype. 
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4.2 Generation of the PAP-A2 cell line 
The strategy to generate a HPV16 E6/E7-positive tumor model suitable for A2.DR1 mice was 
to transduce the chemically induced sarcoma cell line 2277NS with HPV16 E6/E7. However, 
since the 2277NS cell line is derived from A2.DR1old mice, a slightly different version of the 
A2.DR1 mouse model than the one used in this study, the potential of 2277NS cells to form 
tumors in “our” A2.DR1 mice had to be established. Indeed, the injection of 0.8x106 2277NS 
cells induced tumor growth in 3 out of 3 mice (Figure 14).  
 
After having validated the tumorigenicity of 2277NS cells in A2.DR1 mice, we assessed the 
expression of HLA-A2 in the form of the chimeric HHD molecule on the cell surface since only 
a model with sufficient expression of HLA-A2 can be targeted by antigen-specific 
immunotherapy. We found the expression of HLA-A2 on 2277NS cells to be low (example 
shown in Figure 15) but to be consistently detectable (data not shown). Healthy cells 
upregulate MHC class I expression upon exposure to IFN-γ. We tested if this was also true 
for 2277NS cells and could observe an upregulation of HLA-A2 after treatment with IFN-γ for 
48 hours (Figure 15). 
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Figure 14. Growth of 2277NS cells in A2.DR1 mice 
A2.DR1 mice were injected with 1x106 (n=2) or 5.5x106 (n=1) 2277NS cells in matrigel. Tumor size was 
measured with digital calipers and tumor volume was calculated with the formula volume = length x width2 
x 0.6. 
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4.2.1 Transduction of 2277NS cells with pWPI E6/E7 
Cell lines suitable as a tumor model for testing therapeutic vaccinations against HPV16-
induced malignancies in the A2.DR1 mouse model should have three characteristics: First, 
tumorigenic growth in A2.DR1 mice, second, expression of HLA-A2 and third, expression of 
HPV16 E6/E7. After having established the adequacy of 2277NS cells for the characteristics 
of tumorigenic growth and HLA-A2 expression, HPV16 E6/E7 expression had to be induced 
in these cells. To this end, 2277NS were transduced with the lentiviral vector pWPI HPV16 
E6/E7 (vector map shown in Figure 16) by Ruwen Yang (DKFZ). Also the vector was kindly 
supplied by R. Yang. 
 
 
Figure 15. 2277NS cells upregulate HLA-A2 expression after exposure to IFN-γ 
2277NS cells were either incubated with murine IFN-γ for 48 h or left untreated. Cells were subsequently 
stained with anti-HLA-A2 ABs coupled to FITC, with the respective FITC-coupled isotype control or left 
unstained. Intensity of staining was assessed by flow cytometry. 
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Figure 16. Vector map pWPI HPV16 E6/E7 
The lentiviral pWPI vector used for the introduction of HPV16 E6 and E7 into 2277NS cells. The expression 
of strep-tagged E7, flag-tagged E6 and a puromycin resistance cassette are under the control of a single EF-
1α promotor. The use of a P2A sequence and an IRES sequence allows the expression of three different 
proteins from one mRNA. Figure taken from Kruse et al., provided by Ruwen Yang. 
 
Successfully transduced 2277NS were puromycin-resistant and were called 2277NS (pWPI). 
These cells were analyzed by Western blot (WB) for E6 and E7 expression and were found to 
express the introduced tagged versions of E6 and E7. The expression levels of E6 and E7 were 
found to be higher than in CaSki cells, which are derived from a metastatic cervical carcinoma 
(Pattillo et al., 1977) and express the natural untagged HPV16 E6/E7 proteins. Parental 
2277NS cells, used as negative controls, did not give rise to E6 or E7 bands (Figure 17).  
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Figure 17. 2277NS cells transduced with pWPI HPV16 E6/E7 express HPV16 E6/E7 
15 µg of lysates of the indicated cell lines and tumors (30 µg for 2 x 2277NS (pWPI) tumor) were separated 
by SDS-PAGE in an AnykD™ polyacrylamide gel and blotted subsequently onto a PVDF membrane. 
Membranes were incubated with primary ABs specific for E6 (left, clone E6-6F4) and E7 (right, clone NM2) 
and were subsequently incubated with suitable HRP-coupled secondary ABs. The membrane parts with the 
E6/E7 proteins were developed with high-sensitive ECL solution, the α-tubulin-containing membrane parts 
with normal ECL solution.  
 
Next, we assessed if 2277NS (pWPI) cells were still able to form tumors in A2.DR1 mice. This 
was necessary since by the introduction of viral antigens, the immune system of the mice 
could recognize these cells as foreign or virus-infected and therefore reject them. Injection 
of 106 2277NS (pWPI) cells in three A2.DR1 mice proved that either no immune response 
was triggered or that the immune response induced against these cells was not strong 
enough to cause rejection since all three mice developed outgrowing tumors with growth 
kinetics similar to tumors induced by 2277NS cells (data not shown). The continued HPV16 
E6/E7 expression of these tumors was confirmed by WB (Figure 17). 
To obtain a homogenous cell line with the required characteristics, we generated clonal cell 
lines by single cell sorting. We sorted the top 1 % HLA-A2 expressing cells from the 2277NS 
(pWPI) polyclonal cell line into single wells of a 96-well plate, from which we expanded the 
clones to sufficient cell numbers for subsequent analysis (Figure 18).  
 Results 
  
 
 
71 
 
 
Figure 18. Single cell sorting of 2277NS (pWPI) for clones with high HLA-A2 expression 
2277NS (pWPI) cells were stained with anti-HLA-A2 AB. The top 1 % of HLA-A2-expressing cells were sorted 
(1 cell per well) into 96-well plates to generate clonal cell lines. 
 
The 2277NS (pWPI) clonal cell lines were examined for the three characteristics specified 
before. WB analysis revealed that not all clones expressed E6 and E7 (Figure 19), despite 
being puromycin resistant. Additionally, E6/E7 expression levels varied between clones. In 
general, clones expressing comparably high levels of E6 also expressed comparably high 
levels of E7. All clones expressed higher levels of E6 and E7 than the two cell lines acting as 
positive controls, TC-1 and CaSki. The TC-1 cell line was established by transducing C57BL/6-
derived lung cells with HPV16 E6/E7. Interestingly, we failed to detect E6 protein in CaSki 
and E7 protein in TC-1 cells in these WBs.  
Parts of the work concerning the analysis of the clonal cell lines were generated during the 
course of Philipp Scherer’s bachelor thesis under the direct supervision of Sebastian Kruse. 
Therefore, some of the results shown here were also presented in Philipp Scherer’s bachelor 
thesis.  
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Figure 19. Clonal 2277NS (pWPI) cell lines show different E6/E7 expression patterns 
15 µg of lysates of the indicated cell lines were separated by SDS-PAGE in an AnykD™ polyacrylamide gel and 
blotted subsequently onto a PVDF membrane. Membranes were incubated with primary ABs specific for E6 
(left, clone E6-6F4) and E7 (right, clone NM2) and were subsequently incubated with suitable HRP-coupled 
secondary ABs. The membrane parts with the E6/E7 proteins were developed with high-sensitive ECL 
solution, the α-tubulin-containing membrane parts with normal ECL solution. 
 
Since it could be shown before (Figure 15) that 2277NS cells express only low levels of HLA-
A2, we also tested the HLA-A2 expression of the clonal cell lines. Figure 20 shows the 
quantification of HLA-A2, E6 and E7 expression of the clonal cell lines, each normalized to 
the value of the cell line with the highest expression levels. The differences in HLA-A2 
expression are remarkably high, with the clone IIIF2 having approximately 20 times less 
surface HLA-A2 than the highest expressing clone IVF7. This is especially interesting 
considering the fact that all clonal cell lines were derived from clones that ranked among the 
top 1 % of HLA-A2 expressing cells in the polyclonal 2277NS (pWPI) cell line. Out of the eight 
tested clones, three did not express E6 or E7, which rendered them unusable as a tumor 
model. Therefore, the clones left to be tested for their tumorigenicity were clones IVA2, IIB2, 
IVF7, IB10 and IIIF2. 
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4.2.2 Reisolation of IVA2 cells after in vivo passage 
To test the tumorigenicity of the E6/E7-expressing clones (IVA2, IIB2, IVF7, IB10 and IIIF2), 
three or four mice for each clone were injected with 0.75x106 cells of the respective cell line. 
No sustained tumor growth could be observed for all clones (data not shown) except for one 
mouse injected with the IVA2 clone (Figure 21). This tumor was removed and transferred 
into in vitro cell culture. The resulting cell line was named PAP-A2 (for papillomavirus 
HLA-A2). 6 master cryo-stock vials of PAP-A2 cells were generated and stored in liquid 
nitrogen. One of the master stocks was thawed to be expanded to generate 120 single-use 
cryo-stock vials of PAP-A2 cells that were also frozen and stored in liquid nitrogen. All 
following experiments presented in this thesis could therefore be conducted with PAP-A2 
cells with a defined passage number, since a new single-use cryo-stock was thawed prior to 
the experiments.  
 
 
Figure 20. HLA-A2, E6 and E7 expression of clonal 2277NS (pWPI) cell lines 
Values are normalized to the highest value. HLA-A2 expression (white bars) of the clonal cell lines was 
quantified by flow cytometry analysis. Data for E6/E7 expression levels (black/striped bars) are derived from 
the E6/E7 WBs shown in Figure 19. The optical density of the bands in these WBs was quantified with the 
software ImageJ. Clones marked with an asterisk exhibited E6/E7 expression and were later tested for 
tumorigenicity in in vivo experiments. 
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Figure 21. Clone IVA2 gives rise to tumor growth in one A2.DR1 mouse 
Four A2.DR1 mice were injected with 0.75x106 IVA2 cells in matrigel. Subsequently, mice were monitored 
for tumor growth. The only mouse exhibiting tumor growth was sacrificed at day 23 after tumor injection 
and the tumor cells were isolated for further in vitro culture. 
 
4.2.3 Characterization of PAP-A2 cells  
We tested the newly generated PAP-A2 cell line for E6/E7 sequence identity, HLA-A2-
expression, E6/E7 expression and in vivo growth. The E6/E7 sequences found in PAP-A2 cells 
were found to be identical to the E6/E7 sequences in the pWPI HPV16 E6/E7 vector (data 
not shown). Flow cytometry-based assessment of HLA-A2 expression showed more HLA-A2-
expression by PAP-A2 cells than was seen in 2277NS cells (Figure 15, Figure 22). Since it had 
been established in previous experiments that there is virtually no background binding of 
the FITC-coupled isotype control AB to 2277NS derived cells, this control was omitted in this 
experiment. 
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Figure 22. PAP-A2 cells express high levels of HLA-A2  
PAP-A2 cells were stained with anti-HLA-A2 AB or left unstained. The intensity of the staining was assessed 
by flow cytometry. 
 
WB analysis revealed that PAP-A2 cells express HPV16 E6 and E7 and still do so after having 
grown as a tumor in A2.DR1 mice (Figure 23). As already shown in Figure 17, the HPV16+ 
cervical cancer-derived cell line CaSki expresses the natural HPV16 E6/E7 whereas the 
2277NS (pWPI)-derived PAP-A2 cells express the tagged versions of E6/E7 that were 
introduced via the lentiviral construct pWPI HPV16 E6/E7. As expected, the parental 2277NS 
cells do not express the E6 and E7 proteins. Interestingly, the relative E6 expression level of 
CaSki is lower than the one for PAP-A2. In contrast, the relative E7 expression level of CaSki 
is higher than the one for PAP-A2. 
 Results 
  
 
 
76 
 
 
Figure 23. HPV16 E6/E7 expression of the PAP-A2 cell line 
15 µg of lysates of the indicated cell lines and tumor were separated by SDS-PAGE in an AnykD™ 
polyacrylamide gel and blotted subsequently onto a PVDF membrane. Membranes were incubated with 
primary ABs specific for E6 (left, clone E6-6F4) and E7 (right, clone NM2) and were subsequently incubated 
with suitable HRP-coupled secondary ABs. The membrane parts with the E6/E7 proteins were developed 
with high-sensitive ECL solution, the α-tubulin-containing membrane parts with normal ECL solution. 
 
Finally, the in vivo growth of PAP-A2 cells was assessed. Injection of 1x106 PAP-A2 cells 
induced tumor growth in 60 % of mice, injection of 2.5x106 and 5x106 led to tumor growth 
in 100 % of the injected mice (Figure 24). To induce as high a tumor-take as possible and at 
the same time induce tumor growth slow enough to allow for therapeutic intervention, in all 
subsequent tumor experiments 1.5x106 PAP-A2 were used for tumor inoculations.  
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Figure 24. Cell number titrations with PAP-A2 cells 
A2.DR1 mice were injected with different numbers of PAP-A2 cells and monitored for tumor growth. A, 
tumor growth curves and B, survival curves of groups. Groups consisted of n=3 for 5x106 and n=5 for all other 
groups. In A, mean and error bars (standard deviation (SD)) are depicted. 
 
4.3 Epitope-specific vaccination against HPV16 E6/E7-positive tumors 
Various vaccine formulations have been developed for therapeutic anti-HPV16 vaccines, 
among them vaccines that contain the full protein sequences as well as vaccines containing 
only parts of the two main targets E6 and E7 (Khallouf, Grabowska and Riemer, 2014; 
Chabeda et al., 2018; Hancock, Hellner and Dorrell, 2018). It was shown by mass 
spectrometry analysis that not all possible HLA-A2-restricted E6/E7 epitopes are presented 
by HPV16+ cell lines derived from human cervical cancer (Riemer et al., 2010; Blatnik et al., 
2018). Therefore, we hypothesized that it is important to select only E6/E7 epitopes for 
vaccination that are presented on HPV16+ tumor cells since T cells specific for all other 
epitopes cannot contribute to anti-tumor effects. Consequently, we tested only vaccine 
formulations in our newly established A2.DR1 mouse model that allow the use of defined 
epitopes since only this ensures that the vaccination-induced immune response consists of 
T cells which can recognize tumor cells. 
For first immunogenicity tests we selected the epitope E7/11-19 since this epitope was found 
to be presented on HLA-A2 on several cell lines of human cervical cancer at relatively high 
abundance (Riemer et al., 2010; Blatnik et al., 2018) and also T cells specific for this epitope 
were found in the blood of healthy donors (Blatnik et al., 2018). In the latter study, 50 % of 
HPV16-reactive healthy donors responded strongly against E7/11-19. 
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4.3.1 Determination of the most suitable vaccine formulation for CD8+ T cell 
induction in A2.DR1 mice 
4.3.1.1 Emulsion-based vaccines 
Emulsion-based vaccines are generated from two different liquids, a hydrophobic and a 
hydrophilic phase, in which the hydrophilic phase contains the water-soluble antigens. The 
antigens used in this formulation are often minimal epitopes or SLPs that are only weakly 
immunogenic on their own. The mineral oil that is often used as the hydrophobic phase 
cannot be degraded physiologically and therefore ensures a depot effect at the injection site. 
For our experiments, we used the mineral oil formulation ISA51, since it is commercially 
available in a high quality that allows conducting experiments with an exactly defined 
compound. Furthermore, ISA51 has been previously used in clinical studies for the induction 
of anti-cancer immune responses (Pol et al., 2015) and has a well-established safety profile 
(van Doorn et al., 2016).  
We tested this vaccination formulation with our lead epitope E7/11-19. We chose the 
emulsion-based formulation since it is known to reliably induce CD8+ responses when 
containing minimal epitopes. Furthermore, this formulation is easily produced with different 
synthetic peptides. Additionally, since this formulation is considered the gold standard 
adjuvant for the induction of T cells, obtained results serve as a benchmark to compare the 
quality of the induced immune response with immune responses induced by other vaccine 
formulations. 
We vaccinated A2.DR1 mice with E7/11-19 together with PADRE (pan HLA-DR epitope) in a 
water-in-oil emulsion (PBS in ISA51) and determined the frequency of E7/11-19-specific CD8+ 
T cells 12 days after vaccination. PADRE was included to ensure CD4+ T cell-mediated help 
for CD8+ T cell activation. For all vaccination experiments, determination of frequencies of 
epitope-specific CD8+ T cells was done by restimulation of splenocytes of vaccinated mice 
with either the cognate epitope (E7/11-19) or the irrelevant survivin-derived HLA-A2-binding 
epitope Surv/96-104 followed by intracellular IFN-γ staining. In all experiments, the 
frequencies of CD8+ T cells producing IFN-γ after stimulation with the irrelevant epitope were 
negligible.  
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Figure 25 shows that low frequencies (in general lower than 0.5 % of CD8+ T cells) were 
induced with this vaccination approach. To increase the frequency of antigen-specific CD8+ 
T cells, we subsequently included two different TLR agonists in the formulation: either 
monophosphoryl lipid A (MPLA), a lipopolysaccharide (LPS) derivative and thus a TLR4 
agonist, or XS15, a synthetic variant of the TLR2/3 agonist Pam3Cys. Indeed, the inclusion of 
MPLA into the vaccine formulation induced on average 0.65 % E7/11-19-specific CD8+ T cells 
and thus three times more E7/11-19-specific CD8+ T cells than the formulation without MPLA 
(mean frequency of 0.2 % E7/11-19-specific T CD8+ cells). In the MPLA group, however, the 
mean frequency is strongly influenced by three animals that exhibited high frequencies of 
E7/11-19-specific CD8+ T cells (1.4 %, 1.6 % and 3 %). The median frequency is a more robust 
measure when outliers occur. When comparing the median frequency of the two treatment 
groups, the inclusion of MPLA induces a median frequency that is twice as high as the median 
frequency in the group without TLR agonist (0.4 % compared to 0.2 %). Interestingly, the 
inclusion of XS15 did not induce higher frequencies of E7/11-19-specific CD8+ T cells when 
compared with the formulation without TLR agonists. 
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Figure 25. Induction of E7/11-19-specific CD8+ T cells with emulsion formulations 
A2.DR1 mice were subcutaneously injected with 100 µl E7/11-19-containing ISA51 emulsion with the 
indicated TLR agonist (20 µg MPLA/mouse or 40 µg XS15/mouse). 12 days after the injection, mice were 
sacrificed, splenocytes were isolated and stimulated with E7/11-19 peptide in the presence of Golgi 
apparatus-transport inhibitors. After subsequent intracellular IFN-γ staining, the frequency of IFN-γ+ 
(E7/11-19-specific) CD8+ T cells was determined by flow cytometry. Results displayed for no TLR and MPLA 
are for n=12 mice each, for XS15 for n=6 mice. Data for no TLR and MPLA are from two independent 
experiments with each n=6. Mean (black bar), median (red bar) and SD are depicted. 
 
4.3.1.2 mRNA vaccines 
RNA vaccines offer several advantages over other vaccine formulations. For example, they 
are self-adjuvanting and allow fast and easy production (Kreiter et al., 2015). Furthermore, 
the antigen presentation efficiency can be increased by designing mRNA constructs that 
couple antigens to MHC class I trafficking signals (Kreiter et al., 2007). Additionally, the route 
of application and the formulation of the mRNA influences the sites and cell types in which 
the mRNA is expressed. It was shown that intravenous injection of mRNA-lipoplexes can 
target the RNA expression to professional antigen-presenting cells in spleen and lymph 
nodes and thus drastically increase vaccination-induced immune responses (Kranz et al., 
2016). In a preliminary experiment, we tested the HPV16 E7 full length (FL) mRNA produced 
by BioNTech (Mainz) for the induction of HPV16 E7-specific CD8+ T cells in A2.DR1 mice. 
Interestingly, in this test experiment, which was designed to screen several mRNA vaccines 
in small-scale experiments and that was therefore conducted with only one mouse, no 
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antigen-specific T cells could be found. mRNA encoding only for the minimal epitope 
E7/11-19 also did not give rise to specific T cells. However, this was an expected result, since 
earlier experiments performed by BioNTech (personal communication Dr. Christian 
Grunwitz) demonstrated that the elongation of a minimal epitope with three amino acids N- 
and C-terminally is necessary to ensure proper epitope processing. This finding was 
confirmed by our test of mRNA coding for E7/8-21, since both the version with and without 
the PADRE helper epitope induced CD8+ T cells specific for E7/11-19. Sequence analysis with 
the epitope prediction server NetMHC 4.0 prior to the experiment showed that the mRNA 
sequences flanking E7/8-21 (proprietary information of BioNTech) together with E7/8-21 
result in a new HLA-A2-binder (SLHEYMLDL). Therefore, we tested also for the induction of 
CD8+ T cells against this peptide and indeed could find SLHEYMLDL-specific CD8+ T cells in 
frequencies up to five-fold higher than the ones for E7/11-19. To generate mRNAs that do 
not induce a response against SLHEYMLDL, we exchanged the serine at position 1 in 
SLHEYMLDL to alanine, thus removing an anchor amino acid for HLA-A2. However, in mice 
injected with this mRNA, no E7/11-19 specific CD8+ T cells could be found (data not shown), 
probably due to impaired antigen processing as a result of the amino acid exchange. The 
integrity of the mRNA used in this experiment and the general induction of an immune 
response could be confirmed by the detection of PADRE-specific CD4+ T cells (data not 
shown). 
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Figure 26. Antigen-specific CD8+ T cells after mRNA vaccination 
A2.DR1 mice (n=1 per construct) were injected intravenously on days 0, 7, 14, 21 with 40 µg mRNA mixed 
with lipoplexes. On day 28, mice were sacrificed, splenocytes were isolated and restimulated with the 
peptides or the peptide pool indicated by the color code in the presence of Golgi apparatus-transport 
inhibitors. After subsequent intracellular IFN-γ staining, the frequency of IFN-γ+ (specific) CD8+ T cells was 
determined by flow cytometry. A survivin-derived epitope was used as an irrelevant HLA-A2-binding control 
epitope. SLHEYMLDL is an epitope that results from E7/8-21 and the flanking sequences of the mRNA that 
ensure correct intracellular targeting and epitope processing. 
 
4.3.1.3 Amphiphilic vaccines 
Coupling of peptide vaccines to fatty acids induces a strong T cell immune response (Cho et 
al., 2013; Liu et al., 2014). Since these antigen carriers do not have an inherent ability to 
activate antigen-presenting cells, they are used together with different TLR agonists such as 
poly I:C (pIC) or CpG. The study by Liu et al. demonstrated that the amphiphilic constructs 
bind to albumin and “hitchhike” on albumin to the lymph nodes where they are taken up by 
professional APCs. Subsequently, the activated professional APCs initiate a specific immune 
response by activating T cells.  
We tested the two amphiphilic constructs developed by Liu et al. and Cho et al. for their 
compatibility with the minimal HPV16 epitope E7/11-19.  
4.3.1.3.1 Pam2 and Stea2 
In the amphiphilic construct developed by Cho et al., the epitope of interest is coupled via a 
four amino acid linker (KFVM, structure in Figure 27) to two palmitic acids (Pam). The 
synthesis of this construct coupled to E7/11-19 turned out to be challenging since the 
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purification process was hampered by the fact that the palmitic acid chains attach to the 
columns that are used for peptide purification. The purity of the construct therefore was 
estimated to be only 20 %.  
 
Figure 27. E7/11-19 in the Pam2 amphiphilic construct (Pam2-E7/11-19) 
The Pam2-E7/11-19 construct has a hydrophobic domain (black) made up of two palmitic acid chains (C16 
bodies). These fatty acid chains are coupled to the amino groups of a lysine, which is the first amino acid of 
the KFVM linker (red). The E7/11-19 epitope (blue) is coupled to the KFVM-linker via a peptide bond. 
 
Nevertheless, a strong E7/11-19-specific CD8+ T cell response was induced after intravenous 
injection of this compound together with the TLR3 agonist pIC (Figure 28). This result was 
even improved by injecting a Pam2-E7/11-19 dose that was twice as high (called Pam2-
E7/11-19 2x) as the dose used in the first experiment. However, since this increase in 
vaccination response was mostly due to one strongly responding mouse (13.4 % E7/11-19-
specific CD8+ T cells), the median frequencies of E7/11-19-specific CD8+ T cells were similar 
after vaccination with the low and the high Pam2-E7/11-19 dose. As a comparison, we 
injected the free minimal epitope E7/11-19 together with pIC intravenously. After this 
treatment, we did not observe any E7/11-19-specific CD8+ T cells. 
Interestingly, the addition of free PADRE peptide to the vaccine solution drastically reduced 
the E7/11-19-specific T cell response (data not shown). Therefore, we refrained from using 
amphiphilic peptides together with free PADRE peptide in subsequent vaccination 
experiments. Remarkably, the vaccine efficacy enhancing effect of palmitic acid could only 
be observed when two palmitic acid chains were coupled to the epitope, since the construct 
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Pam1-E7/11-19 only induced very low frequencies of epitope-specific CD8+ T cells (Figure 
28). 
 
Figure 28. E7/11-19-specific CD8+ T cells induced by Pam2-E7/11-19, Pam1-E7/11-19 and 
Stea2-E7/11-19 vaccination 
A2.DR1 mice (n=3 for E7/11-19 i.v., n=6 per group for the other groups) were injected with the indicated 
peptide or amphiphilic construct together with 50 µg pIC via the indicated injection route. E7/11-19 i.v. were 
injected on days 0 and 6 and mice were sacrificed on day 19. Pam2-E7/11-19 1x, Pam2-E7/11-19 2x and 
Pam1-E7/11-19 were injected on days 0 and 7 and mice were sacrificed on day 21. Pam2-E7/11-19 1x 
signifies a low dose of Pam2-E7/11-19, Pam2-E7/11-19 2x signifies a double dose. Both Stea2 groups were 
injected on days 0, 7, 14 and sacrificed on day 21 (2B=2 boosts). Splenocytes of all treatment groups were 
isolated and stimulated with E7/11-19 peptide in the presence of Golgi apparatus-transport-inhibitors. After 
subsequent intracellular IFN-γ staining, the frequency of IFN-γ+ (E7/11-19-specific) CD8+ T cells was 
determined by flow cytometry. Mean (black bar), median (red bar) and SD are depicted. 
 
To overcome the problem of the low purity of the Pam2-E7/11-19 compound, in cooperation 
with Dr. Max Sauter and Dr. Philipp Uhl from the Department of Nuclear Medicine, 
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Heidelberg University Hospital, we devised a strategy that allowed synthesizing a similar 
compound with 2 fatty acids with higher purity. To do so, a compound named Stea2-
E7/11-19 was produced. The fatty acids (stearic acids) of this compound are 2 carbon atoms 
longer than the ones of Pam2 and it was reported that these slightly longer fatty acids induce 
even better albumin binding than palmitic acid chains (Liu et al., 2014). This compound could 
be purified to 70 % purity (data not shown). We tested this newly developed compound first 
with intravenous injection, as performed before with the Pam2-E7/11-19 compound, but in 
a two-boost regimen. The two-boost regimen was introduced to further increase the 
frequency of specific T cells. The intraexperimental variance of E7/11-19-specific CD8+ T cell 
frequencies was much lower with this compound when compared with the results of the 
vaccination with Pam2-E7/11-19 2x, likely due to the higher purity of Stea2-E7/11-19. 
However, when disregarding the one very strong responder in Pam2-E7/11-19 2x, 
frequencies of E7/11-19-specific CD8+ T cells induced by intravenously injected Stea2-
E7/11-19 were similar to the ones induced by intravenously injected Pam2-E7/11-19 (Figure 
28). In the study by Liu et al., a lipo-PEG-peptide (LPP) amphiphilic compound (see 4.3.1.3.2) 
was injected subcutaneously and induced high frequencies of epitope-specific CD8+ T cells. 
Therefore, we also tested our Stea2-E7/11-19 construct with subcutaneous injection. This 
different route of administration increased the mean frequency of E7/11-19-specific CD8+ T 
cells from 1 % induced by intravenous injection to 2.2 % (Figure 28).  
4.3.1.3.2 LPP 
Another amphiphilic minimal epitope construct that we tested to enhance the 
immunogenicity of E7/11-19 was called lipo-PEG-peptide (LPP), which was developed by Liu 
et al. (Liu et al., 2014). The structure of LPP and the coupling process to E7/11-19 is depicted 
in Figure 29. The structure shows that two stearic acid chains (C18 bodies) are connected via 
phosphoethanolamine to a long polyethylene glycol (PEG) spacer, which is in turn connected 
to maleimide. Maleimide readily reacts with the sulfhydryl group of a cysteine. This 
mechanism is used during the modular synthesis because it allows coupling every minimal 
epitope to the maleimide as long as it is extended by an N-terminal cysteine. Using cysteine-
extended E7/11-19 (CYMLDLQPET), LPP-E7/11-19 could be generated with a purity of more 
than 70 %.  
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Figure 29. E7/11-19 in the LPP amphiphilic construct 
Top row: the two components of LPP, DSPE-PEG-maleimide (1,2-distearoyl-3-sn-
phosphatidylethanolamine)-PEG-maleimide) and an N-terminally cysteine-extended peptide (in this case 
E7/11-19) are mixed together and coupled through a spontaneous chemical reaction between the cysteine’s 
sulfhydryl group and the maleimide. The coupled compound is referred to as LPP-E7/11-19 (lipo-PEG-
E7/11-19).  
 
Subcutaneous injection in a one-boost regimen together with pIC robustly induced E7/11-19-
specific CD8+ T cells in frequencies of up to 6.5 % (Figure 30). Remarkably, the intravenous 
injection of LPP-E7/11-19 together with pIC as a TLR agonist did not give rise to substantial 
frequencies of E7/11-19-specific CD8+ T cells. Interestingly, an exchange of the TLR agonist 
from pIC to CpG in the vaccine formulation abrogated the induction of measurable CD8+ T 
cell responses against E7/11-19. Using the same subcutaneous 2-boost vaccination regimen 
as for Stea2-E7/11-19, mean frequencies of approximately 6-9 % epitope-specific CD8+ T cells 
could be reproducibly induced (Figure 30, Figure 33).  
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Figure 30. Comparison of vaccination routes and TLR agonists with LPP-E7/11-19  
A2.DR1 mice (n=12 for LPP-E7/11-19 + pIC s.c., n=6 for all other groups) were injected with 50 nmol LPP-
E7/11-19 mixed with either 50 µg pIC or 1.24 nmol CpG. The first three groups were injected on days 0 and 
14, the LPP-E7/11-19 + pIC s.c. 2B group was injected on days 0, 7 and 14 (2B=2 boosts). Mice were sacrificed 
on day 21 and splenocytes were isolated and stimulated with E7/11-19 peptide in the presence of Golgi 
apparatus-transport inhibitors. After subsequent intracellular IFN-γ staining, the frequency of IFN-γ+ 
(E7/11-19-specific) CD8+ T cells was determined by flow cytometry. Each dot represents one mouse. Mean 
(black bar), median (red bar) and SD are depicted. 
 
4.3.1.4 Overall comparison of the tested vaccine formulations 
To appreciate the full extent of differences in induction of epitope-specific CD8+ T cells it is 
insufficient to monitor only the frequencies of specific CD8+ T cells, but it is also important 
to know the total number of specific CD8+ cells in the individual. This number can be 
calculated if the frequency of specific CD8+ T cells among the total CD8+ T cells and the total 
number of CD8+ T cells in an individual is known. Since it is experimentally not possible to 
quantify the total number of CD8+ T cells in an individual mouse, the total number of CD8+ T 
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cells in the spleen represents a potential surrogate measure. We quantified the numbers of 
splenocytes of each mouse by electronic counting with the Countess® cell counter. However, 
small differences in the settings of the machine, such as the focus, result in relatively large 
differences of cells counted for the same sample. To minimize this error, we used the same 
settings for every experiment. Nevertheless, the interexperimental variance due to this 
technical characteristic can be considerable. Due to these uncertainties, we chose not to 
include the total number of CD8+ T cells in our analysis comparing the efficacy of the different 
vaccine formulations. Instead we decided to base our comparison on the frequencies of 
E7/11-19-specific CD8+ T cells among CD19- splenocytes as these frequencies can be 
calculated from the frequency of E7/11-19-specific CD8+ T cells among CD8+ T cells and the 
frequency of total CD8+ T cells among the CD19- splenocytes. Both data points can be reliably 
assessed by flow cytometry analysis.  
The quantification of the CD8+ T cells in the spleens of vaccinated mice showed large 
differences between the different treatments (Figure 31). The mean frequency of CD8+ T 
cells in the spleen of naïve A2.DR1 mice is approximately 5 % of the CD19- splenocytes. This 
frequency is not changed when A2.DR1 mice are vaccinated with emulsion-based 
formulations with or without the TLR agonists MPLA and XS15. Vaccination with mRNA leads 
to a remarkable increase in the overall frequency of CD8+ T cells. This increase to mean 
frequencies of 13 % is induced irrespective of the specificity of the mRNA, as also mRNAs 
that did not induce HPV16 E6/E7-specific T cells increased frequencies of CD8+ T cells among 
the CD19- splenocytes. The intravenous injection of the free E7/11-19 peptide together with 
pIC did not give rise to increased frequencies of CD8+ T cells. All amphiphilic vaccines 
increased the overall frequencies of CD8+ T cells in the spleen to approximately 6-9 % of the 
CD19- cells. Interestingly, there seems to be a dose dependency in the case of Pam2-E7/11-19 
since the small dose (Pam2-E7/11-19 1x) induced a lower frequency of CD8+ T cells than the 
higher dose (Pam2-E7/11-19 2x). Furthermore, subcutaneous and intravenous injection of 
Stea2-E7/11-19 with pIC also induced an increase in CD8+ T cell frequency, in this case to 
7.5 % and 9.5 %, respectively. A remarkable finding was that a second booster injection in 
the subcutaneous LPP-E7/11-19 injection regimen did not further increase the frequency of 
CD8+ T cells in the spleen compared to the one boost-regimen, as can be seen in the 
comparison of the two regimens LPP-E7/11-19 and LPP-E7/11-19 2B.  
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Figure 31. Frequency of total CD8+ T cells among CD19- splenocytes after vaccination 
A2.DR1 mice were treated as described before for the respective experiments (see Figure 25, Figure 26, 
Figure 28, Figure 30). The frequency of CD8+ T cells among CD19- splenocytes was determined by flow 
cytometry. Each dot represents one mouse. Mean (black bar), median (red bar) and SD are depicted. 
*p≤0.05, **p≤0.01, ***p≤0.001 (ANOVA with Dunnett’s multiple comparison test). All comparisons are 
made against naïve A2.DR1 mice. 
 
To calculate the frequencies of E7/11-19-specific CD8+ T cells among CD19- splenocytes, the 
product of E7/11-19-specific T cells among CD8+ T cells (Figure 25, Figure 26, Figure 28, Figure 
30) and total CD8+ among the CD19- splenocytes (Figure 31) was formed (Figure 32). The 
comparison of these frequencies shows that the emulsion-based formulations induced the 
lowest overall numbers of E7/11-19-specific CD8+ T cells (median frequency for ISA51: 
0.007 % and for ISA51 + MPLA: 0.024 %). The two mRNA vaccines that induced E7/11-19-
specific CD8+ T cells (E7/8-21 and E7/8-21 + PADRE) showed better performance (median 
frequency: 0.065 %) than the emulsion-based formulations but still induced lower specific 
cell frequencies than the amphiphilic formulations. The amphiphilic formulations performed 
best since they induced high frequencies of E7/11-19-specific T cells among the CD8+ T cells 
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and at the same time increased the frequencies of CD8+ T cells among the CD19- splenocytes. 
In this analysis, the LPP construct used in a two boost-regimen, adjuvanted with pIC, 
exhibited the highest efficacy of all tested vaccine formulations. The induced frequencies 
were significantly higher than the ones induced by all other formulations. Only the 
comparison to the Pam2-E7/11-19 pIC i.v. group is not statistically significant, however, this 
is due to the outlying data point in this group as the medians are vastly different (0.07 % and 
0.63 %).  
 
 
Figure 32. Frequency of E7/11-19-specific CD8+ T cells among CD19- splenocytes after 
vaccination  
The displayed frequencies are the product of the frequencies of E7/11-19-specific CD8+ T cells among CD8+ 
T cells (Figure 25, Figure 26, Figure 28, Figure 30) and the frequencies of CD8+ T cells among CD19- 
splenocytes (Figure 31). Each dot represents one mouse. Mean (black bar), median (red bar) and SD are 
depicted. *p≤0.05, **p≤0.01, ***p≤0.001 (ANOVA with Dunnett’s multiple comparison test). All 
comparisons are made against LPP-E7/11-19 + pIC s.c. 2B. 
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Due to the strong induction of E7/11-19-specific CD8+ T cells by vaccination with the LPP-
E7/11-19 compound, its easy synthesis and the high achievable purity, we continued to work 
with this compound and not with the Pam2-E7/11-19 or Stea2-E7/11-19 compounds.  
4.3.2 In-depth analysis of LPP vaccination 
4.3.2.1 Comparison of four HPV16 E6/E7 epitopes 
Once we had established a vaccination approach that reliably induced E7/11-19-specific 
CD8+ T cells, we used LPP constructs also with two other HPV16 E7 epitopes (E7/7-15 and 
E7/82-90) that were found to be presented on HLA-A2 on a human cervical cancer cell line 
and against which T cells could be found in the blood of healthy donors (Blatnik et al., 2018). 
In addition, we used HPV16 E6/25-33 as an example of an E6-derived epitope. The use of 
these additional epitopes as LPP constructs was facilitated by the modular synthesis process 
of LPP.  
The three additional LPP constructs were compared side by side with a new batch of LPP-
E7/11-19 in their ability to induce epitope-specific CD8+ T cells as assessed by intracellular 
IFN-γ staining after restimulation with the cognate peptide. All three newly tested epitopes 
were found to be immunogenic in A2.DR1 mice (Figure 33). Although LPP-E7/11-19 induced 
the highest mean frequencies of epitope-specific T cells, the frequencies induced by the 
other LPP constructs were comparable.  
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Figure 33. Immunogenicity of LPP-HPV16 E6/E7 epitopes 
A2.DR1 mice (n=6) were injected with 50 nmol of the respective LPP construct mixed with 50 µg pIC on days 
0, 7 and 14. Mice were sacrificed on day 21 and splenocytes were isolated and stimulated with the indicated 
cognate peptide in the presence of Golgi apparatus-transport inhibitors. After subsequent intracellular IFN-γ 
staining, the frequency of IFN-γ+ (epitope-specific) CD8+ T cells was determined by flow cytometry. Each dot 
represents one mouse. Mean (black bar), median (red bar) and SD are depicted. 
 
Additionally, we compared the expression levels of IFN-γ measured as the geometric mean 
fluorescence intensity (MFI) for the IFN-γ flow cytometry channel in the IFN-γ+ CD8+ T cells 
after restimulation with either the irrelevant or the cognate peptide (Figure 34). This analysis 
showed that the IFN-γ MFI after restimulation with the cognate peptide in the IFN-γ+ CD8+ T 
cells was significantly higher in all four treatment groups than after restimulation with the 
irrelevant peptide, demonstrating the specificity of the CD8+ T cells for the respective 
cognate epitope. Furthermore, IFN-γ expression was significantly higher in IFN-γ+ CD8+ T cells 
specific for E7/11-19 than in the ones specific for E7/7-15. All other comparisons were not 
statistically significant. 
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Figure 34. IFN-γ expression of LPP-induced CD8+ T cells 
A2.DR1 mice (n=6) were injected with 50 nmol of the indicated LPP construct mixed with 50 µg pIC on days 
0, 7 and 14. Mice were sacrificed on day 21 and splenocytes were isolated and stimulated with the irrelevant 
peptide or the indicated cognate peptide in the presence of Golgi apparatus-transport inhibitors. After 
subsequent intracellular IFN-γ staining, the geometric mean fluorescence intensity (MFI) of IFN-γ+ CD8+ T 
cells was determined by flow cytometry. Each dot represents one mouse. Mean (black bar), median (red bar) 
and SD are depicted. Mean and SD are depicted. *p≤0.05, **p≤0.01, ****p≤0.0001 (one-way ANOVA with 
Bonferroni’s multiple comparison test). 
 
4.3.2.2 Cytokine profile of vaccination-induced T cells 
Several studies show that multifunctional T cells, i.e. T cells capable of expressing more than 
one cytokine, are more effective than monofunctional T cells in eradicating viruses and 
cancer cells ((van Duikeren et al., 2012; Van Der Sluis et al., 2015) and reviewed in (Seder, 
Darrah and Roederer, 2008)). Therefore, we assessed the ability of LPP-E7/11-19-induced 
CD8+ T cells to express TNF-α in addition to IFN-γ. Indeed, especially among the CD8+ T cells 
specific for E7/11-19, many cells that were IFN-γ+ were also found to be positive for TNF-α 
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(0.61 %) (Figure 35). Thus, on average more than 10 % of the E7/11-19-specific CD8+ T cells 
produced TNF-α in addition to IFN-γ. Interestingly, we barely observed any TNF-α single-
positive cells in all four tested groups, meaning that virtually all epitope-specific CD8+ T cells 
respond to activation with IFN-γ expression.  
 
Figure 35. Cytokine profile of vaccination-induced T cells after cognate epitope stimulation 
A2.DR1 mice (n=6) were injected with 50 nmol of the indicated LPP construct mixed with 50 µg pIC on days 
0, 7 and 14. Mice were sacrificed on day 21 and splenocytes were isolated and stimulated with the irrelevant 
peptide or the indicated cognate peptide in the presence of Golgi apparatus-transport inhibitors. After 
subsequent intracellular TNF-α/IFN-γ staining, the frequency of TNF-α+, IFN-γ+ and TNF-α+/IFN-γ+ double-
positive CD8+ T cells was determined by flow cytometry. Mean and SD are depicted.  
 
4.3.2.3 Cytotoxicity of vaccination-induced T cells 
To assess the ability of the vaccination-induced CD8+ T cells to kill target cells in an epitope-
dependent manner, we used the Vital-FR assay, a highly sensitive flow cytometry-based 
cytotoxicity assay (Stanke et al., 2010) that was initially designed for human T cells and that 
we adapted for the use with murine A2.DR1-derived, vaccination-induced T cells. This assay 
is based on the coculture of differentially labeled specific and unspecific target cells together 
with T cells. Specific killing is thus indicated by a decline in the relative frequency of specific 
target cells to unspecific target cells when more T cells are added (Figure 36).  
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Figure 36. Working principle of the Vital-FR flow cytometry-based cytotoxicity assay 
Effector cells (in this case CD8+ T cells that were MACS-isolated from splenocytes of LPP-E7/11-19-vaccinated 
A2.DR1 mice which had been cultured for 7 days in the presence of E7/11-19 peptide) are added at different 
effector-to-target (E:T) ratios to wells containing a 1:1 mixture of specific target cells labeled in green (here: 
PAP-A2 cells, CFSE-labeled) and unspecific target cells labeled in red (here: the parental untransduced 
2277NS cells, FR-labeled). 48 h after addition of CD8+ T cells, target cells are trypsinized, fixed and analyzed 
by flow cytometry.  
(A) Exemplary flow cytometry plots. With increasing E:T ratios, more specific target cells (CFSE-labeled) are 
killed and their relative amount decreases in the flow cytometry plots, while the absolute number of 
unspecific target cells (FR-labeled) remains the same, thus their relative amount increases. (B) The ratio of 
specific/unspecific target cells is plotted as “% of specific killing”. An increase with increasing E:T ratios is 
indicative of specific killing of the specific target cells compared to the unspecific target cells.  
 
First, we assessed the cytotoxic potential of the E7/7-15-, E7/11-19-, E7/82-90- and 
E6/25-33-specific CD8+ T cells induced by LPP vaccination (Figure 37). This was achieved by 
using cognate epitope-loaded 2277NS cells as specific target cells and irrelevant epitope-
loaded 2277NS cells as unspecific target cells. We observed that with increasing numbers of 
spleen-derived CD8+ T cells from mice vaccinated with the respective LPP construct, the 
frequency of specific target cells was reduced in comparison to the frequency of unspecific 
target cells, which indicates specific killing. For three (E7/7-15, E7/11-19, E7/82-90) of the 
four CD8+ T cell specificities, specific killing of more than 70 % was observed (Figure 37). Only 
for E6/25-33-specific CD8+ T cells, specific killing was less pronounced and reached only 
approximately 40 %. 
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Figure 37. Cytotoxicity of vaccination-induced CD8+ T cells towards epitope-loaded 2277NS 
target cells 
Splenocytes of LPP-vaccinated A2.DR1 mice were isolated and cultured 7 days in the presence of the 
respective indicated cognate peptide. CD8+ T cells were isolated by untouched MACS isolation. CD8+ T cells 
(effector cells) were added to wells containing a 1:1 mixture of specific target cells (2277NS loaded with the 
indicated peptide, CFSE-labeled) and unspecific target cells (277NS cells loaded with an irrelevant HLA-A2-
binding epitope, FR-labeled). 48 h after addition of CD8+ T cells, cells were analyzed by flow cytometry. “% of 
specific killing” was calculated from the ratio of specific to unspecific target cell killing. The experiment was 
performed in triplicates; error bars: SD.  
 
In a second step we used the verified killing capabilities of the vaccination-induced T cells to 
find out if the E6/E7 proteins expressed by PAP-A2 cells are processed into the respective 
MHC class I epitopes and subsequently presented on HLA-A2 on the cell surface. Using 
PAP-A2 cells as specific target cells, 2277NS cells as unspecific target cells and vaccination-
induced, epitope-specific CD8+ T cells as effector cells, we observed that PAP-A2 cells were 
specifically killed by CD8+ T cells of all four specificities (E7/7-15, E7/11-19, E7/82-90, 
E6/25-33) (Figure 38). This result demonstrated that E6 and E7 are indeed processed in 
PAP-A2 cells into the four epitopes, which are subsequently presented on HLA-A2 in 
 Results 
  
 
 
97 
 
sufficient quantities to allow specific CD8+ T cells to recognize these epitopes and kill the 
presenting cell.  
 
Figure 38. Cytotoxicity of vaccination-induced CD8+ T cells towards PAP-A2 target cells 
Splenocytes of LPP-vaccinated A2.DR1 mice were isolated and cultured 7 days in the presence of the 
respective indicated cognate peptide. CD8+ T cells were isolated by untouched MACS isolation. CD8+ T cells 
(effector cells) were added to wells containing a 1:1 mixture of specific PAP-A2 target cells (CFSE-labeled) 
and unspecific target cells (parental 2277NS cells, FR-labeled). 48 h after addition of CD8+ T cells, cells were 
analyzed by flow cytometry. “% of specific killing” was calculated from the ratio of specific to unspecific 
target cell killing. The experiment was performed in triplicates; error bars: SD. 
 
4.3.2.4 Vaccination with combinations of HPV16 E6/E7 LPPs 
We hypothesized that by administering several LPPs simultaneously, it should be possible to 
increase the overall numbers of HPV16 E6/E7-reactive and thus potentially tumor-reactive 
CD8+ T cells. To test this hypothesis, we injected mice with all possible combinations of 
LPP-E7/11-19 with the other LPPs that were previously found to be immunogenic. 
As we utilized a new batch of LPP-E7/11-19 in the combination experiments, we repeated 
the LPP-E7/11-19 single vaccination to establish the functionality of this batch (Figure 39, 
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panel A). The median frequency of E7/11-19-specific CD8+ T cells induced by this batch 
(3.58 %) was lower than the median frequencies induced by the other used batches (13.2 % 
and 7.4 %). However, the induced frequencies are still comparable, especially when 
considering the single data points which showed that also the new batch was capable of 
inducing 16.5 % of E7/11-19-specific CD8+ T cells in one mouse. 
Remarkably, the frequencies of HPV16 epitope-specific CD8+ T cells were much lower in 
combination vaccinations when compared to the single LPP immunizations (Figure 39, panels 
B-D, Figure 40). The combination of LPP-E7/11-19 and LPP-E7/7-15 resulted in median 
frequencies of E7/7-15-specific CD8+ T cells of only 0.4 % (compared to 1.4 % in the single 
LPP-E7/7-15 immunization) and median frequencies of E7/11-19 CD8+ T cells of only 0.47 % 
(compared to 3.58 % in the single LPP-E7/11-19 immunization). The combination of LPP-
E7/11-19 and LPP-E7/82-90 lowered the median frequency of E7/82-90-specific CD8+ T cells 
from 2.03 % in the single LPP-E7/82-90 vaccination to 1.1 % and for E7/11-19-specific CD8+ 
T cells from 3.58 % to 0.39 %. A similar observation was made for the combination of LPP-
E7/11-19 and LPP-E6/25-33, since in the single LPP-E6/25-33 vaccination the median 
frequency of E6/25-33-specific CD8+ T cells was 4.1 %, but in the combination immunization 
the median frequency of E6/25-33-specific CD8+ T cells was only 1.4 %. For E7/11-19 specific 
CD8+ T cells, the frequency was reduced from 3.58 % to 0.49 %, respectively. Interestingly, 
in all three groups there was one mouse that responded exceptionally strongly against either 
E7/11-19 or the other epitope that was used for vaccination. Therefore, the median 
frequencies of IFN-γ+ CD8+ T cells are more suitable to describe the population as a whole 
than the mean frequencies (Figure 39).  
The mice that received the combination of two LPPs had low but detectable CD8+ T cells 
responses against two different epitopes that are presented on PAP-A2 tumor cells (see 
4.3.2.3). Therefore, to compare the potential anti-tumor efficacy of the combination 
vaccinations, the total frequency of tumor-reactive CD8+ T cells is relevant. This number was 
calculated by adding the frequencies of the E7/11-19-specific T cells to the frequencies of 
CD8+ T cells specific for the respective other epitope (= total potentially tumor-reactive CD8+ 
T cells). Remarkably, the median sums of total potentially tumor-reactive CD8+ T cells (0.84 % 
for 7+11, 1.55 % for 82+11, 2.81 % for 25+11) were all lower than the median frequencies of 
potentially tumor-reactive CD8+ T cells in the single vaccinations (1.4 % for E7/7-15, 3.58 % 
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for E7/11-19, 2.85 % for E7/82-90, 4.1 % for E6/25-33). In addition to calculating the sum of 
the total potentially tumor-reactive CD8+ T cells, we also experimentally determined the 
frequency of potentially tumor-reactive CD8+ T cells by incubating splenocytes from the 
vaccinated mice with a mixture of all epitopes used for that vaccination. We observed some 
differences between the two numbers (e.g. in 11+25 for mouse 4) but in general the two 
ways of evaluation gave very similar results. 
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Figure 39. Vaccination with combinations of two different HPV16 LPPs leads to epitope-
specific immunosuppression 
Panel A represents the data for E7/7-15, E7/82-90 and E6/25-33 single LPP vaccinations as shown in Figure 
33 for comparison purposes. The LPP-E7/11-19 single vaccination shown in A was conducted according to 
the same regimen as for the other epitopes with the same batch of LPP-E7/11-19 that was used for B-D. For 
the LPP combination experiments, A2.DR1 mice (n=5-6) were injected with 50 nmol of each of the LPP 
constructs indicated in the title of each graph together with 50 µg pIC per mouse on days 0, 7 and 14. Mice 
were sacrificed on day 21 and splenocytes were isolated and stimulated with the indicated peptides or the 
indicated peptide mix in the presence of Golgi apparatus-transport inhibitors. After subsequent intracellular 
IFN-γ staining, the frequency of IFN-γ+ (epitope-specific) CD8+ T cells was determined by flow cytometry. The 
fourth group (“sum”) in the graphs B-D shows the calculated sum of the frequency of IFN-γ+ (CD8+) for the 
respective single epitope restimulations. Each dot represents one mouse. Mean (black bar) and median (red 
bar) are depicted. Abbreviations: 7 = E7/7-15, 11 = E7/11-19, 82 = E7/82-90, 25 = E6/25-33. 
 
The vaccination of A2.DR1 mice with combinations of three or four different HPV16-epitope 
LPPs yielded similar results (Figure 40) as the vaccination with two different LPPs (Figure 39). 
Again, the median frequencies of E7/11-19-specific CD8+ were very low (7+11+82: 0.11 %, 
7+11+25: 0.09 %, 11+82+25: 0.23 %, 7+11+82+25: 0.12 %) and thus similar to the ones in 
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vaccinations with two LPPs. The response to E7/7-15 was diminished in all three treatment 
groups that were treated with this epitope (median frequencies of E7/7-15-specific CD8+ T 
cells: 7+11+82: 0.3 %, 7+11+25: 0.27 %, 7+11+82+25: 0.12 %) compared to single 
LPP-E7/7-15 vaccination (median frequency of E7/7-15-specific CD8+ T cells: 1.4 %). In 
combinations in which E7/82-90 was used, the response to this epitope was always the most 
pronounced when compared to the responses to the three other epitopes (median 
frequencies of E7/82-90-specific CD8+ T cells: 7+11+82: 1.97 %, 11+82+25: 2.12 %, 
7+11+82+25: 1.97 %) and very similar to the median frequency of E7/82-90-specific CD8+ T 
cells in the E7/82-90 single vaccination (2.03 %). Only the combination 7+11+25 gave rise to 
substantial median frequencies of E6/25-33-specific CD8+ T cells (median frequencies of 
E6/25-33-specific CD8+ T cells: 7+11+25: 2.63 %, 11+82+25: 0.26 %, 7+11+82+25: 0.17 %). 
However, even the 2.63 % of E6/25-33-specific CD8+ T cells were still lower than the median 
frequency of these T cells in E6/25-33 single vaccination (4.1 %). 
When analyzing the sum of the potentially tumor-reactive CD8+ T cells in the combination 
experiments with three or four different LPPs, it was observed that the median sum was 
similar in all 4 treatments (median sum of the potentially tumor-reactive CD8+ T cells: 
7+11+82: 3.33 %, 7+11+25: 4.22 %, 11+82+25: 2.64 %, 7+11+82+25: 3.66 %). These numbers 
are mostly dependent on the contribution of E7/82-90-specific CD8+ T cells. 
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Figure 40. Vaccination with combinations of three or four different HPV16 LPPs leads to 
epitope-specific immunosuppression 
A2.DR1 mice (n=3-5) were injected with 50 nmol of each of the LPP constructs indicated in the title of each 
graph together with 50 µg pIC per mouse on days 0, 7 and 14. Mice were sacrificed on day 21 and splenocytes 
were isolated and stimulated with the indicated peptides or the indicated peptide mix in the presence of 
Golgi apparatus-transport inhibitors. After subsequent intracellular IFN-γ staining, the frequency of IFN-γ+ 
(epitope-specific) CD8+ T cells was determined by flow cytometry. The group titled “sum” shows the 
calculated sum of the frequency of IFN-γ+ (CD8+) for the respective single epitope restimulations. Each dot 
represents one mouse. Mean (black bar) and median (red bar) are depicted. Abbreviations: 7 = E7/7-15, 
11 = E7/11-19, 82 = E7/82-90, 25 = E6/25-33. 
 
4.3.3 Anti-tumor vaccinations 
4.3.3.1 Prophylactic vaccination with LPP-E7/11-19 
After having established the cytotoxic potential of the vaccination-induced CD8+ T cells, we 
tested their anti-tumor capabilities in a prophylactic tumor vaccination experiment with 
PAP-A2 tumor cells. The prophylactic vaccination with LPP-E7/11-19 significantly enhanced 
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the overall survival of mice that were subsequently challenged with 1.5x106 PAP-A2 cells 
compared to the vehicle control-injected or the untreated mice (Figure 41). The median 
survival time of LPP-E7/11-19-treated mice was twice as long as that of vehicle control-
treated animals (mean survival for the LPP-E7/11-19-vaccinated group: 41 days, mean 
survival for vehicle control-treated mice: 17 days). In the LPP-E7/11-19-vaccinated group, 
33 % of the animals rejected the tumor cells completely; in contrast to 20 % in both the 
vehicle control-treated and the untreated group.  
 
Figure 41. Prophylactic vaccination with LPP-E7/11-19 
15 mice per group were either left untreated or injected three times with DSPE-PEG-maleimide as a vehicle 
control or LPP-E7/11-19. 7 days after the last vaccination, all mice were injected with 1.5x106 PAP-A2 cells. 
A), survival curves and treatment regimen, B) tumor growth curves of individual mice. Statistical analysis for 
differences in survival was performed with the Gehan-Breslow-Wilcoxon test.  
 
4.3.3.2 Therapeutic vaccination with LPP-E7/11-19  
The goal of our studies is the development of a therapeutic anti-HPV16 vaccine, which would 
be given to patients diagnosed with either a precursor lesion or an established cancer. 
Therefore, we tested the ability of our vaccines to induce control of tumor growth in a 
therapeutic vaccination experiment. For this, A2.DR1 mice were inoculated with 
1.5x106 PAP-A2 cells and were injected after four days with LPP-E7/11-19, followed by two 
boost immunizations after 5 days each. In this experiment, vaccination with LPP-E7/11-19 
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led to complete tumor rejection in 50 % of the mice. These mice remained tumor-free until 
termination of the experiment (Figure 42). In contrast, 100 % of vehicle control-treated mice 
and 87.5 % of untreated mice had to be eliminated due to excessive tumor growth. However, 
since the division of the survival curves became only apparent after 40 days, this difference 
is statistically non-significant with the used number of mice.  
 
Figure 42. Therapeutic vaccination with LPP-E7/11-19 
Mice were injected with 1.5x106 PAP-A2 tumor cells on day 0. 8 mice per group were either left untreated 
or were injected three times with either DSPE-PEG-maleimide as a vehicle control or LPP-E7/11-19 beginning 
from day 4 after tumor injection. A), survival curves and treatment regimen, B) tumor growth curves of 
individual mice. Statistical analysis for differences in survival was performed with the Gehan-Breslow-
Wilcoxon test and all differences were found to be non-significant. 
 
4.3.3.3 Therapeutic vaccination with LPP-E7/7-15, LPP-E7/82-90 and                         
LPP-E6/25-33 
We also tested the efficacy of the other HPV16 epitopes used in this study to induce anti-
tumor responses when administered as LPP together with pIC. In this experiment, exactly 
the same experimental approach as for the therapeutic LPP-E7/11-19 experiment was used 
and it was found that despite inducing small increases in overall survival, none of the three 
tested LPPs (LPP-E7/7-15, LPP-E7/82-90, LPP-E6/25-33) induced improvements in overall 
survival similar to LPP-E7/11-19. 
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Figure 43. Therapeutic vaccination with the other LPP-HPV16 E6/E7 epitopes 
Mice were injected with 1.5x106 PAP-A2 tumor cells at day 0. 10 mice per group were either left untreated 
or injected three times with either DSPE-PEG-maleimide as a vehicle control or the indicated LPP construct 
beginning from day 4 after tumor injection. A), survival curves and treatment regimen, B) tumor growth 
curves of individual mice. Statistical analysis for differences in survival was performed with the Gehan-
Breslow-Wilcoxon test and all differences were found to be non-significant. 
 
4.3.3.4 Therapeutic vaccination with combinations of LPP-HPV16 E6/E7 epitopes 
When we injected mice with different combinations of the four LPP constructs we observed 
suppressed T cell responses (see 4.3.2.4). We nevertheless tested if these reduced T cell 
responses would still result in anti-tumor responses in a therapeutic experiment with the 
very same experimental setup as was used for the single LPP vaccinations. Indeed, the 
combination of LPP-E7/11-19 with any one of the three other LPP-epitopes did not give rise 
to better anti-tumor effects than treatment with LPP-E7/11-19 alone (Figure 44, left panel). 
Furthermore, also the combination of three or four different LPP-epitopes did not induce 
better anti-tumor effects (Figure 44, right panel). The best combination formulation turned 
out to be 11+82, for which the overall survival benefit was statistically significant, but which 
did not induce a higher frequency of long-term tumor rejection than the vehicle control. 
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Figure 44. Therapeutic vaccination with combinations of LPP-HPV16 E6/E7 epitopes 
Mice were injected with 1.5x106 PAP-A2 tumor cells at day 0. 10 mice per group were either injected three 
times with either the indicated LPP combinations (50 nmol per compound) or 50 nmol of DSPE-PEG-
maleimide and 50 µg of pIC beginning from day 4 after tumor injection. Statistical analysis for differences in 
survival was performed with the Gehan-Breslow-Wilcoxon test. 
 
Taking together the results from therapeutic vaccinations with single LPP compounds and 
with combinations of different LPPs, it can be concluded that the best therapeutic anti-tumor 
results were achieved with the single LPP-E7/11-19 vaccination. 
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5 Discussion 
Cervical cancer induced by high-risk HPVs is a major health concern, causing more than 
530,000 cancer cases and approximately 270,000 deaths per year. Additionally, 
100,000 anal, vulvar, penile and, importantly, oropharyngeal cancers are caused by HPV 
annually (de Martel et al., 2017). In total, 5 % of all cancers worldwide are therefore 
estimated to be caused by HPVs (Plummer et al., 2016). Furthermore, the incidence of 
precancerous lesions is by far higher than the number of cancer cases, since 250,000 to 
1 million women are diagnosed with cervical intraepithelial neoplasia (CIN) lesions annually 
in the USA alone (Henk et al., 2010). Treatment for CIN is therefore much more common in 
developed countries than occurrence of cervical cancer (Barken et al., 2012). Treatment 
options to date include surgery, chemotherapy and radiation therapy. An emerging field of 
oncology is immuno-oncology that allows the harnessing of the immune system’s specificity, 
powerful effector and long-lasting memory mechanisms as a treatment tool against cancer. 
Since the highly specific targeting system of T cells allows to selectively target cancer cells, 
the side effects of immunotherapy are expected to be much lower than those of 
conventional therapies (Gulley, 2013). HPV-induced cancers express viral proteins, such as 
E6 and E7, which are recognized by the immune system as foreign, making them especially 
attractive targets for immunotherapeutic interventions. Additionally, the expression of these 
proteins is indispensable for the malignant phenotype of the cancer cells, making immune 
evasion by silencing the respective genes virtually impossible. This is highlighted by the 
finding that mutations in E7 are extremely rare in cervical cancers since mutations abrogate 
the carcinogenic function of this protein (Mirabello et al., 2017). Furthermore, the majority 
of HPV-induced cancers are caused by only one HPV type, HPV16 (de Martel et al., 2017). 
This allows the treatment of a large number of patients with treatments that are specific for 
HPV16. Due to all the reasons mentioned, many attempts have been made to develop 
therapeutic vaccines against HPV16-induced cancers (see 1.2.3 and (Khallouf, Grabowska 
and Riemer, 2014; Chabeda et al., 2018)). Many of these attempts have yielded very 
promising results in preclinical studies, however, clinical trials for the better part could not 
reproduce the favorable preclinical results.  
To improve the translatability of the preclinical findings and to develop a clinically successful 
therapeutic HPV16 vaccine, we consider two aspects to be of special importance: First, the 
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vaccine should contain epitopes that are bona fide presented on cells of HPV16-induced 
cancer, since there is a large amount of evidence showing that HPV infection leads to altered 
antigen processing, which prevents the presentation of some possible epitopes. Second, 
promising vaccine candidates should be tested in a suitable in vivo model that allows the 
exclusive testing of immune responses restricted by human MHC, i.e. HLA molecules. This is 
of special importance since all models used to date allowed for immune responses restricted 
by murine H-2 molecules, thus misrepresenting the clinical situation.  
Following these guidelines, we aimed at developing a therapeutic vaccine containing defined 
epitopes that are known to be presented on tumor cells. Furthermore, we aimed at 
generating a HPV16 tumor model in A2.DR1 mice, which do not express any murine MHC 
molecules. Testing the epitope-specific vaccine in this tumor model was therefore going to 
enable us to improve the clinical relevance of data generated in preclinical studies.  
5.1 Characteristics of A2.DR1 mice 
A2.DR1 mice are transgenic for HLA-A*0201 and HLA-DR1 and thus can mount immune 
responses that are restricted by HLA-types that are among the most prevalent HLA-types in 
the human population worldwide. Additionally, genetic manipulations via knockouts ensure 
that no murine MHC class I/class II molecules can present epitopes to immune cells. Thus, 
any immune response in these mice is necessarily restricted by HLA-A2 and HLA-DR1. For 
this reason, the A2.DR1 mouse represents an ideal mouse model for experimental situations 
where the exclusive study of HLA-restricted immune responses is important. 
Prior to the start of this PhD project, A2.DR1 mice of our colony were accidentally crossed 
with C57BL/6 mice, rendering the offspring of these matings heterozygous for murine and 
human MHC molecules. Immune responses in these heterozygous animals can be restricted 
by human and by murine MHC molecules, which is why renewed contamination of the 
A2.DR1 breeding colony had to be avoided. To rule out the occurrence of renewed accidental 
interstrain breeding, we decided to monitor all animals used for breeding with genotyping 
PCRs. By compiling seven genotyping PCRs, we were able to routinely confirm the correct 
genetic background of our A2.DR1 breeding stock animals (Figure 11, Figure 13). We found 
that when using DNA from C57BL/6 mice as negative control templates for the HLA-DRA1 
and HLA-DRB1 PCRs, a fragment of the length expected for HLA-DRA1 and HLA-DRB1 was 
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amplified in these PCR reactions, albeit with a lower yield than from the A2.DR1 DNA 
templates. We speculated that since murine and human MHC class II genes share high 
sequence homology, these fragments could be generated by cross binding of the HLA-DR1 
primers to the murine MHC class II genes. This theory could be confirmed by using DNA from 
MHC class II KO mice as controls, since these samples did not give rise to any fragments of 
the size corresponding to the PCR-amplified HLA-DRA1 and HLA-DRB1 fragments (Figure 12). 
It is likely that the lower yield observed in the PCRs with C57BL/6 DNA as a template was 
caused by weaker affinity of the primers to the murine MHC class II genes than to their 
respective specific templates, HLA-DRA1 and HLA-DRB1.  
Taken together, the successful compilation of genotyping PCRs and the continuous 
monitoring of the A2.DR1 breeding colony ensured the generation of results in homozygous 
A2.DR1 mice. 
5.2 Tumor model generation 
To generate an A2.DR1-compatible, HPV16 E6/E7-expressing tumor model, several options 
for parental cells were explored. After attempts of using lung cells and keratinocytes isolated 
from A2.DR1 mice had not given rise to tumorigenic cell lines (data not shown), we decided 
to use the already tumorigenic A2.DR1-derived sarcoma cell line 2277NS (Quandt, 2012; 
Schumacher et al., 2014) as a parental cell line to be transduced with HPV16 E6/E7.  
2277NS cells were generated by injection of a carcinogen (methylcholanthrene, MCA) into 
A2.DR1old mice. As a result, these cells carry many somatic mutations, which are likely to also 
give rise to neoepitopes. In addition to MCA, 2277NS cells also were exposed to further 
genome destabilizing effects after transduction with the pWPI vector, since the expression 
of the E6 and E7 proteins leads to genome instability (McBride and Warburton, 2017). Other 
models such as TC-1 (Lin et al., 1996) or HLF16 (Eiben et al., 2002) presumably have fewer 
total mutations than 2277NS cells since their tumorigenicity was induced by transfecting 
somatic cells with vectors coding for constitutively activated versions of ras proteins (e.g. 
V12 h-ras). However, also these two cell lines started accumulating mutations after 
beginning to express E6 and E7 in vitro. It is reasonable to assume that the mutation profile 
that is induced by MCA is different from the one induced by the actions of E6 and E7. It is 
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important to keep all these differences in mind when comparing results generated in the 
different models.  
2277NS cells are derived from a slightly different version of A2.DR1 mice (namely A2.DR1old) 
than the A2.DR1 mice used in this study. The two versions differ in two points: First, in 
A2.DR1old mice the H-2Db gene is not knocked out as it is in A2.DR1 mice, but the absence of 
H-2Db molecules on the surface is based on the fact that only complexes of epitope, MHC 
class I heavy chain and β2m are stably assembled and transported to the cell surface. Since 
A2.DR1old mice are KO for murine β2m, no H-2Db complexes should reach the cell surface. 
However, some reports mention that despite the KO of the murine β2m, H-2Db heavy chains 
could be found on the cell surface of β2m KO mice (Allen et al., 1986; Bix and Raulet, 1992). 
Second, while in A2.DR1 mice the complete MHC class II locus is knocked out, A2.DR1old mice 
still express I-Eβ. This molecule could form atypical heterodimers with HLA-DRα and thus be 
present on the cell surface (Lawrance et al., 1989). Due to these two differences there was 
a chance that the immune system of A2.DR1 mice might recognize the 2277NS cells as 
foreign and respond with a xenoreaction against the potentially present H-2Db heavy chain 
and the atypical HLA-DRα/I-Eβ. We analyzed 2277NS cells via flow cytometry for cell surface 
expression of H-2Db molecules, but we could not find any indication for the surface 
presentation of these molecules (data not shown). Nevertheless, before continuing to work 
with 2277NS cells, we tested if the injection of 2277NS cells into A2.DR1 mice would give rise 
to a xenoreaction against the putative non-self H-2Db and HLA-DRα/I-Eβ, which could lead 
to the rejection of the 2277NS tumors. We did not observe any symptoms of a xenoreaction 
as the mice did not exhibit signs of discomfort or obvious signs of an immune response and 
the 2277NS cells formed tumors just as they are reported to do in A2.DR1old mice (Figure 14). 
Even if residual amounts of H-2Db heavy chains, too low to induce a xenoreaction, should be 
expressed on 2277NS cells, these molecules could not induce a specific CD8+ T cell-mediated 
response against H-2Db-presented HPV16 E6/E7 epitopes, since no T cells were positively 
selected to recognize peptides presented on H-2Db in the thymus of our A2.DR1 mice.  
Another potential problem associated with the use of 2277NS cells was their relatively low 
HLA-A2 surface expression (Figure 15), which could make it difficult for T cells to recognize 
any tumor model based on this cell line. On the other hand, there is evidence that only one 
copy of a peptide presented on MHC is sufficient for T cells to recognize and kill an infected 
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cell (Sykulev et al., 1996). Furthermore, two tumor models based on 2277NS cells have been 
previously used to demonstrate therapeutic effects of immunotherapeutic interventions 
(Schumacher et al., 2014; Ochs et al., 2017). However, it is reasonable to assume that very 
low target molecule expression on the cancer cell would make T cell-mediated killing more 
difficult and less frequent. This assumption is supported by the finding that many cancer 
types, among them cervical cancer as an example of HPV-induced cancers, downregulate 
their MHC class I expression, probably to make detection by the immune system more 
difficult (Bubeník, 2003). The fact that 2277NS cells show only low levels of HLA-A2 
expression could therefore even be advantageous for obtaining experimental results that 
have better prognostic value for clinical studies than e.g. results obtained with TC-1 cells 
which exhibit pronounced MHC class I expression (data not shown). However, the HLA-A2 
expression in 2277NS cells can be increased by IFN-γ treatment. If a few T cells recognize 
their epitope in the tumor despite low levels of HLA-A2 expression, they would get activated 
and secrete IFN-γ and thus induce the upregulation of HLA-A2 also in 2277NS cells. 
Interestingly, we found that the PAP-A2 cell line expressed higher levels of HLA-A2 than the 
parental cell line 2277NS, but still lower levels than e.g. the human cervical cancer cell line 
CaSki (data not shown). This is in contrast to the observation that the expression of E7 
reduces the total abundance of MHC on the cell surface (Doorbar et al., 2015). This 
discrepancy can be explained by the workflow we used for the generation of the PAP-A2 cell 
line as we selected the 2277NS (pWPI) clones with the highest HLA-A2 expression in this 
population (Figure 18). 
After we had transduced 2277NS cells with the pWPI HPV16 E6/E7 vector, we analyzed the 
resulting polyclonal 2277NS (pWPI) cells for their expression of E6 and E7. The expression 
levels of E6 and E7 in 2277NS (pWPI) were considerably higher than the ones in CaSki cells, 
presumably as a consequence of the usage of the strong EF-1α promotor in the pWPI vector 
and the selection pressure applied through puromycin. However, after we had generated 
clonal cell lines from the polyclonal pool of 2277NS (pWPI) cells, we found that the E6/E7 
expression levels were highly heterogeneous between clones. This finding, especially with 
correlating relative levels of E6 and E7 expression (Figure 19), makes multiple integration of 
the vector into the genome of 2277NS cells likely. It also makes it probable that E6 and E7 
are actually expressed in an approximate 1:1 ratio (as expected if the P2A sequence works 
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properly (Kim et al., 2011; Liu et al., 2017)). Remarkably, several clones did not exhibit any 
E6/E7 expression at all after puromycin selection. This may be based on the fact that the 
puromycin gene is located behind the E6/E7 genes on the mRNAs (see vector map, Figure 
16) but translation of the puromycin gene is initiated from an internal ribosome entry site 
(IRES) (Komar and Hatzoglou, 2011). Therefore, it is reasonable to assume that in some 
clones only the puromycin resistance cassette was translated.  
In some E6/E7 WBs (Figure 19) we failed to detect E6 in CaSki and E7 in TC-1 cells. This result 
is likely due to the fact that the expression levels of both proteins are relatively low in the 
respective cell lines. However, we could confirm the expression of both proteins in both cell 
lines in different WBs (data not shown).  
Only one of the five 2277NS (pWPI)-derived clonal cell lines that we injected into A2.DR1 
mice formed a tumor and this only in one of 4 injected animals (Figure 21). This low tumor 
take could have different reasons, among them the expression levels of HLA-A2, E6 and E7 
of the different clones. The IVA2 clone exhibited intermediate expression of HLA-A2, of E6 
and of E7. One could speculate that clones with lower expression of these three proteins are 
less likely to be detected by the immune system. This speculation is strengthened by the 
finding that upon reisolation of the IVA2 tumor, these cells, then called PAP-A2, were found 
to express much lower levels of E6 and E7 than the parental IVA2 cell line (data not shown).  
We found that a relatively large number of PAP-A2 cells were necessary to induce a high 
tumor take (Figure 24). We observed that 2.5x106 PAP-A2 cells induced 100 % tumor take 
and very fast tumor growth, but that a reduction of the number of injected cells to 1x106 cells 
induced tumors in only 60 % of mice. Extrapolating from these results, we decided to conduct 
further experiments with 1.5x106 PAP-A2 cells, which should induce a high tumor-take but 
leave enough time for treatment intervention. 
In summary, we established the PAP-A2 cell line as a new tumor model for HPV16-induced 
malignancies, which is suited for the use in fully MHC-humanized A2.DR1 mice. 
5.3 Epitope-specific vaccinations against HPV16 E6/E7-positive tumors 
Therapeutic vaccination against HPV-induced tumors should induce the strongest anti-tumor 
effect possible and should be easily applicable in the clinic. Most vaccine formulations tested 
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in clinical studies so far have only met the second criterion: They are easily applicable in the 
clinic because they do not require an additional patient selection process based on their 
immune characteristics. This is e.g. possible by using DNA vaccines coding for whole HPV 
proteins or a mix of SLPs in the vaccine formulation since they contain epitopes suitable for 
many HLA types (Kenter et al., 2009).  
These SLPs are quickly and efficiently processed and cross-presented (Rosalia et al., 2013), 
which is a prerequisite for effective CD8+ T cell responses. However, SLPs do not allow for 
the selection of truly tumor cell-presented peptides and therefore do not allow for choosing 
the peptides that give rise to a productive immune response in a specific patient. We 
hypothesize that meeting the first and most important prerequisite for a therapeutic HPV 
vaccine, achieving the strongest possible anti-tumor effect, will require focusing the immune 
responses on epitopes that are truly presented on the target cells. This can only be achieved 
by epitope-specific vaccines. However, epitope-specific vaccines have also disadvantages 
since they cannot be applied to all patients but have to be matched to the specific patient’s 
HLA-type. In the age of ever more personalized medicine, epitope-specific vaccines matched 
to the patient’s HLA type represent a realistic treatment option. HLA-typing nowadays 
requires only 48 h by next generation sequencing (NGS) (Illumina Inc, 2018) and the costs 
are no longer prohibitively high and can be expected to decrease further in the years to come 
(Wetterstrand, 2018). The potential workflow required for the application of an epitope-
specific therapeutic vaccine would thus start with the detection of e.g. a CIN lesion. In this 
instance, a small biopsy such as a swab would be taken from the lesion to determine the HPV 
type causing the lesion by already approved tests such as the cobas® HPV test, a DNA-based 
test for HPV detection and typing (Wright et al., 2011). The same sample, a blood sample or 
an oral swab would be used to determine the patient’s HLA type. If the patient is found to 
express e.g. HLA-A2, she would be given a vaccine containing epitopes specifically for this 
HLA type. The combination of several epitopes restricted to different HLA-types in one 
vaccine is also an option, allowing the use of one vaccine for more than one HLA type. If the 
peptides are chosen carefully (meaning that the epitopes are only binding to a specific HLA-
type), this would not lead to non-productive immune responses. 
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5.3.1 Comparison of vaccine formulations 
In our mouse model, we used different vaccine formulations to induce CD8+ T cell immune 
responses against mass spectrometry-confirmed HPV16 epitopes. As a lead epitope for the 
comparison of the different formulations we chose E7/11-19, since this epitope was found 
to be relatively abundantly presented on HLA-A2 on several HPV16+ cell lines (Riemer et al., 
2010; Blatnik et al., 2018). Our laboratory examined healthy female donors for HPV16 E6/E7-
reactive T cells in their blood to detect memory responses that were indicative of a previous 
encounter with HPV16 (Blatnik et al., 2018). In this analysis, 4 out of 8 HPV16-reactive 
healthy female donors had E7/11-19-specific T cells in their blood. Additionally, on average, 
the frequency of T cells being activated by a HPV epitope was the highest among the cultures 
that were stimulated with the E7/11-19 peptide.  
The goal for the comparison of the vaccination formulations was to find the approach that 
induces the highest number of E7/11-19-specific CD8+ T cells as magnitude of the T cell 
response is correlated with treatment success (Cho and Celis, 2010). The three assays most 
commonly used for the detection of epitope-specific T cells are the enzyme-linked immuno 
spot assay (ELISpot), the intracellular cytokine-staining assay (ICS) and the MHC multimer 
assay (Amara, 2009; Murphy et al., 2016). Additional assays are the staining for the effector 
molecule granzyme B (Murphy et al., 2016) and staining for the degranulation marker 
CD107a (Betts et al., 2003).  
The ELISpot assay is very sensitive and also allows the functional assessment of T cell effector 
functions (such as IFN-γ or TNF-α secretion). However, this assay does not permit the 
concomitant analysis of frequencies of T cell populations (e.g. frequencies of CD8+ T cells). 
Therefore, we concentrated on the MHC multimer and IFN-γ ICS assays, which are both flow 
cytometry-based and thus allow the simultaneous analysis of the T cell populations. We 
tested various multimer constructs such as fully human HLA-A2 pentamers, single-chain 
trimers (MHC molecules with bound peptides formed from a single polypeptide chain) 
(Hansen et al., 2010) with different α3 domains, and H-2Kb-HLA-A2 chimeric pentamers (data 
not shown). Fully human HLA-A2 multimers did not exhibit any staining of epitope-specific 
A2.DR1-derived CD8+ T cells, thus confirming the findings concerning the incompatibility of 
murine CD8 and the α3 domain of HLA (Irwin, Heath and Sherman, 1989). H-2Kb-HLA-A2 
chimeric pentamers, which are reported to specifically stain CD8+ T cells of HLA-humanized 
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mice (Choi et al., 2002), did exhibit specific staining to some extent – but their sensitivity was 
always lower than the sensitivity achieved in IFN-γ ICS analyses and also seemed to vary 
between epitopes (data not shown). This finding could be explained by the theory that the 
affinity of some murine T cell receptors to the human α1 and α2 domains of HLA-A2 is high 
enough to activate the T cell but not high enough to bind the cell to the fluorophore-coupled 
multimer for a time long enough to allow detection. Our method of choice was therefore 
IFN-γ/TNF-α ICS with subsequent flow cytometric analysis. Additionally, a clear advantage of 
the IFN-γ ICS is that only T cells that are activated are counted in the flow cytometer. A T cell 
that is stained with an MHC multimer does not have to be functional but only to express a 
suitable TCR with an affinity high enough for prolonged binding to the multimer. In contrast, 
a T cell that is able to express IFN-γ after epitope recognition is capable of fulfilling one of its 
most important effector functions.  
We compared three different vaccine formulation types which differ greatly in their 
mechanism of action: emulsion-based formulations, mRNA vaccines and several amphiphilic 
compounds. In the emulsion-based approach and the amphiphilic compounds we used 
synthetic short peptides (SSP). SSPs are, as SLPs, considered safe, stable and are easy to 
produce (Chabeda et al., 2018). SSPs also induce powerful activation of CD8+ T cells (Rosalia 
et al., 2013). However, synthetic short peptides can also be presented by non-professional 
APCs by binding to MHC class I present on the outside of the cell by e.g. replacing the 
naturally presented ligand (Eisen et al., 2012). Since non-professional APCs do not supply T 
cells with signals 2 and 3 (see Figure 2), this process can lead to immune tolerance (Bijker et 
al., 2007), which is a strategy to prevent autoimmunity. Both vaccine formulations used in 
this study reduce the presentation of epitopes on non-professional APCs. The oil emulsion 
of IFA is mostly taken up by professional phagocytes (Murphy et al., 2016) and the 
amphiphilic vaccines have been shown to bind to albumin and thus migrate along with 
albumin to the lymph node in which they are taken up by DCs and macrophages (Liu et al., 
2014). The mRNA vaccine could potentially also induce tolerance if non-professional APCs 
take up the mRNA, express the encoded peptides and present them as an internally 
generated epitope on MHC class I. However, the lipoplex formulation of this vaccine ensures 
that the mRNA is virtually exclusively taken up by professional APCs, in particular DCs (Kranz 
et al., 2016).  
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We used an emulsion-based formulation for our first experiments with E7/11-19. E7/11-19 
epitope vaccination has, to the best of our knowledge, never been performed in HLA-A2-
humanized mice before. Emulsion-based formulations have long been the gold standard for 
the induction of CD8+ T cells, and thus also for therapeutic anti-cancer vaccines. To verify the 
immunogenicity of E7/11-19 also in A2.DR1 mice, we used a water-in-oil emulsion based on 
the mineral oil ISA51. Indeed, we could observe E7/11-19-specific CD8+ T cells after one 
injection of this formulation. To date, there is only one study that quantifies frequencies of 
anti-HPV16 CD8+ T cells in HLA-A2-humanized mice in response to vaccination with emulsion-
based vaccines (Daftarian et al., 2007). These authors report frequencies of approximately 
1 % of splenocytes specific for E7/82-90 and 0.65 % specific for E7/11-20 in one mouse each 
after a single vaccination with VacciMax®, an emulsion-based vaccine adjuvanted with CpG. 
However, these results were obtained in HLA-A2 transgenic mice in which the HLA-A2 
molecule was not altered to contain a murine α3 domain. Therefore, the authors speculate 
that the TCRs in this mouse model have a particularly high affinity for their MHC:peptide 
complex to allow binding despite the murine CD8/human α3 HLA domain incompatibility. It 
is unclear what the frequency of CD8+ T cells is among the splenocytes of these mice, which 
would be important to know for being able to compare these results directly with the ones 
obtained in A2.DR1 mice. Nevertheless, the results obtained in our experiments seem to be 
within the same range and showed with certainty that E7/11-19 is immunogenic in A2.DR1 
mice. However, the obtained T cell numbers did not justify testing this formulation in an anti-
tumor setting. Especially in the light of recent publications showing the immune response-
debilitating effects of depot vaccines (Hailemichael et al., 2013, 2018) we hypothesized that 
inducing E7/11-19-specific CD8+ T cells via different formulations would yield better anti-
tumor responses than the use of emulsion-based vaccines. 
As a second formulation to induce E7/11-19-specific CD8+ T cells, we tested mRNA vaccines 
in collaboration with the company BioNTech (Mainz). The advantages of mRNA vaccines are 
their relatively fast production, which permits the synthesis of personalized vaccines; the 
mRNA’s self-adjuvanting characteristics; and its capability to be immediately translated once 
taken up by cells. The resultant peptides are directly transported into the ER and loaded onto 
MHC class I, making cross-presentation unnecessary. This is facilitated by a C-terminal MITD 
sequence that further enhances epitope presentation on MHC class I and class II (Kreiter et 
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al., 2007). Furthermore, a phosporothioate cap on the 5’ end of the RNA introduced into the 
RNA vaccines of BioNTech protects the RNA from degradation in the target cells and 
enhances translation specifically in immature DCs (Kuhn et al., 2010). mRNA delivered in 
BioNTech’s systemically applied liposomes is mostly taken up by professional APCs which 
prime T cells in lymph nodes all over the body, making the priming of T cells very efficient 
(Kranz et al., 2016). This mechanism of action of the lipoplex formulation also ensures that 
the professional APC that expresses the mRNA provides the necessary additional two signals 
to prime T cells, since the mRNA itself is a TLR agonist and thus activates the professional 
APC taking up the mRNA construct. One of the disadvantages of mRNA vaccines is that mRNA 
is susceptible to degradation by RNases, therefore careful handling of all substances and 
tools used for the generation of RNA vaccines is of paramount importance. BioNTech’s mRNA 
vaccines are currently tested in several clinical trials (e.g. NCT02410733, NCT02035956). 
Among these is a first-in-human phase I/II trial in patients with HPV16+ positive cancers with 
E6/E7 mRNA that is complexed in lipids (Eudra CT No.: 2014-002061-30). 
In a preliminary experiment with E7 full length mRNA we did not observe an induction of E7-
specific T cells. This experiment was conducted with only one mouse per construct with the 
objective to screen several different mRNAs in a setting in which the availability of the in-
house bred A2.DR1 mice was limited. Since in this experiment only one mouse was used and 
since E7 full length mRNA induced strong anti-E7 responses in other mouse models (personal 
communication Dr. Christian Grunwitz) this result should be regarded with caution. The lack 
of induction of E7/11-19-specific CD8+ T cells after injection of mRNA encoding only E7/11-19 
(Figure 26) was an expected result since also in previous experiments conducted by BioNTech 
elongation of the minimal epitope by three amino acids up- and downstream of the epitope 
was necessary to induce an immune response (personal communication Dr. Christian 
Grunwitz). Following this approach, we observed CD8+ T cells specific for this epitope after 
vaccination with two constructs (E7/8-21 +/- PADRE) that included three amino acids before 
and after the E7/11-19 sequence to allow correct antigen processing. The induced 
frequencies of E7/11-19-specific CD8+ T cells were relatively low (approximately 1 % of CD8+ 
T cells), but since the mRNA vaccines also increased the overall frequency of CD8+ T cells in 
the spleen of the treated animals to approximately 13.5 %, the frequencies of E7/11-19-
specific CD8+ T cells cannot be compared directly with the frequencies of E7/11-19-specific 
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CD8+ T cells in mice treated with other vaccines. Accounting for this confounding factor, the 
overall number of E7/11-19-specific CD8+ T cells was still lower in mRNA treated animals than 
in animals treated with the most successful amphiphilic vaccines (Figure 32).  
In addition, we observed a response against an epitope that was created by the linker 
sequences connecting the mRNA backbone and the E7/8-21 sequence (SLHEYMLDL). The 
immune response directed against this epitope was approximately two times stronger than 
the one against the target epitope E7/11-19. Since it is our explicit aim to exclude 
unproductive immune responses, this finding was highly unfavorable. Therefore, steps were 
undertaken to ensure that induced immune responses were exclusively directed against the 
target epitope. To do so, we changed the anchor amino acid leucine of the artificial 
SLHEYMLDL epitope to an alanine, which should abrogate binding of this peptide to HLA-A2. 
After this amino acid exchange, we did not observe any immune responses directed against 
E7/11-19 or against SAHEYMLDL (data not shown). We hypothesize that the most likely 
reason for this finding is that the new amino acid sequence is not processed by peptidases 
into the respective epitopes. An in silico test with the proteasome cleavage prediction server 
NetChop 3.1 (Keşmir et al., 2002; Nielsen et al., 2005) gave backing to this hypothesis. Using 
a combination of MHC epitope binding prediction servers (NetMHC 4.0 and SYFPEITHI) and 
NetChop we found that the exchange of the serine contained in the linker sequence to other 
amino acids than alanine could lead to mRNAs that can induce immune responses specifically 
against E7/11-19. These mRNAs will be tested in future experiments for the exclusive 
induction of CD8+ T cells recognizing E7/11-19.  
Amphiphilic vaccines are reported to function by albumin hitchhiking of the peptide-
containing compounds to lymph nodes (Liu et al., 2014). Apparently, in addition to lymph 
node targeting, amphiphilic vaccines also result in improved uptake by DCs (Wang et al., 
2018). The albumin binding strategy has previously been used together with nanoparticles 
(Zhu et al., 2017) and amphiphilic vaccines were also successfully combined with other 
immunotherapeutic interventions such as anti-tumor ABs, IL-2 and checkpoint blockade 
(Moynihan et al., 2016). We adapted two different approaches from the literature to make 
minimal epitopes amphiphilic: the Pam2 approach developed by Cho et al. (Cho et al., 2013) 
and the LPP approach developed by Liu et al. (Liu et al., 2014). Furthermore, we generated 
two more compounds that were designed with the rationale to improve the applicability of 
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the Pam2 approach by allowing easier and more specific synthesis (Pam1 and Stea2 
compounds).  
All compounds were tested for their ability to induce CD8+ T cell responses against our lead 
epitope E7/11-19. Except Pam1-E7/11-19, all compounds induced substantial frequencies of 
E7/11-19-specific CD8+ T cells in A2.DR1 mice. Since the only difference between Pam1-
E7/11-19 and Pam2-E7/11-19 is that Pam2-E7/11-19 contains one more palmitic acid, it is 
likely that the lack of a T cell immune response after vaccination with Pam1-E7/11-19 is 
founded in this difference. This finding matches the observations of Liu et al. that CpG 
coupled to a monoacylated compound does not migrate to lymph nodes as readily as CpG 
coupled to a diacylated compound. This decrease in lymph node localization could explain 
the decrease in vaccination efficacy.  
Putting the results obtained with the amphiphilic vaccines in A2.DR1 mice in relation to 
results of other groups with these compounds is difficult since no results of experiments with 
these compounds in humanized mice have been published so far. Nevertheless, some 
conclusions can be drawn from observations made in this study that have an impact on the 
general understanding of the working principle of amphiphilic vaccines. 
Cho et al. report that their Pam2 compounds only elicit very high frequencies of epitope-
specific CD8+ T cells when pIC is used as a TLR agonist and not with other TLR agonists such 
as CpG (Cho et al., 2013). The LPP compound was also tested with pIC and an amphiphilic 
variant of CpG and it was shown that this amphiphilic CpG was a better adjuvant than non-
amphiphilic CpG to be used in conjunction with LPP, since this combination induced higher 
frequencies of epitope-specific CD8+ T cells (Liu et al., 2014). Interestingly, our LPP-E7/11-19 
adjuvanted with CpG did not elicit substantial CD8+ T cell responses, which is in contrast to 
LPP-E7/11-19 adjuvanted with pIC (Figure 30). Therefore, our results regarding the TLR 
agonist to be used to adjuvant amphiphilic epitopes are more in line with the findings made 
by Cho et al.. However, we did not use amphiphilic versions of either CpG or pIC. 
One major difference between pIC and CpG is that TLR9, which recognizes CpG, is different 
in mice and humans (Bauer et al., 2001). Different CpG motifs are needed to boost immune 
responses in these two species. In contrast, TLR3, is of sufficient similarity between mice and 
humans to recognize pIC in both species (Martins, Bavari and Salazar, 2015). Therefore, 
 Discussion 
  
 
 
120 
 
results generated with pIC in mice can be more directly translated into the human setting 
than results generated with CpG.  
Another interesting observation that we made concerns the optimal route of injection. Cho 
et al. report that intravenous injection of the Pam2 compounds was approximately three 
times more effective in inducing epitope-specific CD8+ T cells than the subcutaneous 
injection route. We could not reproduce these findings as the chemically extremely similar 
compound Stea2-E7/11-19 induced slightly more epitope-specific CD8+ T cells when injected 
subcutaneously (Figure 28). In the study by Liu et al., the LPP compounds were always 
injected subcutaneously. We speculated that the intravenous injection of LPPs could 
increase the vaccines’ efficacy – as had been shown before by Cho et al. with their 
amphiphilic compound. Remarkably, we could not confirm this hypothesis since the 
intravenous injection of LPP did not give rise to any epitope-specific T cells. This surprising 
result may be explained by the different chemical structures of the Pam2 and the LPP 
compound. Due to the long PEG spacer, the LPP compound is much larger than the Pam2 
compound. It is possible that the LPP compound is more easily taken up by e.g. liver cells and 
thus taken out of the circulation before a DC has the chance to take it up. This process would 
not be relevant in subcutaneously injected LPP because the subcutaneous liquid is not 
passed through the liver before albumin binding and transport to the lymph nodes takes 
place.  
We compared the efficacy of the various vaccination approaches by their capability to induce 
high frequencies of E7/11-19-specific CD8+ T cells. Due to experimental reasons, we used the 
frequency of specific CD8+ T cells among CD19- splenocytes as a surrogate for the whole-
body frequency of specific CD8+ T cells in the animals. This surrogate is justified because the 
vast majority of specific CD8+ T cells have left the lymph nodes and have entered the 
circulation (and thus can be found in the spleen) seven days after the last vaccination.  
One of the most important factors that determine if a therapeutic vaccination will be 
successful is the total number of tumor-reactive T cells in the individual, if the quality of 
these cells is held constant. This can be seen in studies in which animals were treated with 
adoptive transfer of T cells. In these studies, higher total numbers of tumor-reactive T cells 
are correlated with better treatment efficacy (Klebanoff et al., 2012). Knowing the frequency 
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of epitope-specific CD8+ T cells within the CD8+ T cell compartment is therefore not enough, 
because the size of the CD8+ T cell compartment is also important. The total size of the CD8+ 
T cell compartment can be described as the mathematical product of two factors: The total 
number of immune cells and the percentage of CD8+ T cells among the immune cells. To 
determine the second factor, we quantified the percentage of CD8+ T cells among the 
immune cells in the spleen. In this analysis, we observed a remarkable increase in the 
frequency of CD8+ T cells among CD19- splenocytes after vaccination with mRNA and all 
amphiphilic constructs but not after vaccination with emulsion-based vaccines (Figure 31). 
The most remarkable increase in the frequency of CD8+ T cells could be observed in the mice 
that were treated with mRNA. In this group, the mean overall frequency of CD8+ T cells 
among splenocytes was 13.5 % (compared to 5 % in naïve A2.DR1 mice). The mean overall 
CD8+ frequency in animals treated with amphiphilic vaccines was approximately 8 %.  
As mentioned before, it is not feasible to determine the total number of immune cells or 
CD8+ T cells in a whole animal and the spleen represents a potential surrogate measure. Due 
to interexperimental uncertainties regarding the comparability of the number of splenocytes 
per mouse, we chose not to include the differences we observed in these assays into our 
analysis (see 4.3.1.4). Therefore, it is important to estimate the size of a potential error 
introduced by omitting this factor and if this could change the outcome of the comparison 
between the groups. We observed splenocyte counts between 30x106 and 55x106 
splenocytes per spleen in naïve mice (data not shown). Splenocyte counts in vaccinated 
animals usually ranged from 30x106 to 75x106 splenocytes per mouse. Only in exceptional 
cases the splenocyte count was as high as 150x106 per spleen. We observed these high 
counts only in experiments in which mRNA had been injected. Therefore, the treatment 
group most affected by not including the spleen size is the mRNA group since we observed 
the highest number of splenocytes per spleen in this group. Assuming the largest possible 
error resulting from the difference between 30x106 and 150x106, the median frequency of 
E7/11-19-specific CD8+ T cells induced by vaccination with mRNA vaccines could be 
underestimated by a factor of five. To correct for this potential error, the median frequencies 
of E7/11-19-specific CD8+ T cells among CD19- splenocytes induced by the mRNA vaccines 
(0.065 %) have to be multiplied by five. The resulting frequency of 0.325 % can then be 
directly compared with the frequency of E7/11-19 specific CD8+ T cells that are induced by 
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LPP-E7/11-19 (0.63 %). Thus, the mRNA vaccines would still only induce half the median 
frequency of E7/11-19-specific CD8+ T cells that are induced by LPP-E7/11-19. Therefore, it 
can be concluded that the chosen comparison approach excludes a critical underestimation 
of some vaccines’ performance that could have altered the outcome of the comparison 
between the vaccine formulations. 
All amphiphilic vaccines that induced substantial frequencies of specific CD8+ T cells (Pam2 
i.v. pIC, Stea2 s.c. pIC, LPP s.c. pIC) induced more E7/11-19-specific CD8+ T cells than the 
emulsion-based vaccines and the mRNA vaccines by direct comparison of frequencies of 
E7/11-19-specific CD8+ T cells and also when taking into account the increase in overall CD8+ 
T cell frequencies (Figure 32). The injected quantities of these three compounds were not 
perfectly comparable due to the impurities mainly in the Pam2 compound that motivated us 
to generate the Stea2 compound. Even with this slight limitation in comparability, we found 
the LPP compound to have the most favorable overall performance in terms of induction of 
E7/11-19-specific CD8+ T cells, ease of production and handling.  
5.3.2 Characterization of immune responses induced by LPP vaccines 
Therefore, we used the modular synthesis scheme of this compound that facilitates the use 
of various peptides to generate three further HPV16 minimal epitope LPPs (LPP-E7/7-15, 
LPP-E7/82-90 and LPP-E6/25-33). We chose the two additional HPV16 E7 epitopes because 
CD8+ T cells against these epitopes could be found in healthy donors and the presentation of 
these epitopes on CaSki cells was confirmed by mass spectrometry (Blatnik et al., 2018). This 
study showed that E7/7-15 and E7/82-90, in addition to E7/11-19, represent target 
structures on cancer cells and that CD8+ T cell responses against these epitopes are 
immunodominant enough to appear during a natural infection. An additional reason to focus 
on E7-derived epitopes was that the E7 sequences found in cervical cancers are virtually 
devoid of any mutations, whereas conservation of E6 does not seem to be as critical for 
carcinogenesis (Mirabello et al., 2017). We still decided to also include one E6-derived 
epitope, LPP-E6/25-33. In our experiments, we found that all of the three additional LPPs 
induced substantial frequencies of epitope-specific CD8+ T cells (Figure 33) when they were 
injected subcutaneously together with pIC.  
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It has been reported that T cells that produce more than one cytokine, which are therefore 
called multifunctional, particularly contribute to tumor clearance (van Duikeren et al., 2012). 
Therefore, we tested the ability of the vaccination-induced, epitope-specific CD8+ T cells to 
express TNF-α in addition to IFN-γ. T cells of all four specificities responded to activation with 
TNF-α expression. This was most pronounced in the E7/11-19-specific CD8+ T cells in which 
approximately 10 % expressed TNF-α in addition to IFN-γ. Liu et al. found approximately 12 % 
of epitope-specific CD8+ to be expressing TNF-α, which matches our results for E7/11-19-
specific CD8+ T cells. Interestingly, only very few CD8+ T cells responded to activation with 
only TNF-α expression and no IFN-γ expression. 
To be considered fully functional, CD8+ T cells have to exhibit cytotoxicity in addition to 
cytokine production – hence the term „cytotoxic T cells“ (CTLs), which is often used 
interchangeably to „CD8+ T cells”. In this study, we observed specific killing of peptide-loaded 
target cells (Figure 37) for CD8+ T cells of all four specificities of interest (E7/7-15-, E7/11-19-, 
E7/82-90- and E6/25-33-specific) and were therefore able to confirm that these vaccination-
induced CD8+ T cells truly are fully functional cytotoxic T cells. However, it is important to 
keep in mind that the setting of externally loaded target cells with peptides added in high 
concentrations does not resemble the natural situation where, usually, only few MHC 
molecules on the cell surface present the respective epitope.  
To test the T cells’ killing capacity in a more natural scenario, we made use of the newly 
developed PAP-A2 cell line that expresses HPV16 E6 and E7. Thus, PAP-A2 cells should also 
present internally processed peptides contained in the E6/E7 sequence on MHC class I. The 
expression levels of E7 in PAP-A2 are much lower than in CaSki cells (Figure 23), a human cell 
line that was derived from a HPV16-induced cervical carcinoma. It is therefore reasonable to 
assume that PAP-A2 cells present fewer copies of E7-derived peptides on their surface than 
CaSki cells. The killing of PAP-A2 cells by E7-specific cytotoxic T cells should consequently 
represent a bigger challenge than the killing of CaSki cells. Nevertheless, we observed 
specific killing of PAP-A2 cells by T cells of all four specificities, which was especially 
pronounced in the case of E7/11-19-specific CD8+ T cells. This result demonstrates that 
murine PAP-A2 cells process and present the respective epitopes on HLA-A2, proving the 
suitability of our newly generated tumor model to test anti-tumor vaccinations with these 
epitopes. This result is in contrast to the findings of Street et al. who report that E7/82-90-
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specific T cells derived from AAD mice were unable to kill cells endogenously expressing 
HPV16 E6/E7 (Street et al., 2002). Since in that study it was found that the same E7/82-90-
specific T cells were able to kill target cells that were externally loaded with E7/82-90 
peptide, the authors concluded that there are differences in the epitope-processing 
machinery of mice and humans that do not allow the processing of E7 into E7/82-90. 
Consistent with their findings, the group argues that due to these differences the value of 
humanized mouse models for the study of therapeutic vaccines is limited. The results 
obtained in this PhD project cannot support this hypothesis, since all four epitopes, among 
them E7/82-90, that were found on naturally transformed HPV16+ human cells were 
generated from endogenously expressed E6/E7 and presented on our PAP-A2 murine cells. 
The magnitude of killing of epitope-loaded target cells and PAP-A2 target cells can be directly 
compared as for both experiments T cells from the very same culture were used. The less 
pronounced killing of PAP-A2 compared to epitope-loaded 2277NS cells by E7/7-15-, 
E7/11-19- and E7/82-90-specific CD8+ T cells could be explained by the theory that fewer 
HLA-A2 epitope complexes with these epitopes can be found on the surface of the PAP-A2 
cells than on 2277NS cells that were externally loaded with synthetic minimal epitopes. It is 
however not possible to compare the killing capacities of the CD8+ T cells of different 
specificities because the numbers of epitope-specific CD8+ T cells within the T cell cultures 
were not controlled in this experiment. Adjusting the numbers of specific CD8+ T cells to 
equal numbers would have required an additional ICS staining, which was not possible with 
the limited cell material at our disposal. However, if one was to control for the number of 
cells and observe a difference in the killing capacity of CD8+ T cells of different specificities, 
two explanations for this are possible: First, the TCRs have different affinities for their 
respective MHC:peptide complex and second, the different HLA-A2-binding affinities and/or 
the differences in efficiency of the processing of the epitopes lead to different abundance of 
the respective epitopes presented on HLA-A2 and therefore alter the number of potential 
target molecules on the cells, and thus the likelihood of a T cell finding its specific target 
complex.  
In a test experiment (data not shown) we observed that the mixing and injection of LPP-
E7/11-19 and LPP-E7/82-90 resulted in a median frequency of E7/11-19-specific CD8+ T cells 
of 0.44 % (compared to 4.2-13 % in a single vaccination). We also found that the median 
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frequency of E7/82-90-specific CD8+ T cells was slightly diminished compared to single 
vaccination (1.5 %, compared to a median frequency of 2.0 % in single E7/82-90-vaccination). 
However, since we observed precipitation of the two LPPs that were mixed, the finding of 
reduced frequencies of epitope-specific CD8+ T cells may have been explained by the 
precipitation, since precipitated LPPs e.g. might not attach well to albumin. To exclude 
effects caused by precipitation before injection, we injected different combinations of 
HPV16 LPPs into different subcutaneous injection sites in a follow-up experiment (see 
4.3.2.4). We found that the anti-E7/11-19 CD8+ T cell response was again greatly diminished 
compared to the single LPP immunization (median of 4.2-13 % in single vaccinations, 
approximately 0.45 % in combinations) by administering different LPPs at the same point of 
time. Furthermore, also the frequencies of the CD8+ T cells specific for the other injected 
epitope(s) were reduced. This resulted in a generally lower frequency of potentially tumor-
reactive CD8+ T cells as evaluated by incubating the splenocytes with a combination of the 
different epitopes in one well and by adding up the frequencies of IFN-γ+ CD8+ T cells after 
incubation with the single epitopes used in the treatment. The small differences between 
the two methods used could be explained by different affinities of the epitopes to HLA-A2 
leading to competition for HLA-A2-binding and therefore also differential T cell activation in 
the restimulation with all peptides combined in one well.  
After the first test experiment we considered immunodominance as a potential reason since 
the magnitude of the response against E7/82-90 was only slightly diminished compared to 
single LPP-E7/82-90 vaccination, while the E7/11-19 response was nearly completely 
suppressed. However, in the follow-up experiment we observed reduced frequencies of 
CD8+ T cells specific for all the epitopes when combined. Thus, immunodominance of one 
epitope over the others can be excluded as a potential reason. 
In the combination experiments, the total pIC amount of 50 µg per mouse was distributed 
equally to all injection sites. Potentially, this reduced local amount of pIC may have led to 
reduced DC activation, which in turn resulted in less T cell activation. However, also in other 
experiments the 50 µg pIC per mouse were distributed over a larger area, namely in all 
experiments in which amphiphilic vaccines (Stea2-E7/11-19, Pam2-E7/11-19) were injected 
intravenously. In these experiments, the priming of E7/11-19-specific CD8+ T cells was not 
impaired. 
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Another potential reason for the impaired activation of epitope-specific CD8+ T cells may lie 
in the LPP dose, which was twice as high as in the single immunizations (three times and four 
times for the combinations with three and four LPPs, respectively). Potentially, the high 
amount of fatty acids could either cause mechanical problems, such as impaired lymph 
drainage of the injection sites, or impair DC behavior. This hypothesis could be tested by 
injecting a double dose of LPP-E7/11-19. If this vaccination, despite the injection of a large 
amount of LPP, gives rise to similarly high frequencies of E7/11-19-specific CD8+ T cells as 
observed in single LPP-E7/11-19 vaccination, the theory of an impairing effect of too high a 
concentration of fatty acids would be falsified.  
Taken together, our results argue for the use of minimal epitopes which need to be matched 
carefully to avoid epitope-specific immunosuppression, if a combination of epitopes is 
desired (Figure 39, Figure 40).  
VGX-3100 is the most successful therapeutic vaccine in clinical trials so far and the DNA in 
this vaccine encodes for longer stretches of E6/E7 sequences (Trimble et al., 2015). It would 
be interesting to see if the epitope-specific immunosuppression would also be observed 
after immunization with this construct. Since this vaccine showed clinical efficacy, the 
specificity of the induced CD8+ T cells is of large interest. This DNA vaccine may not induce 
epitope-specific immunosuppression, or the potentially very wide breadth of T cell 
specificities allows the development of high enough total numbers of tumor-reactive T cells 
to have a therapeutic effect. 
5.3.3 Efficacy of anti-tumor vaccinations 
Thus far, we have shown the establishment of the tumorigenic HPV16 E6/E7-expressing cell 
line PAP-A2 and of a vaccination formulation (LPP) that induces high frequencies of HPV16 
epitope-specific CD8+ T cells. We were able to show in in vitro experiments that the 
vaccination-induced, epitope-specific CD8+ T cells are capable of killing the PAP-A2 cells. 
After these successful experiments, it remained to be seen if this in vitro anti-tumor cell 
effect would also translate into an anti-tumor effect in vivo.  
To test if this was the case, we first chose a prophylactic vaccination approach, i.e. we 
vaccinated A2.DR1 mice with LPP-E7/11-19 and subsequently challenged them with PAP-A2 
tumor cells (Figure 41). This approach was also chosen to rule out potential anti-tumor 
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effects by a general stimulation of the immune system by pIC injection, since the last pIC 
injection took place seven days before the tumor challenge. This hypothesis was confirmed 
by the finding that the survival curves of the untreated group overlapped with the vehicle 
control-treated group. In this experiment, we observed a significant difference in mean 
survival times as well as in overall survival between the vehicle control-treated group and 
the LPP-E7/11-19-treated group. Since the only difference in treatment between these two 
groups was the inclusion of the E7/11-19 epitope in the vaccine formulation, the difference 
in survival is most likely based on the induction of E7/11-19-specific CD8+ T cells in the LPP-
E7/11-19 group.  
Since our declared goal is the development of a therapeutic HPV16 vaccine that can be used 
against precursor lesions and cancer, it was necessary to test the LPP-E7/11-19 efficacy also 
in a therapeutic experimental setting (Figure 42). In this experiment, we observed complete 
tumor rejection in 50 % of the LPP-E7/11-19-vaccinated mice, which is substantially more 
than in the untreated (12.5 %) or the vehicle control-treated (0 %) groups. Studies of 
therapeutic HPV16 vaccines in C57BL/6 mice with TC-1 tumors have sometimes reported 
higher tumor rejection rates than the ones observed in our experiments (Cho et al., 2013; 
Liu et al., 2014; Bissa et al., 2015; Heidenreich et al., 2015; Kranz et al., 2016). However, in 
the TC-1 model, immune responses are often induced against the extremely immunogenic 
H-2Db-restricted E7/49-57 epitope. It is likely that the HLA-A2-restricted E7/11-19-epitope is 
less immunogenic than E7/49-57 and therefore induces lower frequencies of epitope-
specific CD8+ T cells with direct influence on treatment success. For example, Liu et al. 
observed frequencies of more than 20 % E7/49-57-specific CD8+ T cells among all CD8+ T cells 
with LPP-E7/49-57 and only one booster injection instead of the two booster injections used 
in our treatment regimen. Cho et al. even report that more than 40 % of all CD8+ T cells were 
specific for E7/49-57 after two injections of Pam2-E7/49-57 in C57BL/6 mice. In addition to 
the potential difference in immunogenicity of the two used epitopes, it is important to keep 
in mind that not only the tumor inoculation and treatment schemes in the various studies 
were different (such as numbers of injected cells and time until treatment initiation), but 
that in the other studies a completely different cell line and mouse model was used. Naïve 
C57BL/6 mice have approximately threefold higher frequencies of total CD8+ T cells (15 % of 
CD19- cells in splenocytes, (BioRad, 2018)) compared to A2.DR1 mice (5 % of CD19- cells in 
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splenocytes, Figure 31). This is most likely due to inferior affinities of murine TCRs to HLA-A2, 
leading to negative selection during the thymic development of T cells in A2.DR1 mice. The 
difference in overall CD8+ T cell numbers certainly has a direct influence on the overall 
number of epitope-specific CD8+ T cells in each given mouse. Furthermore, the susceptibility 
of TC-1 tumors and PAP-A2 tumors to T cell-mediated killing may be completely different. 
Susceptibility to T cell killing depends on MHC class I expression, expression of immune 
modulatory surface molecules by the tumor cells and a tumor microenvironment (such as 
the presence of myeloid-derived suppressor cells (MDSC) (reviewed in (Umansky et al., 
2016)) or hypoxic areas in the tumor) that is more or less permissive for CD8+ T cell actions 
(reviewed in (Gajewski, Schreiber and Fu, 2013)). The same caveats about tumor cell line-
inherent differences also hold true for results obtained in AAD mice with e.g. HLF16 cells. 
Therapeutic vaccination with other LPP-HPV16 epitopes did not induce anti-tumor effects as 
strong as LPP-E7/11-19, even though treatment with LPP-E7/7-15 and LPP-E7/82-90 resulted 
in a small increase in tumor rejection compared to the vehicle control-treated animals 
(Figure 43). This is especially interesting in the light of the result that all four LPP compounds 
induced similar frequencies of epitope-specific CD8+ T cells (Figure 33). However, we 
observed a significant difference in IFN-γ expression between E7/7-15 and E7/11-19-specific 
CD8+ T cells, which could explain the better performance of E7/11-19 (Figure 34). On the 
other hand, the IFN-γ expression between E7/82-90-, E6/25-33- and E7/11-19-specific CD8+ 
T cells was not different, making this hypothesis unlikely. Of course, different affinities of the 
respective TCRs to their MHC:peptide complex could explain this phenomenon. Similarly, a 
lower avidity of the TCR of the CD8+ T cells specific for E7/7-15, E7/82-90 and E6/25-33 to 
the tumor cells could also explain the observed results. This explanation would also take into 
account differential antigen processing in the tumor cells. The hypothesis of differential 
antigen processing in tumor cells is supported by the finding that in mass spectrometry 
analysis of HPV16 epitopes presented on HLA-A2 on CaSki cells, E7/11-19 was the most 
abundantly detected epitope (Riemer et al., 2010). Another potential explanation is based 
on the observation that the highest frequencies of multi-cytokine expressing epitope-specific 
CD8+ T cells were detected in animals treated with LPP-E7/11-19. The multifunctional CD8+ 
T cells could mediate much stronger anti-tumor effects than T cells only expressing IFN-γ 
after activation, as was reported before (van Duikeren et al., 2012).  
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Interestingly, we often observed a two-armed distribution of mice in regard to their ability 
to mount an epitope-specific CD8+ T cell response in vaccination experiments in non-tumor 
bearing mice. Some mice responded with considerably higher frequencies of specific CD8+ T 
cells than others within the same group. This seems to be a characteristic of the A2.DR1 mice, 
since we observed this phenomenon with all vaccine formulations including the LPP 
formulation (Figure 28, Figure 30, Figure 33). Unfortunately, we could not assess if this 
observation translates into corresponding survival in tumor-bearing mice, since the readout 
with IFN-γ ICS requires more cells than can be isolated from a blood sample from a single live 
mouse, and thus necessitates sacrificing of mice and spleen isolation. However, it is tempting 
to speculate that the animals which exhibited less pronounced anti-tumor effects within a 
group indeed also belonged to the group of animals with fewer vaccination-induced CD8+ T 
cells.  
When we vaccinated tumor-bearing mice with combinations of the previously tested HPV16 
minimal epitope constructs, we observed anti-tumor effects that were similar in magnitude 
to single immunizations with E7/7-15, E7/82-90 and E6/25-33 and that were therefore 
inferior to single immunization with E7/11-19. Since we also observed reduced overall 
frequencies of CD8+ T cells that were specific for the four used epitopes upon combination 
vaccination with LPPs (4.3.2.4) it is likely that the inferior anti-tumor efficacy is based on 
reduced frequencies of these cells. This is in contrast to the findings of Daftarian et al. 
(Daftarian et al., 2007) who reported equal anti-tumor effects with E7/82-90 in a single 
epitope-vaccine and in a mix with three additional HPV16 minimal epitopes (E7/11-20, 
E7/86-93 and E6/29-38). However, the epitopes were supplied in an emulsion-based vaccine, 
which could lead to equal immune responses against all these epitopes. The observed results 
could therefore be explained by differences in delivery form (emulsion-based vaccine vs. 
LPP) and the different epitopes.  
One way to prevent the suppression of CD8+ T cell responses against single epitopes upon 
injection of several LPP compounds in our system could be to use LPPs with different 
epitopes in an alternating vaccination regime such as 1st injection: LPP-E7/11-19, 2nd 
injection: LPP-E7/82-90, 3rd injection: LPP-E7/11-19 et cetera. However, the question would 
remain if the additional presence of even high frequencies of e.g. E7/82-90-specific CD8+ T 
cells would result in a pronounced increase in anti-tumor effects, since also the single 
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immunization with LPP-E7/82-90 did not induce large anti-tumor effects. This is underlined 
by the fact that the median frequencies of potentially tumor-reactive CD8+ T cells were not 
very low in the combination treatments (7+11+82: 3.33 %, 7+11+25: 4.22 %, 11+82+25: 
2.64 %, 7+11+82+25: 3.66 %). Nevertheless, these T cells, which contained close to no 
E7/11-19-specific CD8+ T cells, did not induce pronounced anti-tumor effects. Therefore, it 
seems likely that of the T cell specificities thus far induced in the A2.DR1/PAP-A2 tumor 
model, only E7/11-19-specific CD8+ T cells mediate pronounced anti-tumor effects.  
Overall, the therapeutic and prophylactic tumor vaccination experiments show that single 
immunization with LPP-E7/11-19 induces strong anti-tumor effects that are more 
pronounced than the ones induced by the other tested HPV16 LPP minimal epitope 
constructs or by combinations of different HPV16 minimal epitope LPPs. 
The fact that an E7-derived epitope was effective in the mediation of anti-tumor effects in 
our PAP-A2 model is especially promising since the E7-expression levels of PAP-A2 cells are 
markedly lower than in the human cervical cancer cell line CaSki (Figure 23). Therefore, it is 
likely that CaSki cells – and maybe other naturally HPV16-induced tumors – present higher 
amounts of E7/11-19 epitopes on their surface, which would in turn facilitate T cell-mediated 
killing.  
Taking into account the results of this PhD thesis when evaluating the results of clinical 
studies that have used therapeutic peptide HPV vaccines, several observations can be made. 
Overall, only two completed clinical studies have treated patients of a specific HLA-type with 
defined epitopes. These studies have used either lipidated E7/86-93 peptide (Steller et al., 
1998) or E7/12-20 in an oil-emulsion with or without the addition of lipidated E7/86-93 
(Muderspach et al., 2000). These trials have shown only very moderate or no success in 
terms of disease reduction. Contributing to the poor performance of the treatment is the 
fact that all patients enrolled in the first study had advanced metastatic disease (Steller et 
al., 1998). However, both studies demonstrated the immunogenicity of the chosen peptides, 
but immune responses were not induced in all patients and were weak. This could be due to 
the fact that the lipopeptides in both studies were injected without TLR agonists and 
therefore activation of the innate immune system was not induced, leading to limited T cell 
priming. 
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Human T cell lines specific for E7/86-93 and E7/11-20 can effectively kill CaSki cells (Ressing 
et al., 1995), therefore these epitopes must be presented by these cancer cell line. Also in 
the course of our studies E7/11-20 was found on the surface of CaSki cells by mass 
spectrometry (Blatnik et al., 2018). The epitope E7/86-93 (TLGIVCPI) could not be confirmed 
to be presented on CaSki cells by Blatnik et al. because this peptide contains a cysteine at 
position 6. In the Blatnik study, cysteine-containing peptides were not monitored as the 
reactivity of cysteines allows the formation of many potential adducts that prevent detection 
by the employed targeted mass spectrometry approach (Blatnik et al., 2018).  
The study by Muderspach et al. and nearly all other clinical studies using peptide vaccines, 
including the most recent studies ((van Poelgeest et al., 2013; de Vos van Steenwijk et al., 
2014; Takeuchi et al., 2015), NCT02128126, NCT02426892, NCT02865135), have used SLPs 
or minimal epitopes in emulsion-based formulations, mostly ISA51, which was also used in 
this thesis. ISA51-based vaccines, in particular if used without the addition of TLR agonists 
such as MPLA, induced only very low frequencies of E7/11-19-specific CD8+ T cells compared 
to the amphiphilic formulations in this study (Figure 32). In addition to the low induction of 
epitope-specific CD8+ T cells, these few specific T cells are sequestered to the vaccination 
site where persistent granulomas form in some cases (van Doorn et al., 2016). We never 
observed such granulomas or other vaccination-related adverse effects in animals treated 
with amphiphilic vaccines, which represents another advantage of these formulations.  
In the light of the results of this PhD thesis, the suboptimal outcomes of the clinical studies 
mentioned above are not surprising. Future clinical studies will be able to benefit from the 
experiences gained in this thesis and the previous clinical studies and will hopefully yield 
better results.  
Taken together, the data presented in this thesis show that amphiphilic vaccines induce the 
highest frequencies of epitope-specific CD8+ T cells among the tested formulations, that 
vaccination-induced CD8+ T cells can specifically kill the newly established PAP-A2 cell line 
and that therapeutic vaccination with E7/11-19 induces strong anti-tumor effects.   
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6 Summary & Outlook  
Cancer immunotherapy holds the possibility to become a major pillar of future oncologic 
treatments. HPV16-induced cancers represent ideal targets for cancer immunotherapy, due 
to the obligatory expression of the HPV16 proteins E6/E7, against which no central 
tolerization has taken place. However, some hurdles still have to be overcome before anti-
HPV16 immunotherapies will become standard therapies in the clinic. Therefore, the aim of 
this study was to further improve the efficacy of anti-HPV16 immunotherapy by targeting 
problems that are specifically connected to this cancer entity.  
To this end, we established a new tumor model of HPV16 E6/E7-positive cancers in fully 
MHC-humanized A2.DR1 mice. Furthermore, several epitope-specific vaccination 
approaches were compared for their induction of cytotoxic T cells directed against mass 
spectrometry-verified HPV16 epitopes. Finally, a therapeutic vaccine formulation based on 
lipo-PEG-peptides (LPPs) generated in this study was successfully tested for its anti-tumor 
effect in the novel mouse tumor model.  
In our experiments, we used pIC as an adjuvant for the LPP vaccine. In contrast, the initial 
study by Liu et al. used an amphiphilic version of CpG to adjuvant their LPP formulation (Liu 
et al., 2014). This amphiphilic version of CpG reduced systemic toxicity and improved 
vaccination success since it is, like the LPP, trafficked to lymph nodes and taken up by 
professional APCs. A potential option to further increase the immune response in response 
to LPP vaccination would therefore be to generate an amphiphilic version of pIC. 
We achieved the best anti-tumor responses using the E7/11-19 epitope. This epitope is 
currently also tested in the clinic in a phase Ib/II trial in HLA-A*02+ patients with incurable 
HPV16-related oropharyngeal, cervical, or anal cancer (NCT02865135). The goal of this trial 
is to assess the safety and efficacy of DPX-E7, an emulsion-based vaccine containing E7/11-19 
in combination with cyclophosphamide. Emulsion-based formulations were the ones with 
the worst performance in our experiments. Therefore, it remains to be seen if the E7/11-19 
epitope can confer substantial anti-tumor effects in this setting. 
When we vaccinated A2.DR1 mice with combinations of HPV16 LPPs we observed a general 
decrease in the epitope-specific CD8+ T cell immune responses. So far, the precise reasons 
for this phenomenon have not been determined. Overcoming the problems that were 
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associated with the use of combinations of LPPs could diversify the anti-tumor immune 
response and thus also increase the overall number of tumor-reactive CD8+ T cells leading to 
improved anti-tumor effects. 
So far, MHC class II-restricted epitopes have not been used as LPPs for vaccinations. MHC 
class II-restricted CD4+ T cell responses provide help for CD8+ T cell responses and can 
therefore increase the efficacy of vaccinations aimed at expanding tumor-specific CD8+ T 
cells. In future experiments, we will test MHC class II (HLA-DR)-restricted responses in our 
A2.DR1 mice. Potential epitopes to be coupled to the amphiphilic construct can be either 
universally applicable non-natural epitopes like PADRE or be derived from HPV16 E6/E7. 
Epitopes that promiscuously bind to several MHC class II types are of particular interest since 
they can be used in larger groups of patients. Several MHC class II epitopes that 
promiscuously bind to HLA-DR molecules have been defined by our group (Grabowska, 
Kaufmann and Riemer, 2014) which represent the ideal starting point for in vivo vaccination 
studies with MHC class II LPP constructs.  
Furthermore, our laboratory is currently using the PAP-A2 cell line that was generated during 
this PhD thesis to establish orthotopic models of HPV16-induced cancers. For this, the 
PAP-A2 cells were transfected with a vector coding for luciferase, which makes the 
observation of tumor growth possible even when the tumor is not accessible and therefore 
cannot be measured with calipers. The use of orally and vaginally placed tumors as 
orthotopic models will enable researchers to modify the vaccination approach tested in this 
study to make it suitable for inducing strong immune responses in the mucosal environment 
with its special characteristics. So far, no orthotopic model of HPV-induced cancers has been 
established for MHC-humanized mice and the orthotopic models under development are 
expected to further increase the translational value of the results generated in this PhD 
thesis. Since the mucosal microenvironment is different from the subcutaneous 
microenvironment and since subcutaneously induced T cells do not readily migrate to 
mucosal sites, different methods to induce migration of the vaccination-induced T cells to 
the mucosal tumor will have to be tested. Potential ways to influence the migration of T cells 
towards the tumors would be special vaccination regimens (Çuburu et al., 2017), the local 
application of the chemokines CXCL9 and CXCL10 (Shin and Iwasaki, 2012) and the local 
application of immune modulators/TLR agonists such as R848 (Soong et al., 2014).  
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In addition to the above-mentioned future goals of our group several other approaches to 
improve anti-HPV cancer immunotherapy are used by other groups. Immune checkpoint 
blockade has been the major breakthrough in oncology during the last years (Sharma and 
Allison, 2015). The boosting of vaccine-induced immune responses by concomitant 
application of checkpoint blockade ABs is a very attractive option to achieve better 
treatment results. Several clinical studies targeting HPV16-induced malignancies are already 
using this strategy. Among these are studies using the DNA vaccine VGX-3100 together with 
a PD-L1 AB (NCT03162224) and a study that combines the emulsion-based SLP vaccine 
ISA101 with nivolumab (NCT02426892). The use of checkpoint blockade ABs is especially 
interesting against HPV-induced cancers since these cancer cells do not only express virus-
derived epitopes but also express many mutation-derived neoepitopes (Alexandrov et al., 
2013) due to the genome destabilizing actions of E6/E7-expression (McBride and Warburton, 
2017).  
Another focus to improve anti-HPV immunotherapies lies in the combination of therapeutic 
vaccination with concomitant chemotherapy or radiation therapy. Chemotherapy can 
improve the vaccination results by depleting Treg (reviewed in (Emens and Middleton, 2015)) 
and low dose radiation therapy induces a reprogramming of the tumor microenvironment 
(Klug et al., 2013), immunogenic cell death and an influx of professional APCs that prime T 
cells that are either specific for tumor mutation-derived neoantigens or viral epitopes 
(reviewed in (Golden and Apetoh, 2015)). These treatment options are pursued in clinical 
studies such as one trial combining ISA101 with paclitaxel and carboplatin (NCT02128126) 
or the previously mentioned trial using E7/11-19 in the DPX-E7 formulation that uses 
cyclophosphamide (NCT02865135). 
We advocate the use of epitope-specific vaccines. However, many successful preclinical 
experiments show effectivity also for vaccine formulations that are not epitope specific. So 
far, these could not be tested in a mouse model without the bias introduced by the 
immunodominant E7/49-57 epitope. Our new tumor model in combination with A2.DR1 
mice now allows the test of such vaccines in humanized mice. The models and results 
generated in this study will thus help to increase the translatability of preclinical studies to 
clinical situations in the future.  
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8 Annex 
 
E6 Protein Sequence (from NCBI Reference Sequence: NC_001526.2): 
MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAFRDLCIVYRDGNPYAV
CDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWT
GRCMSCCRSSRTRRETQL 
 
E7 Protein Sequence (from NCBI Reference Sequence: NC_001526.2): 
MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCV
QSTHVDIRTLEDLLMGTLGIVCPICSQKP 
 
